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Abstract
The objective of this research was to develop new polymeric nanomaterials for biomedical
applications. It was envisioned that through careful design and synthesis, as well as the study
of structure-property relationships, the development of materials with new properties and
functions could be achieved. As a starting point, several poly(ester amide)s (PEAs)
composed of α-amino acids, diols, and diacids, with varying chemical structures, molecular
weights, and polydispersity indices were prepared and their thermal, rheological and
mechanical properties were studied. The resulting data will aid in the design and selection of
PEAs with optimal properties for targeted applications. Subsequently, a novel PEA-paclitaxel
(PTX)-poly(ethylene oxide) conjugate was prepared and assembled into micelles to achieve
controlled release of PTX via the hydrolysis of ester linkages. This system was compared
with an analogous micellar system into which PTX was physically encapsulated and it was
shown that the release of PTX from the covalent system was slower and more sustained. To
provide an alternative release mechanism, a functionalized PEA with a photodegradable
backbone covalently conjugated to both PTX and PEO was designed and prepared. Upon UV
irradiation, micelles, formed from this graft copolymer through self-assembly, disintegrate.
This feature accelerates the release of PTX compared with non-irradiated micelles, likely due
to the increased exposure and hydrolysis of the ester linkages conjugating the drug to the
support, upon micelle disruption. Finally, cross-linked polymer nanoparticles (nanogels)
functionalized with Gd(III) chelates were designed, synthesized and characterized as
enhanced contrast agents for magnetic resonance imaging (MRI). These nanogels exhibited a
T1 relaxivity nearly 6-fold higher than the clinical contrast agent Magnevist. This result is
rationalized by the decrease in tumbling and rotational rates as a result of rigidity introduced
by the cross-linking. A preliminary in vivo evaluation of this new agent was performed and
the agent exhibited good contrast and enhanced circulation in the vasculature relative to
Magnevist.

Keywords
poly(ester amide)s, micelles, covalent conjugation, paclitaxel, UV irradiation, MRI contrast
agent, nanogels
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Chapter 1

1

General introduction
applications

on

polymers

for

biomedical

The development of new biodegradable polymers is a rapidly emerging field that holds great
promise for revolutionizing drug delivery systems, tissue engineering applications and
biomedical sensors. The first reported biomedical application of polymers was in Nylon
sutures in the early 1940s.1 At that time, biomedical polymers were limited to the
commercially available materials such as poly(methyl methacrylate) (PMMA), poly(ethylene
terephthalate) (PET) and poly(vinyl chloride) (PVC), as only limited synthetic tools were
available for synthesizing new materials (Figure 1.1).1,2 These polymers have since been
commercialized for medical applications including use as artificial bone, artificial heart
valves, hip implants, artificial lenses and vascular grafts. Research continues to optimize the
stability and performance of these materials in vivo.
Recently, the pharmaceutical and biotechnology industries have developed a wide array
of drug candidates based on proteins and nucleic acids, which cannot be delivered by
conventional methods because of issues such as low solubility, first-pass metabolism and
site-specificity. The successful clinical application of these new drugs is providing the
driving force for the development of new biomaterials for controlled drug delivery and gene
therapy applications. Likewise, an increased need in the emerging field of tissue engineering,
where polymers are used to assist regeneration of three-dimensional tissue, is also providing
an impetus for the development of new biocompatible and implantable polymers. Over the
last few years, the synergistic advances in molecular and developmental biology along with
the invention of new synthetic methods and polymer designs have resulted in a large
expansion of biomedical polymer architectures and applications.

2

Figure 1.1. Chemical structures of PMMA, PET and PVC.

1.1 Biomaterials
A biomaterial is a substance that has been engineered to affect the course of a therapeutic or
diagnostic procedure in human or animal medicine, either alone or as part of a complex
system, by controlling various material interactions with biological components.3 Although
biomaterials are primarily used for medical applications, they are also used for growing cells
in cultures,4 synthesizing biosensors,5 executing bio-separations,6 and forming the scaffolds
for diagnostic gene arrays.7 Recently, nano-scale materials have been investigated for
biomedical applications including drug carriers,8 tumour imaging tools,9 cell-targeted
therapy,10 cell sensors/microchips,11 and cell tissue scaffolds.12 Nano-sized biomaterials are
attractive for many biomedical applications because they are comparable to many biological
structures such as enzymes, antibodies and DNA plasmids with respect to their size and
shape.13 Nanomaterials exhibit unique physical, mechanical, electronic and magnetic
properties due to their submicron size and consequently, their large surface-to-volume ratio.
Furthermore, their large functional surface allows these materials to be modified to tailor the
chemical and/or physical properties of the material for a specific biomedical application.14
Specifically, nanomaterials such as polymer conjugates,15 polymeric nanoparticles,16
liposomes,17 micelles,18 nanogels,19 and dendrimers20 have been successfully used in the
development of pharmaceutical delivery systems.
Each of the possible applications has unique structural and functional requirements that
are best met by a specific polymeric architecture and material. Consequently, the field has
two over-arching goals at this early date, the development of a wider selection of polymeric
materials and structures and the development of a functional model better able to predict the
desired formulation for a given application through a better comprehension of the direct
relationship between structure and properties in synthetic biopolymers.

3

1.2 Polymer structure-property relationships
1.2.1

Thermal properties

In the study of biodegradable polymers and their applications, knowledge of the thermal
properties such as glass transition temperature (Tg), melting temperature (Tm) and thermal
degradation are essential in the selection of materials for various applications.
Thermogravimetric analysis (TGA) is used primarily to determine the thermal stabilities of
materials as well as their compositional properties.21 While all polymers have a Tg, a
transition that occurs in the amorphous regions of polymers, only polymers with a regular
chain structure can crystallize and exhibit a Tm.21 It has been shown that both the Tg and the
degree of crystallinity have significant effects on both the mechanical properties and the
degradation rates of biodegradable polymers.22 For example, poly(L-lactide) (PLLA) is a
semi-crystalline polymer with a Tg of 60–65 °C and a Tm of approximately 175°C (Figure
1.2). PLLA has a slow-degradation rate, good tensile strength, low extension and a high
modulus (approximately 4.8 GPa) and hence, has been considered an ideal biomaterial for
load bearing applications, such as orthopaedic fixation devices.23 In contrast, Poly(D/Llactide) (PDLLA) is an amorphous polymer has a glass transition temperature of 55–60 °C
(Figure 1.3).24 Due to its amorphous nature the polymer exhibits much lower strength (1.9
GPa) compared to PLLA. Being a low strength polymer with a faster degradation rate
compared to PLLA, it is a preferred candidate for developing drug delivery vehicles and as
low strength scaffolding material for tissue regeneration.24 Polydioxanone (PDS) which is a
semi-crystalline polymer, exhibits a very low glass transition temperature ranging from 10 to
0 °C (Figure 1.3). Due to the high crystallinity and hydrophobicity of the polymer, it can be
considered a slow to moderately degrading polymer. PDS has also been investigated for
several orthopaedic applications including use as fixation screws for small bones and
osteochondral fragments.25
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Figure 1.2. Chemical structure of PDLLA, PLLA and PDS.

1.2.2

Mechanical properties

The mechanical properties of polymers are affected by the combined effects of crystallinity,
molecular weight (MW), Tg, branching, crosslinking and sometimes the thermal history of
the particular samples.26 Mechanical tests provide useful information on the material’s
ultimate tensile strength (UTS), Young’s Modulus (modulus of elasticity), yield strength and
elongation at break. These properties are important in materials selections for end use
applications. For example, polyglycolide (PGA) showed excellent mechanical properties due
to its high crystallinity with a Young’s modulus of approximately 12.5 GPa and has been
investigated for use in bone internal fixation devices (Biofixs) (Figure 1.3).27 On the other
hand, the mechanical performance of polyanhydrides were found to be less than optimal for
load bearing applications, such as for orthopaedic implants.28 For example, the Young’s
modulus for poly[1,6-bis(carboxyphenoxy) hexane] (PCPH) is only 1.3 MPa,29 which is well
below the modulus for human cancellous bone (40-60 MPa) (Figure 1.3).30 Recently, the
mechanical properties of poly-(1,8-octanediol-co-citric acid) with ultimate tensile strengths
of approximately 6 MPa, Young’s moduli ranging from 0.9 to 16 MPa and maxium
elognations of around 265% of initial length31 similar to that of arteries and veins (up to
260%)32 and elastin (up to 150%)33 suggest that it is a promising biodegradable polymer for
vascular tissue engineering. Therefore, to summarize, although the mechanical responses of
polymers are complex, it is possible to gain an understanding of the broad principles that
determine these parameters. Polymers can potentially be rationally designed and synthesized
for a particular application.
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Figure 1.3. Chemical structure of PGA and PCPH.

1.2.3

Rheological properties

Rheological properties are useful in evaluating biomaterials for their suitability in processing
operations and can be used to estimate and predict the molecular orientations that are formed
in these materials while shear stress is applied or removed during a process. For example,
proper ﬂow properties allow hydrogels to be excellent candidates for injectable therapeutic
delivery vehicles. Schneider et al. reported a peptide-based hydrogel which undergoes
considerable shear thinning, resulting in a low viscosity gel upon the application of a proper
shear stress.34 However, once the external stress is removed, the material rapidly self-heals
into a solid again. This feature allows small molecules that were encapsulated during gel
formation to be delivered via syringe with precision to target sites.
In another study, Langer and co-workers investigated the rheological properties of a
polymer blend of hyaluronic acid (HA) and hydroxypropylmethyl cellulose (HPMC),
including yield stress, rheological synergism and shear thinning to optimize their properties
as injectable drug delivery vehicles (Figure 1.4).35 Rheology is also a powerful tool for
understanding the gelation mechanisms for forming a specific network, paving the way for
further development of hydrogels for tissue repair and drug delivery.36
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Figure 1.4. Chemical structure of HA and HPMC (R=CH3 or CH2CH(CH3)OH or H).

1.3 Drug delivery
While many advances have been made in the development of therapeutics to treat human
diseases over the past several decades, many drugs and drug candidates still face the
traditional conflict between efficacy and bioavailability. Some common challenges
encountered with highly active current and potential drugs include low aqueous solubility,
short plasma circulation half-life, susceptibility to rapid degradation in plasma, and high
toxicity.37,38 As blood circulates, small molecule drugs pass through the liver where
Cytochrome P450 and other enzymes metabolize them, rendering drugs inactive or increase
their toxicity.39 With half-lives on the order of minutes, small molecule drugs are rapidly
excreted from the body. In kidneys, circulating macromolecules with hydrodynamic radii
smaller than the glomerular pores (4 nm to 14 nm) will permeate the membrane and be
excreted, thus requiring large doses and/or lengthy infusions.40 The organs responsible for
drug clearance are easily damaged by many potential drug candidates. For example, cisplatin
causes severe nephrotoxicity (kidney toxicity).41 In addition to clearance by the kidneys, free
drugs may be removed via the reticuloendothelial system (RES).41 In a process called
opsonization, a circulating protein, opsonin, binds to foreign particles, increasing the ability
of phagocytic cells to recognize the foreign substance. Particles that are over 200 nm in
diameter, highly charged or hydrophobic are highly susceptible to opsonin binding and
removal via the RES. Once bound by opsonin, the liver and spleen can more effectively
remove these circulating particles or phagocytic cells can break them down to be removed by
the lymphatic system.42
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Delivery platforms such as polymers, micelles, liposomes, and nanoparticles (NP) are
being explored as effective methods to modulate drug activity (Figure 1.5).43-46 Some
potential advantages of therapeutic macromolecular supports include: (1) improving drug
water solubility; (2) carrying drugs to the site of action, thereby limiting metabolism and
toxicity and enhancing the therapeutic efficacy; (3) improving the pharmaceutical and
pharmacological properties of drugs, potentially without the need to alter drug molecules; (4)
enhancing circulation times to half-lives ranging from hours to days and (5) carrying a high
capacity loading of drug within a single macromolecular entity or assembly.

Figure 1.5. Different platforms for drug carriers: a) micelles b) liposomes c) nanoparticles.
Because the pharmacokinetics of a drug are significantly influenced by the carrier,
important factors such as drug release rates and blood circulation times can be altered simply
by changes to the delivery system rather than of the active pharmaceutical agent itself,
obviating the need to balance efficacy and bioavailability. Furthermore, there is the potential
for significantly higher specific accumulation in tumors as opposed to the small molecule
drug alone, due to the passive targeting phenomenon known as the "enhanced permeation
and retention" (EPR) effect.47 The EPR effect was described in great detail and validated by
Maeda et al.42,48,49 Their investigations showed that most solid tumors have poorly formed
vasculature, with loose junctions between the endothelial cells near the tumor, and little to no
lymphatic system (Figure 1.6).42,48 Therefore they exhibit enhanced vascular permeability,
which will ensure a sufficient supply of nutrients and oxygen to tumor tissues for rapid
growth. Macromolecules larger than 40 kg/mol in the blood stream can escape from tumor
vessels and accumulate in tumor tissues due to the lack of lymphatic drainage.44,49 In
contrast, in healthy tissue tight junctions between the cells lining the blood capillaries prevent
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macromolecules, but not small molecules, from entering normal tissue. The use of smallmolecule anticancer drugs leads to systemic toxicity, as a result of poor tumor targeting.

Figure 1.6. Increased uptake of macromolecular carriers in tumor tissue as compared to healthy
tissue due to the EPR effect. Adapted from reference 44. (Nature Nanotechnology 2007, 2 (12),

751-760, Reproduced with permission from Nature Publishing Group).
Targeting refers to differential spatial localization and describes directing drugs
specifically to desired cells and tissues. This differential spatial localization of nano-carriers
encompasses two different approaches referred to as ‘‘passive’’ or ‘‘active’’ targeting.50
Passive targeting involves the prolonged circulation of the carrier bearing no affinity ligands
and its preferential accumulation in the active site directly due to the inherent
biophysicochemical properties of the nanocarrier such as size, shape, charge and flexibility
via factors such as the EPR effect.16,50 In contrast, active targeting requires surface
modification of the nanocarrier to incorporate affinity ligands with specificity to disease
tissues and cells.16,50
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1.3.1

Polymer–drug conjugates

The attachment of drugs or other biological species directly to a polymer backbone has been
the subject of extensive investigation over last few decades.51-53 Polymers with functional
handles provide the opportunity to covalently graft the drug to polymer chains, allowing
them to deliver high doses of drugs. The advantages of polymer–drug conjugates compared
to free drugs have been well documented.54,55 For example, in clinical trials, the
biocompatibility of N-(2-hydroxypropyl)methacrylamide (HPMA) as a drug carrier has been
demonstrated, as has a decrease of

non-specific side effects when compared to low

molecular weight drugs alone.56,57 The polymers used as drug conjugates can be divided into
two groups: natural and synthetic polymers.
Polymers such as albumin, chitosan, and heparin occur naturally and have been a material
of choice for the delivery of oligonucleotides, DNA, and protein, as well as drugs.58 A
current example of a clinically used natural polymer-drug conjugate (noncovalent) is PTX
albumin bound nanoparticles (brand name: Abraxane) for the treatment of patients with
breast cancer resistant to conventional therapy.59
Today, the most commonly used synthetic polymers for the development of drug
conjugates include HPMA and its copolymers, poly(D,L-lactide-co-glycolide) (PLG),
poly(lactic acid) (PLA), poly(L-glutamic acid) (PLGA), poly(caprolactone) (PCL), and
poly(amino acids) (Figure 1.7).60 In particular, PLGA was the first biodegradable polymer to
be used for the synthesis of drug conjugates. For example, in Xyotax, PTX was conjugated to
PLGA through an ester bond (Figure 1.8).62,63 Xyotax was shown to preferentially target
ovarian tumours and is now in clinical trials.61,62 Another example is IT 101, which is a
conjugate of the anticancer drug camptothecin (CPT) and a linear β-cyclodextrin-based
polyethylene oxide (PEO) to PLGA (Figure 1.8). Pharmacokinetic and preclinical studies
have demonstrated that this conjugate exhibits a longer plasma half-life and better
accumulation in the tumor tissue than CPT alone.63 PK1, comprised of doxorubicin (DOX)
covalently bound to HPMA copolymer by a peptidyl linker is another example of a polymer–
anticancer drug conjugate. It entered clinical trials more than a decade ago and the clinical
phase II trial for women with advanced breast cancer is still ongoing (Figure 1.8).64
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Figure 1.7. Chemical structure of some common synthetic polymer for drug conjugation.

Figure 1.8. Chemical structure of Xyotax , IT-101 and PK1.
Although polymer-drug candidates show excellent promise, their transition from bench to
clinic has been slow. This is at least partly due to the complex biological behavior of the
formulation in that small modifications, to either the conjugation efficiency or the polymer
molecular weight and architecture, can have non-linear effects on the pharmacokinetic
parameters. Thus, the resulting materials can be considered a novel material requiring
additional regulatory attention.
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1.3.2

Micellar drug delivery systems

Micelles are one of the most heavily investigated types of nano-carriers and some examples
are currently in clinical trials as advanced as phase II.65 Micelles are formed through self
assemblies of amphiphilic block copolymers with large solubility differences between the
hydrophilic and hydrophobic segments in aqueous medium, allowing them to form micelles
in the nanoscopic size range with fairly narrow size distributions.
Micelles have been developed as drug delivery carriers for hydrophobic drugs.66-69
Potential advantages of micelles over other nanoparticle delivery systems include: (1)
enhancing the solubility of hydrophobic drugs through encapsulation in the micelle’s
hydrophobic core region or, alternatively, through grafting the drugs to the hydrophobic side
chain of the polymer; (2) increasing the in vivo drug circulation times and tumor targeting via
EPR effect due to the small size of the particles; (3) controlling the rate of drug release from
the carrier through tuning the chemical structure of the core-forming block; (4) improving the
targeting efficiency of micelles by preparing micelles responsive to an external stimulus such
as temperature or pH through modification of the chemical structure of the micelle-forming
block copolymer. Numerous studies have been published on the preparation of polymeric
micelles and on their properties. Many good recent reviews exist, dealing with various
aspects of polymeric micelle preparation, physicochemical and biological properties, and
possible applications as pharmaceutical carriers.67-70 Micelles have been used successfully for
delivering drugs such as PTX and DOX. These drugs can be loaded into polymeric micelles
in two ways: physical encapsulation or chemical covalent attachment. Each method has its
own advantages and disadvantages, which are discussed below in more detail.

1.3.2.1

Micelles containing non-covalently encapsulated drugs

The existence of hydrophobic interactions or hydrogen bonds between the micelle-forming
block copolymer and the drug provides the basis for the encapsulation of drugs in polymeric
micelles. In this system, the encapsulation efficiency of the micelle system is strongly
dependent on the payload/core interaction.67 For example, in the encapsulation of PTX in
polymeric micelles that consist of PEO- poly(2-(4-vinylbenzyloxy)-N,N-diethylnicotinamide)
(PDENA), the polymer with longer PDENA block resulted in an increased loading of PTX.71
Partial replacement of the benzyloxy group in PEO–poly(β-benzyl- L-aspartate) (PEO-b-
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PBLA) with acetyl ester has also been used by Yokoyama et al. to incorporate (6-[4-deoxy4-(2E,4E)-tetradecadienoylglycyl]amino-l-glycero-β-l-mannoheptopyranosyl]amino-9Hpurine (KRN-5500, a water-insoluble anticancer drug) in polymeric micelles.72-74 Another
example is SP1049C which is a pluronic polymeric micelle NP composed of a DOX and
non-ionic, triblock copolymers formed from a hydrophobic polypropylene (PPO) block
flanked by two PEO blocks (Figure 1.9). It is currently undergoing phase II studies in
patients with metastatic cancer of the esophagus and esophageal junction that have been
refractive to standard chemotherapy treatments.65
The use of micelles to deliver hydrophobic drugs has become a prominent strategy in the
field of drug delivery. Micelles can be designed to be biocompatible and biodegradable.
Furthermore, the physicochemical properties of micelles can be tuned, resulting in materials
with various adjustable properties. More importantly, in this delivery system, where the drug
is physically encapsulated, it can be delivered without any chemical modification to its
structure. Thus for, polymeric micelles are much more efficient and safer other methods
currently in use. However, this strategy is usually associated with premature drug release
prior to EPR-mediated tumor accumulation. In order to minimize this limitation, one
approach would be to chemically conjugate the drug to the hydrophobic block of a micelleforming material through a covalent bond.

Figure 1.9. Chemical structure of SP1094C formulation.
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1.3.2.2

Micelles containing covalently conjugated drugs

The covalent immobilization of drug molecules within a micellar carrier can be achieved
through the formation of hydrolyzable chemical bonds between the functional group(s) on
the polymer and the drug. In this case, drugs can be chemically conjugated to either an
activated free terminus or to the side chain of a hydrophobic block in the micelle. For
example, 7-ethyl-10-hydroxy-campothecin (SN-38), a hydrophobic anticancer drug, was
attached covalently to the pendant carboxyl groups of PEG-b-polyglutamate copolymer via
an ester linkage. This formulation enhances the water-solubility of SN-38 and allows the
delivery of higher doses of SN-38 than those possible with SN-38 alone (Figure 1.10).75 In
another example, DOX was conjugated to a PEO-b-poly(aspartic acid)(Asp) block
copolymer to increase the entrapment of DOX inside the hydrophobic core of PEO-b-P(Asp)DOX micelles.76 PTX was attached covalently to the pendant carboxyl groups of PLGA of
{PLAA-co-[(PGA-alt-PLGA)]}-b-PEG-b-{PLAA-co-[(PGA-alt-PLGA)]}

via

an

ester

linkage. The resulting micelles did not exhibit initial burst release but release was pH
dependent and the PTX maintained its cytotoxic profile against RBG-6 cells (Figure 1.10).77
Drug conjugated micellar carriers hold a promising future due to their superior
performance relative to other drug carriers. The conjugation of drugs to the hydrophobic
cores of micelles not only sustains their release but also protects them against degradation,
decreases their side effects and increases their overall therapeutic efficiency. The peripheries
of micelles also can be used to conjugate targeting agents, and then the micelles can be
accumulated selectively in certain tissues in the body. However, batch to batch
reproducibility and also small changes in the micelle's drug conjugation efficiency may
significantly change the pharmacokinetic parameters and tissue biodistribution. The resulting
formulation would also be considered a new chemical entity, complicating regulatory
approval.
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Figure 1.10. Schematic structure of a) SN-38- PEG-b-PLGA b) {PTX- PLAA-co-[(PGA-altPLGA)]}-b-PEG-b-{PTX-PLAA-co-[(PGA-alt-PLGA)]}.

1.4 Paclitaxel delivery
PTX, was first isolated from the bark of Taxus brevifolia, first discovered by Wall and Wani.
It is one of the most effective chemotherapeutic drugs and is used to treat a broad range of
cancers such as lung, ovarian, and breast cancer, amongst others.78 PTX is a hydrophobic
drug and has very poor aqueous solubility (~0.4 μg/mL). To enhance its solubility, it is
commercially formulated in Cremophor EL (CrEL), which is polyoxyethylated castor oil,
and dehydrated ethanol (50/50, v/v) under the trademark “Taxol”. However, CrEL is known
to cause serious side effects, such as hypersensitivity reactions, and considering the amount
of CrEL (26 mL of CrEL) that is needed for an average patient for a single intravenous
administration dose, it is a major limitation for clinical use of PTX.79
As discussed above, nano-carrier delivery systems are promising vectors for clinical use.
Among the first generation of NP for PTX delivery, Abraxane, a PTX protein-bound NP
formulation with the particle size of around 130 nm, was approved by the FDA in 2005 for
the treatment of metastatic breast cancer.80 Although, this formulation reduced toxicity by
removing the need for the use of the toxic excipient-CrEL, and a dose can be administered
within 30 min without pretreatment, Abraxane does not impact the circulation half-life as it
rapidly dissociates into its constituent albumin and PTX molecules.81 Furthermore, PTX is a
substrate of protein named P-glycoprotein (P-gp), which can export PTX from the cell and
likely induces drug resistance.82 Therefore, alternative PTX formulations are still in demand.
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1.4.1

Polymeric micelles for PTX delivery

Much research has been conducted towards the development of a micellar PTX delivery
systems. Two approaches that have been frequently used are the incorporation of PTX in
micelles or the conjugation of PTX to the hydrophilic block of micelle-forming block
copolymers. For example, the NK105 micellar formulation was constructed using PEO as the
hydrophilic segment and modified polyaspartate as the hydrophobic segment. To increase the
hydrophobicity and thus increase the interactions between PTX and the polymer backbone,
half of carboxylic groups of the polyaspartate block were modified and converted to 4phenyl-1-butanolate.83,84 A drug loading up to 23% (w/w) and a particle size of
approximately 85 nm was achieved. NK105 showed similar cytotoxicity in human tumor cell
lines include lung, gastric, oesophagus, colon, breast and ovarian compared to PTX.85
Currently, a phase II study in patients with advanced stomach cancer is underway
(Figure.1.11).85

Figure 1.11. Structure of NK105 formulation.
Paxceed® is another polymeric micellar formulation where PTX is encapsulated in
PDLA-b-methoxypolyethylene oxide (mPEO) diblock copolymers. The micellar formulation
significantly improved the maximum tolerated dose (MTD) of the drug upon intraperitoneal
injection in an MV-522 lung tumor bearing mouse model.86 Currently, Paxceed® is in phase
II clinical trials.87 Genexol-PM is the most successful PTX micellar formulation to date,
which is composed of PDLA-b-PEO diblock copolymers. Genexol-PM was approved in
Korea in 2007.80 It is currently in phase II clinical development in the USA.88,89
Other PTX-loaded PLA-based micelles have also been reported. For example, PEO-PLAPEO exhibited slower drug release compared to PLA-PEO-PLA micelles. Both of the
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micelles showed a 4-fold decrease in monocyte cell uptake compared to a simple PLA
nanoparticles.90-92 In another study, a four-armed (star-branched) copolymer of PLA and
PEO was synthesized. The micelles from star-shaped copolymers exhibited more complete
release of drug than diblock copolymers. Furthermore, the lower hydrodynamic radius of
star-shaped polymers may result in better clearance of the carrier polymer from the body
(Figure 1.12).91

Figure 1.12. Chemical structure of a) PLA-PEO-PLA and PEO-PLA-PEO b) a four-armed
(star-branched) co-polymer of PLA-PEO.
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Compared to micellar PTX physical encapsulation, there are only a few examples of PTX
covalently immobilized at the micelle core. For example, PTX modified with a levulic, 3(acetyl)acrylic acid) and 4-(2-oxopropyl)benzoic acid spacer was conjugated to random
copolymers of HPMA with 6-methacrylamidohexanohydrazide via hydrazone linkages
provided a pH sensitive micellar system. These micelles showed better antitumor efficacy in
the 4T1 model of mammary carcinoma than free PTX (Figure 1.13).93
Recently, Kim et al. developed a PTX conjugate polymeric micelle, consisting of PEO
and arginine-grafted (cystaminebisacrylamide-diamine) ABP for the co-delivery of DNA and
PTX. APP micelles showed increased cell uptake efficiency and higher anticancer potency
than PTX alone (Figure 1.13).94 Recently, Zhong et al. reported a PTX conjugate using PEOb-poly(acrylic acid) (PEO-PAA) block copolymers as the support. The drug was attached via
an acid-labile acetal linkage to the PAA block using ethylene glycol vinyl ether as a linker.
The resulting micelles of these copolymers exhibited potent antitumor activity to KB, HeLa,
and PTX-resistant A549 cell lines (Figure 1.13).95
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Figure 1.13. Chemical structure of a) PTX-APP b) PTX-HPMA c) PTX-PEG-ABP.

1.5 Stimuli-responsive polymers
Despite considerable advances having been made in the development of controlled drug
delivery technologies over the last few decades, most still have the shortcoming that drugs
release at a predetermined rate that can’t be tuned to the particular patient needs or changing
physiological environment. This shortcoming may be overcome by developing stimuliresponsive materials, also termed "smart", “intelligent" or “environmentally sensitive"
systems, in which materials undergo sharp responses to environmental changes such as
pH,96,97 temperature,98,99 light,100,101 redox102,103 or other chemical changes, potentially
leading to enhanced drug efficacy and improved therapeutic index.
Possible advantages of the use of stimuli-responsive polymers in drug delivery include:
(1) the ability to control the timing, duration and dosage of the drug in response to a given
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stimulus; (2) the ability to release the drug at a specific location by exploiting the difference
in environmental properties at the site of disease and (3) the ability to minimize the drug
release when the trigger is in an off state. The response of these materials has to be
predictable, reproducible, and proportional to the intensity of the signal for applications in
drug delivery.
A few illustrative examples of stimuli-responsive micellar systems are offered for clarity.
In one model, a mixed polymeric micellar system composed of poly(L-histidine)-b-PEO
(PH-PEO) and PLLA-b-PEO displayed ultra-sensitive pH dependence which could be tuned
by varying the mixing ratio of the two polymers. A two-stage destabilization process was
observed when the pH was changed from 7.4 to 6.0. First, significant destabilization of the
micelle core occurred when the pH dropped from 7.0 to 6.8, which induced an increase in
micelle size. As the pH was further lowered to 6.0, further disruption of the micelle core
caused ionized PH-PEO unimers to dissociate from the micelles.104 A second example is a
temperature-sensitive micelle based on poly(N-(2-hydroxypropyl)methacrylamide lactate)
and PEO (pHPMAmDL-b-PEO). PTX was loaded into these micelles at up to 2 mg/mL by
simply mixing a PTX solution in ethanol with an aqueous polymer solution in the presence of
heat.98 Another example is a micelle consisting of an HA-deoxycholic acid (HA-ss-DOCA)
conjugate that has been used to deliver PTX. This micelle contains characteristic disulﬁde
linkages on the side chains which are prone to rapid cleavage through thiol-disulﬁde
exchange reactions with intracellular reducing molecules, especially glutathione, resulting in
rapid drug release under reducing conditions.105
Among all possible triggers, light is a particularly attractive stimulus for drug delivery
because its intensity and wavelength can easily be modulated through the use of filters.101
Furthermore, photo-processes start or stop when the light is switched on or off, allowing for
complete control of the release process, unlike relying on physiological pH, temperature or
enzymatic strategies. Thus, both complete spatial and temporal control of the drug release
can be achieved.106
The most common design of photo-responsive amphiphilic polymers involves the
incorporation of a photocleavable unit in the main-chain of one of the blocks.100 These are
designed so that once formed, the micelles may be disrupted by photo-irradiation. As the
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amphiphilic copolymer degrades, the micelle becomes increasingly compromised, resulting
in the release of the encapsulated molecules. For instance, Zhao et al. developed a micelleforming ABA triblock copolymer containing a PEO-based hydrophilic block

and a

hydrophobic polyurethane block containing o-nitrobenzyl groups (PEO-b-PUNB-b-PEO).
Upon, UV irradiation, the fast degradation of the photocleavable units inserted into micellar
core was implied by the rapidly observed disintegration of the micelles. In this case, burst
release of the loaded hydrophobic guest molecules was also achieved (Figure 1.14a).107

Figure 1.14. Structure of a) PEO-b-PUNB-b-PEO b) PEO-b-poly(disulfide-alt-nitrobenzyl)b-PEO.
Alternatively, the same group designed a triblock copolymer of PEO-b-poly(disulfide-altnitrobenz)-b-PEO incorporating both a redox-cleavable disulfide group and a photocleavable
o-nitrobenzyl group. This dual feature allowed either burst release of an encapsulated agent
through UV light irradiation, slow release by the action of a reducing agent, or release with
concomitant fast and slow profiles using the two stimuli concomitantly (Figure 1.14b).108
Polymeric micelles based on block copolymers that form stimuli-sensitive structures have
drawn interest for delivery applications, particularly for hydrophobic compounds. However,
they suffer from a number of drawbacks. For example, in the case of photo-responsive
polymers, UV and visible-wavelengths cannot be used for deep-tissue triggering.
Furthermore, the biodegradability, biocompatibility and the toxicity of the products resulting
from the degradation reactions have not yet been extensively studied.
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1.6 MRI contrast agents
1.6.1

Basic principles of MRI

Over the last few decades, MRI has become a primary imaging modality. The popularity of
this non-invasive technique is likely due to the fact that it does not require ionizing radiation
as in X-ray computed tomography (CT), or radioactive material as in positron emission
tomography (PET).109,110 MRI also exhibits excellent spatial resolution and provides soft
tissue contrast for the conveyance of anatomical information.111 An MRI image is often
based on the relaxation time of water proton spins in a sample in the presence of an external
magnetic field, following a radiofrequency (RF) pulse. The resulting image is also based on
the spatial distribution of the density of water protons.
There are two types of relaxation that the protons in water molecules can undergo
following perturbation with a radiofrequency pulse: longitudinal and transverse. The first
type of relaxation, called longitudinal relaxation, is defined by the nuclei returning to their
parallel alignment with the magnetic field (Bo) direction after being aligned perpendicularly
to it. The amount of time that is required for 63% of the magnetization in the Bo direction to
be recovered is termed T1. Transverse relaxation, the second type, occurs when the nuclei
that had been in coherence in a single vector perpendicular to Bo become randomly
distributed around Bo (i.e. the perpendicular vector would be zero). The time required for
63% of the magnetization to undergo this relaxation is termed T2.112 These relaxation times
can be probed by the use of selective pulse sequences in MRI.
Although MRI was initially hoped to provide a contrast between different tissues based
on the differences in water densities and proton relaxation times in these tissues, this inherent
contrast is sometimes insufficient to distinguish between healthy and diseased tissues. To
address this limitation, MRI contrast agents have been developed.113

1.6.2

Gadolinium contrast agents

Gd(III) chelates have been in use for decades as contrast agents in clinical diagnostic
radiology. The presence of paramagnetic Gd(III) ions affects the relaxation properties of
neighboring protons and influences the intensity of the image. T1 relaxivity is described by
equation (1.1).
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(1/T1)obs= (1/T1)d + r1[ Gd(III)] (1.1)
where T1obs is the observed relaxation time, T1d is the relaxation time of the sample prior to
addition of contrast agent, [Gd(III)] is the concentration of gadolinium contrast agent and r1
is the relaxivity. Relaxivity is typically expressed in units of mM-1s-1. In fact, the lanthanide
ion, Gd(III), is usually preferred as an MRI contrast agent. It is not only because it has high
spin number (seven unpaired f -electrons) which allow for a very large magnetic moment of
7.9 Bohr magneton (BM) but also for its symmetric electronic state (8S7/2 ground state),
which makes the electronic relaxation time much longer than compare to other lanthanide
(III) ions, 10-8-10-9 s.114 The water bound Gd(III) ion is toxic and therefore to avoid toxicity
of the free ion, Gd(III) is typically attached to a chelating agent. For example, the octadentate
ligand diethylene triamine pentaacetic acid (DTPA) and Gd(III) form a strong complex that
remains intact for the length of time it is in vivo.111 The interaction of water with the Gd(III)
ion is mediated by two coordination mechanisms - water molecules that are directly
coordinated with the metal center and those that are diffusing near the complex, known as
inner and outer sphere water respectively. It is primarily the inner sphere coordination to the
Gd(III) ion that can be altered to enhance its relaxivity.
The chemical structure of Figure 1.15 illustrates some of the major parameters that
govern the relaxation properties of complexes as they relate to inner sphere water
interactions. The rotational correlation time, τR, is the rate of which the chelating agent
tumbles in space. The mean residence lifetime, τm, is the time that the coordinated water
molecule interacts with the Gd(III) ion. The number of water molecules bound to the metal
center is defined by q, the hydration number. Relaxivity can be enhanced by altering each of
these parameters. Altering the rotational correlation time can dramatically affect the
relaxivity.109 As the molecular tumbling is slowed, relaxivity is typically increased.
Therefore, one approach to increase relaxivity is to increase the molecular weight of the
complex. This can be achieved by using a receptor unit or protein as the chelating agent. It
has been shown that when Gd(III) complexes are bound to proteins such as serum albumin,
their relaxivity increases due to the higher molecular weight of the entire complex, which
causes the tumbling rate to decrease.113 For example, solution studies of human serum
albumin showed that albumin-Gd-DTPA possesses a longitudinal relaxivity r1 of 14.8 mM-1
s-1, a value three times that of the monomeric chelate when measured under the same
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conditions, a result of the larger molecular weight of the contrast agent and hence its higher
rotational correlation time τR.113 In spite of its initial success, covalently labeled albumin
suffers from several undesirable traits. Elimination of the agent is slow and incomplete, and it
has been shown to remain in circulation for more than a week, eventually accumulating in
liver and bone.113 Furthermore, a general limitation of protein-based agents is the
requirement for large quantities of protein, as well as their potential immunogenicity.

Figure 1.15. Illustration of the major parameters governing the relaxivity of Gd(III) chelates.
To address the limitations of protein-based MRI contrast agents, significant effort has
been put forth into the conjugation of Gd(III) complexes to high molecular weight molecules
such as polymers,115-117 dendrimers

118

and other macromolecular structures
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in hopes of

slowing their tumbling rates. For example, a well studied macromolecular Gd-DTPA contrast
agent, involved the attachment of Gd-DTPA to poly-L-lysine, resulting in a T1 relaxivity
three times higher than that of Gd-DTPA.120 Kobayashi and coworkers have developed a new
class of macromolecular Gd-DTPA contrast agents which are bound to poly(propylene
imine)(PPI) dendrimers (Figure 1.16). The fifth generation dendrimer exhibited a relaxivity
of 29 mM-1s-1.121
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Figure 1.16. PPI dendrimer conjugated to Gd-DTPA complex.
Recently, Shiraishi et al. developed a polymeric micellar contrast agent. A block
copolymer, PEO-b-poly(L-lysine) was used for conjugation of the chelate 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to all amine groups of the lysine
residues. An MRI analysis showed that the signal intensity of the tumor was enhanced 2-fold
by the use of this contrast agent (Figure 1.17).122

Figure 1.17. Chemical structure of PEO-P(Lys-DOTA-Gd).
However, one aspect that is critical in the design of macromolecular Gd(III) chelates is
the rigidity of the macromolecule. Flexible macromolecules lead to relatively low
relaxivities,123 similar to those of small molecules as the conjugated chelates can still tumble
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in solution in a manner similar to small molecules. In contrast, the use of more rigid
macromolecules such as proteins124 and dendrimers125 have led to higher relaxivities.

1.7 PEAs
While aliphatic poly(α-esters) such as PLA,126-128 PLGA129,130 and PCL131-133 and their
copolymers have been extensively investigated and used as biodegradable polymers for a
wide range of biomedical application, they still lack of some desirable properties. For
example, PGA or PLA can undergo a bulk degradation process by the non-specific scission
of the ester backbone into glycolic and lactic acids.24,134 Although these byproducts are
present in natural human metabolic pathways, a large accumulation of these acidic species
has been demonstrated to result in some cell toxicity and tissue inflammation in certain
applications.135 This, combined with their low mechanical performance due to weak
intermolecular forces and lack of inherent functional groups required for biological
recognition or covalent conjugation of drugs has limited to some extent their utility in some
biomedical application.134 Compared to aliphatic polyesters, aliphatic polyamides possess
higher thermal and mechanical stability due to strong intermolecular interactions caused by
hydrogen bonding.136,137 Although, susceptibility of the amide linkages of synthetic
polyamides to enzymatic hydrolysis can be achieved by improving their chain flexibility and
hydrophobicity, they are generally quite resistant to enzymatic hydrolysis. Synthetic poly(αamino acids) and other polyamides containing α-amino acids have been considered, but their
preparation on large scale is still challenging due to the use of expensive and unstable Ncarboxyanhydride monomers.138 In addition, poly(amino acid)s have been found to be
immunogenic under some circumstances.139
To address these limitations, it is reasonable to combine the favorable properties of these
two classes of polymers to produce new polymeric materials possessing not only good
biodegradability but also good materials and processing properties. Therefore, a variety of
PEAs containing different monomers have been developed with different preparation
methods. For example, polydepsipeptides composed of α-hydroxy acids and α-amino acids were
prepared by the ring-opening polymerization of morpholine-2,5-dione derivatives (Figure
1.18a).140 Polycondensations methods have also been utilized to react diamide-diol and esterdiamine monomers with dicarboxylic acid derivatives (Figure 1.18b). New families of PEAs
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including water soluble,140 unsaturated,141 and epoxy142 and polycationic140 PEAs have also
been developed for different biomedical applications (Figure 1.19).

Figure 1.18. Examples of PEAs prepared by a) ROP and b) polycondensation
polymerization.

Figure 1.19. Examples of PEAs with different structures and properties: a) water-soluble; b)
unsaturated; c) epoxy; d) polycationic.
PEAs derived from α-amino acids, diols, and dicarboxylic acids (Figure 1.20) are of
particular interest for the current work, as they have been demonstrated to undergo hydrolytic
and enzymatic degradation at physiological pH, thus providing the possibility for degradation
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in a wide range of biological environments.140,143 Furthermore, the monomer components of
the polymer can be selected from nontoxic metabolic intermediates including the natural
amino acids as well as dicarboxylic acids such as succinic and fumaric acid, thereby allowing
for the degradation products to also be non-toxic. In addition, by rational design of the
backbone, the polymer’s chemical functionality and properties including solubility,
crystallinity, biocompatibility, and degradation rate can be readily tuned.140

Figure 1.20. General structure of the PEA.
Puiggali et al. have prepared a variety of PEAs based on amino acids including glycine,
alanine, or β-alanine with saturated aliphatic diols and diacids of different chain lengths.144146

It was found that PEAs containing stiff units such as oxalic acid and terephthalic acid had

higher glass transition temperatures (Tgs), which are anticipated to result in enhanced
mechanical properties.147 Chu and coworkers have also prepared a number of PEAs based on
hydrophobic amino acids including valine, leucine, isoleucine, norleucine, L-phenylalanine,
and methionine with aliphatic diols and diacids. The thermal properties and crystallinities of
the polymers were found to vary depending on the constituents. For example, PEAs
containing L-phenylalanine were the most crystalline and had the highest Tgs.148 The same
group has also recently reported a variety of L-phenylalanine-based poly(ether ester amide)
(PEEA) composed of saturated or unsaturated dicarboxylic acids with different
oligo(ethylene glycol)s.149 It was found that incorporation of flexible ether bonds in the
backbones decreased the Tg compared to the similar PEAs based on saturated hydrocarbon
diols. These PEEAs also showed a much higher tendency toward α-chymotrypsin catalyzed
biodegradation than the corresponding PEAs derived from conventional aliphatic diols.149

1.7.1

Functional PEAs

Recently, the incorporation of functional groups along the backbone of PEAs using α-amino
acids has opened prospects for many exciting new applications. For example, functional
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handles are essential for the covalent attachment of drug molecules and targeting groups for
drug delivery or growth factors and adhesion molecules, which are emerging as important
components of medical implants and tissue engineering scaffolds. In addition, such side
chains may provide dramatic effects on the polymer solubility, charge, biocompatibility, and
biodegradation.
Jokhadze et al. have reported the preparation of PEAs with pendant carboxylic acids by
using both the α and ε-amines of L-lysine in the polymer backbone. These free carboxylic
acids were further functionalized with 4-amino-2,2,6,6-tetramethylpiperidine-1-oxy (TAM),
a biomedically useful cell growth inhibitor.150 Montserrat et al. have incorporated an ester of
L-lysine as a diamine in the PEAs, but the ethyl ester protecting group of the pendant lysine
carboxylic acid was not, and likely cannot be removed from the resulting polymer.151 Our
group in collaboration with the Mequanint group has focused on the incorporation of amino acids with side chain functional handles and has recently reported the first synthetic
approach for preparing PEAs with functionalizable pendant amine groups. In this strategy,
the protected, functional amino acids such as carboxybenzyl-lysine-(t-butoxycarbonyl)-OH
or

carboxybenzyl-aspartic

dicyclohexylcarbodiimide

acid-(t-butyl
(DCC)

ester)-OH

couplings

with

were

esterified

butanediol

to

using

provide

N,N′diamine

monomers.152-155 Varying percentages of these monomers along with other monomers of
varying structures were used in solution or interfacial based polymerization methods to
demonstrate the synthetic versatility of the method and to arrive at polymers with varying
physical properties. It was demonstrated that the pendant side chain amine/acid protecting
group could be removed without degradation of the polymer backbone to provide pendant
amine/acid groups on the polymer that could be coupled to model compounds including an
amino acid and an oligo(ethylene glycol) derivative.152

1.7.2

Biomedical applications of PEAs

As discussed, PEAs have the potential to exhibit unique properties compared to other
biodegrable polymers. For example, amino acid-based PEAs can easily be biodegraded by
enzymes, such as lipases or α-chymotrypsin. This feature enhances their surface degradation,
limiting the possibility of a large accumulation of acidic species in the local tissue which has
been demonstrated to be problematic for aliphatic(α-esters). However, their biodegradability
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in pure phosphate buffered saline is slow. This would provide the advantage of shelf-life over
PGA, PLA, and their copolymers which are considered hydrolytically degradable. In contrast
to aliphatic poly(α-esters), which possess limited functional groups, limiting their application
for covalent conjugation of biomolecules including proteins and growth factors, monomers
with pendant functional groups, including those based on amino acids such as lysine and
aspartic acid can be incorporated to PEAs to provide functional handle for further
conjugation of biomolecules. As such it is not surprising that these materials have shown
promising potential applications in a wide range of biomedical research.
Guo et al. developed biodegradable PTX-loaded microspheres of amino acid based
PEAs. The particles were capable of encapsulating PTX with high efficiency (close to
100%), suggesting that these PEA microspheres have the potential for the administration of
highly hydrophobic anticancer drugs.156 The same group also prepared biodegradable hybrid
hydrogels based on the amino acid derivative, DL-2-allylglycine (AG) poly(ester amide)
(PEA-AG) and commercial PEO diacrylate (PEO-DA) or Pluronic diacrylate (Pluronic-DA)
by UV photocrosslinking which can used as sustained drug release systems.157
Pan et al. investigated an oral insulin formulation based on microspheres consisting of a
blend of PEAs. In this delivery system, L-lysine-/L-leucine-based PEAs with pendant acid
groups were used as pH-responsive materials for the protection of insulin from the acidic
environment of the stomach. Arginine-based PEAs (Arg-PEA) were also used to improve the
intestinal absorption of the drug. The microspheres exhibited high drug loading and also
improved the oral bioavailability of insulin.158 Liu and coworkers reported the use of
arginine-based PEAs as a non-viral gene delivery vehicles with a high binding capacity
toward plasmid DNA.159
Langer et al. developed elastomeric PEAs based on a multifunctional amine group, 1,3diamino-2-hydroxypropane a polyol (glycerol or D,L-threitol) and sebacic acid. These
polymers exhibited desirable physical and mechanical properties, which combined with in
vitro and in vivo biocompatibility make them potentially suitable for the fabrication of semipermanent resorbable medical devices for use in long-term implantation applications. The
conjugation

of

4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl,

4-Amino-2,2,6,6-

tetramethylpiperidinyloxy (4-amino-TEMPO), an anti-inflammation drug, to a carboxylic-
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acid-functionalized PEA has been investigated for a cardiovascular stent coating. This
coating improved the natural healing response by attenuating the pro-inﬂammatory reaction
to the implant and promoting growth of appropriate cells for repair of the tissue
architecture.160 In another study, Reinhart-King and coworkers prepared PEA-based polymers
that have carboxylic acid functional groups (i.e. negatively charged), and amino-functional
groups (i.e., positively charged) and a nonfunctionalized PEA (uncharged) to investigate the
effect of PEA charge on cellular response. Their study suggested that endothelial cell
attachment, spreading, and growth were favored on positive and neutral PEA substrates when
seeded at high density.161
Knight et al. synthesized series of biodegradable PEAs from the α-amino acids L-alanine,
L-phenylalanine, and L-lysine in an attempt to investigate human coronary artery smooth
muscle cell (HCASMCs) interactions. HCASMCs cultured directly on bare PEA films
attached and spread well up to 7 days of culture. Immunostaining of cells illustrated strong
vinculin expression on all surfaces. These results suggested that PEAs can potentially be used
in vascular tissue engineering applications.154 Recently, Zilinskas et al. reported the synthesis
of a series of amphiphilic PEA-PEO graft copolymers through the conjugation of hydrophilic
PEO to the pendant -amino groups of L-lysine residues in PEAs. The PEO-PEA graft
copolymers were shown to self assemble into micelles that could encapsulate model
hydrophobic drug, nile red in aqueous solution. It was found that the sizes of the micelles
could be tuned by varying the PEO content of the polymers and the method of micelle
preparation. These materials were also demonstrated to be nontoxic to HeLa cells.

1.8 Research objectives
The main objective of this thesis was to design, synthesize and characterize novel polymers
for biomedical applications including drug delivery and MRI. Proof of concept studies were
also performed to demonstrate the potential applicability of the new materials in their
designed applications.
In chapter 2, the design and synthesis of a diverse range of PEAs based on diols,
dicarboxylic acids and -amino acids is described, along with a detailed characterization of
their thermal, mechanical and rheological properties. This work forms a fundamental basis
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for understanding the structure-property relationships of these materials in order to determine
their suitability for different applications.
In chapter 3, the preparation of a novel amphiphilic PEA-PEO graft copolymer with PTX
conjugated via ester linkage is described and its assembly into micelles is studied. The aim of
this work is to address the burst release problem commonly observed for polymer micelleand nanoparticle-based drug delivery systems. The kinetics of the PTX release and the in
vitro toxicity from both this covalent system and an analogous construct where the drug was
simply physically encapsulated are also described.
In chapter 4, the principles of chapter 3 are extended, to develop a photo-responsive
micellar carrier based on an amphiphilic photodegradable PEA. The goal is to provide
spatially and temporally controlled drug release in response to light as a stimulus. As in
chapter 3, an ester linkage is used to conjugate the PTX, with the hypothesis that
photochemically induced degradation of the polymer backbone will result in accelerated ester
cleavage through increased exposure of the ester to water upon micelle disruption. The
release kinetics as well as the in vitro toxicities of both photoirradiated and nonphotoirradiated are also discussed.
Chapter 5 describes the design, synthesis, and study of new cross-linked polymer
nanoparticles (nanogel) bearing conjugated Gd-DTPA complexes. The cross-linking
approach is designed to increase the rotational correlation time of the complexes, thereby
affording high relaxivity. The relaxivity as well as the preliminary in vivo evaluation of the
agents is discussed. Although these nanogel agents are prepared from nonbiodegradable
acrylamide-based backbones, PEAs have the potential to be used in a next-generation
biodegradable version of these agents.
Chapter 6 describes the main conclusions and contributions of this thesis as well as some
prospects for future work.
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Chapter 2

2

Structure-property relationships for a series of PEAs
containing amino acids

2.1 Introduction
In recent years there has been significant interest in the development of polymers that
degrade in the environment or under physiological conditions. Biodegradable polymers are
finding increasingly widespread application in a range of biomedical devices such as sutures,
wound dressings, tissue engineering scaffolds, and drug delivery vehicles, as well as for
various food and beverage packaging. Thus far, much effort has been focused on the
development of polyesters such as PLA,1,2 PGA,3,4 and PCL.5-7 However, their application
has been limited to some extent due to their poor hydrolytic and thermal stabilities as well as
their relatively poor mechanical properties, which result from weak intermolecular
interactions.8 Poly(amino acid)s have also been investigated,9-12 but their relatively expensive
and sensitive synthetic approach13 and slow degradation14,15 have also limited their
application. Conversely, the monomers for preparing PEAs are relatively inexpensive and the
synthetic methods do not require inert atmosphere chemistry. PEAs, containing both ester
and amide linkages in their backbones have been proposed as biodegradable polymers that
may address the limitations of polyesters and poly(amino acid)s.16,17 The presence of ester
moieties introduces the possibility for both enzymatic and non-enzymatic hydrolytic
degradation mechanisms similar to those observed for polyesters while amide linkages
provide opportunities for enzymatic degradation.16,18-24 In addition, the interchain hydrogen
bonding interactions imparted by the amide bonds can potentially improve their properties
and processability.25-27
While a wide range of PEA backbones have been developed,16,19,28,29 the PEAs of interest
in the present work are those composed of diols, dicarboxylic acids and -amino acids
(Figure 2.1). This backbone composition is attractive as the monomers can be selected from a
wide range of readily available, non-toxic metabolic intermediates including a diverse array
of natural -amino acids, as well as natural dicarboxylic acids such as succinic and fumaric
acid. A wide variety of PEAs having these structures have been synthesized and
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studied.16,30,31 Their thermal properties21,30 and degradation rates18,19,23,24 have been found to
depend on their specific chemical structures. Recently they have been explored for various
applications including nanoparticles31 and micelles for drug delivery,
coatings,

33,34

and tissue engineering scaffolds.

31,32

vascular stent

35,36

Figure 2.1. General structure of the PEAs.
Despite the promise of PEAs to provide improved processability and mechanical
properties comparable to polyesters, there have been very few studies reported that explore
the effects of PEA structure on their rheological and/or mechanical properties.19,37,38 An
understanding of these properties will be critical to expand the application of PEAs both
within and beyond the biomedical field. To address this, we describe here the synthesis of a
series of PEAs with diverse chemical structures and a study of their thermal, rheological, and
mechanical properties as a function of their structures and molecular weights (MWs). It is
demonstrated that all properties of the PEAs depend significantly on their chemical
structures, with some properties exhibiting a dependence on MW characteristics.

2.2 Experimental section
Polymer nomenclature. The polymers are labeled by the first letter of amino acid (A = Lalanine; P = L-phenylalanine), the first letter of the diol (O = octanediol; B = butanediol; T =
tri(ethylene glycol); C = cyclohexane dimethanol), the first two letters of the dicarboxylic
acid moiety (Se = sebacic acid; Te = terephthalic acid), the method of preparation (Sol =
solution; Int = interfacial) and finally in the case of the interfacial polymerization whether the
polymer was fractionated (P) or unfractionated (U). For example, AOSe-Int-U represents
Alanine-Octanediol-Sebacic acid, prepared by interfacial polymerization and unfractionated.
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General procedures and materials. AOSe, POSe, and PBSe (Figure 2.1) were prepared by
Sol and Int methods as previously reported.35 The polymers prepared by Int method were
either fractionated by just washing the precipitated polymer with water (U) or by water wash
followed by Soxhlet extraction with ethyl acetate for 48 h (P). The polymers prepared by Sol
method were fractionated by soxhlet extraction with ethyl acetate for 48 h. PBTe was
prepared by a Sol method as previously reported30 then was fractionated by dialysis against
DMF with Spectra/Por regenerated cellulose membrane with an 25 kg/mol molecular weight
cutoff (MWCO) for 24 hours with changing of the dialysate every 8 hours, followed by
dialysis against water and lyophilization. Solvents were purchased from Caledon
Laboratories (Georgetown, ON). All other chemicals were purchased from Sigma Aldrich
(Milwaukee, WI). Unless otherwise noted, all chemicals were used as received. Anhydrous
tetrahydrofuran (THF) was obtained from a solvent purification system. N,NDimethylacetamide (DMA) and triethylamine (NEt3) and CH2Cl2 were distilled from CaH2
under argon. 1H (400 MHz) Nuclear Magnetic Resonance (NMR) spectra were obtained on a
Varian Inova 400 spectrometer (Varian Canada Inc., Mississauga, ON). Chemical shifts are
reported in parts per million (ppm) and are calibrated against the residual solvent signals of
dimethyl sulfoxide (DMSO,  2.50 ppm). Infrared (IR) spectra were obtained using a Bruker
Tensor 27 (Bruker Corporation, Milton, ON) as KBr disks. Absorption frequencies of the
functional groups are reported in wavenumbers (cm-1). Size exclusion chromatography (SEC)
data were obtained using a Waters 2695 Separations Module equipped with a Waters 2414
Refractive Index Detector (Waters Limited, Mississauga, ON) and two PLgel 5 μm mixed-D
(300 mm × 7.5 mm) columns connected in series (Varian Canada Inc., Mississauga, ON).
Samples (5 mg/mL) were dissolved in DMF with 10 mM LiBr and 1 % (v/v) NEt3 and were
injected (100 μL) at a flow rate of 1 mL/min at 85 °C. Molecular weights are reported in
kilograms/mole (kg/mol) relative to polystyrene standards.
Synthesis of PBTe by Int polymerization. Terephthaloyl chloride (2.1) (2.7 g, 14 mmol, 1.0
equiv.) was dissolved in anhydrous dichloromethane (60 mL), and then added dropwise over
30 min to an aqueous solution (60 mL) of the di-p-toluenesulfonic acid salt of Lphenylalanine-butanediol diester (2.2)30 (9.9 g, 13.7 mmol, 1.0 equiv.) and sodium carbonate
(2.9 g, 27 mmol, 2.0 equiv.) and the reaction mixture was stirred at room temperature for 17
hours. Upon completion of the reaction, the solvent was removed in vacuo. The resulting
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solid polymer was then washed with water and dried in vacuo to provide PBTe-Int-U (Yield:
5.9 g, 83%); SEC: Mn = 11 kg/mol, Mw = 51 kg/mol, PDI = 4.7. DSC: Tg = 28, 95 C) and
then further fractionated via soxhlet extraction with ethyl acetate for 48 hours and dried in
vacuo yielding polymer 2.4 (4.7 g, Yield: 65%). NMR spectral data agreed with those
previously reported.30 SEC: Mn = 22 kg/mol, Mw = 63 kg/mol, PDI = 2.9. DSC: Tg = 102 C.
Synthesis of PTSe by Int polymerization. This polymer was prepared as described above
for PBTe except that sebacoyl chloride (2.4) (2.2 mL, 11 mmol, 1.0 equiv.) and di-ptoluenesulfonic acid salt monomer (2.3)39 ( 9.0 g, 11 mmol, 1.0 equiv.) were used as the
starting monomers. Upon completion of the reaction, the solvent was removed in vacuo. The
resulting solid polymer was then washed with excess water to remove salts. (5.7 g, Yield =
82 %). NMR spectral data agreed with those previously reported.39 SEC: Mn =41 kg/mol ,
Mw = 73 kg/mol, PDI = 1.8. DSC: Tg = 28 C.
Synthesis of PCSe by Int polymerization. This polymer was prepared as described above
for PBTe except that sebacoyl chloride (2.4) (2.2 mL, 11 mmol, 1.0 equiv.) and di-ptoluenesulfonic acid salt monomer (2.5)40 ( 8.6 g, 11, 1.0 equiv.) were used as the starting
monomers. The polymer was fractionated as described for PTSe (4.7 g, Yield = 68%). 1H
NMR (400 MHz, DMSO-d6): δppm 8.22 (d, J=7.6, 2H), 7.17-7.28 (m, 10H ), 4.44-4.50 (dd,
J= 5.3 and 12.5, 2H), 3.81-3.92 (m, 4H), 2.86-3.03 (m, 4H), 2.04 (t, J= 3.8, 4H), 1.59-1.65
(m, 4H), 1.37-1.40 (m, 8H), 0.85-1.24 (m, 10H). IR: 3292, 3063, 3030, 2927, 2855, 2854,
1739, 1650, 1539, 1498, 1456, 1194. SEC: Mn =17 kg/mol, Mw = 27 kg/mol, PDI = 1.6.
DSC: Tg = 48 °C.
Thermal analysis. Tgs of the polymers were measured by differential scanning calorimetry
(DSC) using a Q1000 from TA Instruments. The procedure was a heat-cool-heat method. In
the initial cycle, which eliminated the thermal history of the polymers, the sample was
equilibrated at -50 °C then heated at 10 °C/min up to 250 °C. The cooling cycle was also
performed at 10 °C/min to a final temperature of -50 °C. Finally, a second heating cycle,
which provided the reported Tgs and Tms, was carried out to complete the thermal analysis.
TG was performed using a Q5000 from TA Instruments. The sample was heated to 600 °C
under argon, at a rate of 10 °C /min, then heated to 800 °C under air for a complete
decomposition.
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X-ray diffraction. X-ray analysis was carried out using a Rigaku Miniflex X-ray Powder
diffractometer fitted with a Cu anode. Scans were made from 4 – 35 degrees 2-Theta with a
fixed Theta/2 Theta geometry and a variable divergence slit.
Rheology. Viscoelastic properties were investigated using an ARES 2000 rheometer
equipped with electrically heated parallel plates. Frequency sweep measurements were
performed at 175 °C over a frequency range of 1–100 rad/s. The plate diameter was 25 mm
and the gap between the plates was 1000 µm. Temperature-dependent studies were
performed using a cooling ramp from 175 °C to 35 °C with a cooling rate of 2 °C /min.
Mechanical properties. Four dog bone shaped polymer strips were cut (25 × 5 × 0.2 mm)
from a polymer film using a punch press (see appendix). Samples dimensions were measured
for each sample using a caliper. Tensile properties were measured on an Instron 3367
equipped with a 50 N load cell at ambient temperature. The cross head speed was set to 5
mm/min according to ASTM D412. The samples were then elongated to failure.

2.3 Results and discussion
2.3.1

Polymer design

As shown in Figure 2.1, six different PEAs having diverse structures were selected for this
study. AOSe and POSe were selected to compare the effects of having L-alanine versus Lphenylalanine as the amino acid component, while maintaining eight-carbon aliphatic chains
in the diol and dicarboxylic acid components. In particular, L-alanine and L-phenylalanine
were selected as PEAs based on these amino acids have been shown to exhibit high
degradation temperatures, facilitating melt processing.18 PBSe was selected to examine the
effect of decreasing the length of the aliphatic chain in the diol moiety. PBTe was chosen to
incorporate a rigid terephthalic acid spacer in the dicarboxylic acid component. PTSe
contains a tri(ethylene glycol) chain, which has been previously demonstrated to impart
semicrystallinity to PEAs with Tms in the region of 60 °C,39 which could be of interest for
various applications. Lastly, the cyclohexane dimethanol component of PCSe was chosen to
investigate the effect of introducing conformational constraints into the diol moiety, while
maintaining an eight-carbon diol unit as in AOSe.
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In addition to varying the constituent monomers, it was also of interest to investigate the
effects of MW and MW distribution on the properties of the polymers. We have previously
found that the method of synthesis and purification of PEAs has a significant effect on their
MW characteristics. Int polymerization often leads to higher MWs than Sol
polycondensations, likely because it is less impacted by the presence of impurities.35 While
the materials prepared by Int polymerization initially have high polydispersity indices (PDIs),
the PDIs can be significantly reduced by purification processes such as dialysis and soxhlet
extraction, which remove lower MW polymers.35 Therefore, for selected polymers (AOSe,
POSe, PBSe, and PBTe) different batches of materials prepared by Sol and Int methods with
and without fractionation were prepared and studied.

2.3.2

Polymer synthesis

AOSe, POSe, and PBSe were prepared by Sol and Int polymerizations as previously
reported.35 The samples designated as U were fractionated by just washing the precipitated
polymer with water to remove salts, while those designated P were fractionated by water
washing followed by soxhlet extraction or dialysis. The MW characteristics of these
polymers, including the number average molecular weight (Mn), weight average molecular
weight (Mw) and PDI are shown in Table 2.1. As expected, the polymers prepared by the Int
method generally had higher MWs than those prepared by the Sol method. The MW was
further increased and the PDIs were narrowed through purification.
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Table 2.1. Molecular weight characteristics of the PEAs.
PEA

Mn (kg/mol)

Mw (kg/mol)

PDI

AOSe-Int-P

40

48

1.2

AOSe-Int-U

16

38

2.4

AOSe-Sol

23

34

1.5

POSe-Int-P

78

93

1.2

POSe-Int-U

35

59

1.7

POSe-Sol

30

48

1.6

PBSe-Int-P

60

102

1.7

PBSe-Int-U

48

91

1.9

PBSe-Sol

41

82

2.0

PBTe-Int-P

22

63

2.9

PBTe-Int-U

11

51

4.7

PBTe-Sol

23

36

1.6

PTSe-Int-U

41

73

1.8

PCSe-Int-U

17

27

1.6

The synthesis of PBTe by the Sol method was performed as previously reported,30 and
the Int polymerization was performed as shown in Scheme 2.1, using terephthaloyl chloride
(2.1), and the di-p-toluenesulfonic acid salt of L-phenylalanine and butanediol (2.3)30. The
product was fractionated as described above for the P and U batches. In this case, the Int-U
prepared polymer had a significantly lower Mn than that prepared in Sol and the PDI was
very high (4.7). This can likely be attributed to the poor solubility of PBTe in CH2Cl2,
whereas its solubility in DMA, the solvent for the Sol polymerization is better. Still, PBTe
eventually precipitates from DMA, likely limiting its molecular weight.
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Scheme 2.1. Synthesis of polymers PBTe, PTSe and PCSe by Int polymerization.
PTSe and PCSe were prepared by only Int polymerization and were fractionated only by
washing with water. While the Sol synthesis of PTSe has been previously reported,41 for this
study it was prepared Int from the di-p-toluenesulfonic acid salt of L-phenylalanine and
tri(ethylene glycol) (2.4)39 and sebacoyl chloride (2.2) (scheme 2.1). PCSe has not previously
been reported and it was prepared interfacially from the di-p-toluenesulfonic acid salt of Lphenylalanine and cis/trans-cyclohexanedimethanol (2.5)40 and 2.2 (Scheme 2.1).

2.3.3

Structure-thermal properties relations

Although the thermal properties of -amino acid-based PEAs have been well studied, it was
important to study in detail the thermal properties of the specific PEAs described in this
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study in order to correlate these properties with the rheological and mechanical properties.
First, TGA was performed in order to determine the decomposition temperatures of the
polymers. As shown in Figure 2.2, all of the polymers were stable up to greater than 300 °C,
with decomposition temperatures (Td) in the range of 325-365 °C (Table 2.2), which should
easily allow for their processing in the melt. Above this temperature, they underwent
decomposition via multiple stages as previously reported for PEAs.42 It should be noted that
PBTe had a higher residual mass than the other polymers, which was expected due to its
thermally stable aromatic hydrocarbon component.

Figure 2.2. Weight loss as a function of temperature for PEAs (Int-U) as measured by TGA.
Table 2.2. Thermal characterization data for PEAs.
PEA
AOSe-Int-P
AOSe-Int-U
AOSe-Sol
POSe-Int-P
POSe-Int-U
POSe-Sol
PBSe-Int-P
PBSe-Int-U
PBSe-Sol
PBTe-Int-P
PBTe-Int-U
PBTe-Sol
PTSe-Int-U
PCSe-Int-U

Td (°C)
355
345
344
364
355
351
345
335
350
338
335
328
359
325

Tg (°C) Tm (°C)
12
190
4
171
19
98, 168
28
103
22
89,163
22
101
40
40
40
102
28, 95
96
28
107
48
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Only minor effects of MW and MW distribution on the degradation temperatures of the
polymers were observed, with a small lowering of the Td, explainable by differences in MW,
a parameter known to affect the decomposition temperature.43,44 However, the Tds were still
all in the range of 325-365 °C (see appendix).
Tgs and melting temperatures (Tms) for the polymers were measured by DSC. As shown
in Table 2.2 and Figure 2.3, AOSe was semicrystalline with Tgs ranging from of 3 to 19 °C
and Tms ranging from 169 to 190 °C depending on the method of preparation. POSe was also
semicrystalline with Tgs ranging from 22 to 28 °C and Tms ranging from 103 to 163 °C. PTSe
was semicrystalline with a Tg of 28 °C and Tm of 107 °C. In comparing POSe with PTSe,
while the length of the spacer between the amino acids is the same in each case (8 atoms), the
lower Tg of the PTSe may be attributed to the increased flexibility of the polyether units in
comparison with the octyl chain. In some cases, multiple melting transitions were observed,
which can likely be attributed to the melting of crystalline domains with different lamellar
thicknesses. This has frequently been observed for polyamides.45

Figure 2.3. Overlay DSC traces for PEAs (Int-U).
PBSe, PBTe, and PCSe were amorphous with Tgs of 40, 28°C and 95-102 °C, and
48 °C respectively. Comparing POSe and PBSe, the Tg appears to decrease as the number of
methylenes in the diol moiety increases. This was expected as the longer chain makes the
polymer more flexible. The pendent phenyl group on the amino acid moiety increased the Tg
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as demonstrated by the comparison between the AOSe and POSe. This can be attributed to
the phenyl group decreasing the flexibility of the polymer, as has been previously observed.30
PBTe and PCSe exhibited the highest Tgs of 95-102 °C and 48 °C respectively. PBTe is
rigidified by the inflexible aromatic acid backbone, which significantly increases the Tg. The
cyclohexyl spacer in PCSe increases the rigidity of the polymer backbone to some extent, by
comparison with POSe, also having a linear eight-carbon spacer. It also makes the polymer
fully amorphous, unlike POSe.
In comparing batches of the same polymer having different MWs and PDIs, a couple of
trends emerged. In general the Tgs and Tms of the lower MW and more polydisperse samples
were lowered, as expected, though not to a great extent. For example, the Tg of POSe-Int-P
was 28 °C, while that of POSe-Int-U and POSe-Sol were 22 °C (Figure 2.4). In addition,
extra transitions were sometimes observed for the lower MW, more polydisperse samples.
For example, additional melting transitions were clearly observed for AOSe-Sol and POSeInt-U. For PBTe-Int-U an additional Tg at 28 °C was observed. This is likely a result of the
very high PDI of 4.71 for this polymer sample. Additional very minor transitions were also
observed for AOSe-Int-U. However, the amorphous polymers remained amorphous and the
semicrystalline polymers remained semicrystalline regardless of the MW characteristics and
the overall changes in thermal properties across the different batches were relatively modest.

Figure 2.4. Overlay of DSC traces for POSe prepared by different methods.
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2.3.4

X-ray diffraction

Powder X-ray diffraction (XRD) was also performed to further assess the molecular
orientations of the polymers. In general, the XRD patterns for amorphous polymers exhibit
very broad peaks, consistent with the incoherent scatter from the amorphous solid, while
crystalline polymers provide multiple sharp peaks consistent with diffraction from a
crystalline lattice. As MW and PDI had only modest effects on thermal properties of the
polymers, only unfractionated polymers prepared by Int-U were studied by XRD. As shown
in Figure 2.5, the XRD results suggested that PBSe, PBTe and PCSe were amorphous,
consistent with the presence of only a glass transition observed in DSC. POSe, PTSe, AOSe
appear to have some degree of crystallinity with several peaks present, which is also in
agreement with the DSC results, showing that these polymers have broad melting peaks.

Figure 2.5. XRD of PEAs a) amorphous PEAs b) semicrystalline PEAs.

2.3.5

Structure-rheological properties correlations

The complex viscosities versus temperature and frequency were measured for all of the
PEAs. The temperature ramp test is a sensitive test to provide information about phase
transitions in polymer structures. As such, it is complementary to DSC and XRD. As shown
in Figure 2.6, the complex viscosity for AOSe-Int-U and POSe-Int-U dramatically increased
as the temperature was lowered from 175 °C to approximately 170 and 140 °C respectively.
DSC showed that these polymers have broad melting transitions in these regions and the
rapid increases in viscosities were likely a result of crystallization. PBTe-Int-U exhibited a
rapid increase in viscosity at approximately 100 °C, likely a result of its glass transition in
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this region. For PBSe-Int-U and PCSe-Int-U, gradual changes in viscosities were observed
over a large temperature rangeas expected based on their thermal properties. In the case of
PTSe-Int-U, the crystallization that was evident in the DSC and XRD results was not
detected in the complex viscosity versus temperature measurements. This can likely be
attributed to the flexible backbone of PTSe, which may require more time to organize into
crystalline domains.

Figure 2.6. Complex viscosity versus temperature for different PEAs.
The viscoelastic effects on the complex viscosity versus temperature were also evaluated
for AOSe, POSe, PBSe, and PBTe (Figure 2.7 and see appendix). It was found that in
general, there were only modest effects resulting from the MW differences. These differences
reflected the differences observed in the Tms and Tgs of these polymers.
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Figure 2.7. Complex viscosity versus temperature for AOSe, showing the effect of MW and
MW distribution.
The complex viscosity versus frequency was also measured for the PEAs. These
measurements were performed at 175 °C, which allowed all of the polymers to be in the melt
state. As shown in Figure 2.8, all of the PEAs exhibited frequency-independent behavior,
suggesting that they exhibit Newtonian behavior for this range of frequencies. The
magnitudes of the complex viscosities were expected to be dependent on both the PEA
chemical structure as well as Mw. It was found that across the diverse PEA structures, there
was no strong correlation between Mw and complex viscosity. For example, PBTe and PCSe
exhibited higher viscosities than would be expected based on a comparison of their Mws to
those of other polymers, suggesting that the chemical structure had the dominant effect. In
the case of these polymers, the presence of the highly rigid aromatic unit in the PBTe
backbone and the cyclohexyl unit in the PCSe backbone may constrain the motion of these
molecules, increasing their viscosities. On the other hand, despite its relatively high M w,
PTSe had the lowest complex viscosity of all the polymers. This is likely due to the flexible
polyether units enhancing the chain motion of this polymer.
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Figure 2.8. Complex viscosity versus frequency for all PEAs (175 °C).
For AOSe, POSe, PBSe, and PBTe (Figure 2.9 and see appendix), the complex viscosities
versus frequency were compared for the Int-P, Int-U, and Sol batches in order to investigate
the effects of MW and polydispersity. As expected, the complex viscosities decreased with
decreasing Mw and increasing PDI. Therefore, this study confirmed that the rheological
properties are highly dependent on both the chemical structures and MWs of the PEAs and
these values can be readily tuned through the choice of selected monomers as well as through
the polymerization method. Furthermore, unlike polyesters, which are sensitive to hydrolytic
degradation and require careful control of the processing conditions,46 it should be possible to
use common processing technique such as extrusion, injection and compression molding to
fabricate PEA materials.

Figure 2.9. Complex viscosity versus frequency for POSe, showing the effect of MW and
MW distribution.
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2.3.6

Tensile testing

Knowledge of the mechanical properties of PEAs is critical to determine their utility in
various applications. For example, in vascular tissue engineering, a soft, tough, and
elastomeric biodegradable polymer which can provide mechanical stability under
physiologically relevant forces would be ideal to mimic the natural form of the extracellular
matrix.47 In this study, the mechanical properties of the PEAs were first evaluated by tensile
testing. Representative stress-strain curves for AOSe-Int-U, POSe-Int-U, PBTe-Int-U, and
PTSe -Int-U are shown in Figure 2.10 and the measured mechanical properties are
summarized in Table 2.3. PBTe-Int-U and PCTe-Int-U were too brittle and it was not
possible to prepare samples for analysis. As shown in Figure 2. 10a, AOSe-Int-U and PBSeInt-U were also brittle with tensile strengths of 4.0 ± 1 and 20 ± 2 MPa, breaking strains of
1.3 ± 0.4 and 2.3 ± 0.3 and Young’s moduli of 372 ± 103 and 1123 ± 220 MPa respectively.
In case of PBSe-Int-U the brittleness was expected as this polymer has a Tg of 40 °C which is
substantially higher than the test temperature of 23 °C. AOSe-Int-U is a semicrytalline
material, and the crystalline domains likely impart brittleness to the material. However, this
result needs to be further investigated.

Figure 2.10. Tensile stress versus tensile strain a) PBSe-Int-U and AOSe-Int-U b) POSe-IntU and PTSe-Int-U.
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Table 2.3. Tensile properties of PEAs.

AOSe-Int-P

Tensile strength a
(MPa)
4 (±1)

Breaking strain a
(%)
1.3 (±0.4)

Young’s modulus a
(MPa)
372 (±103)

AOSe-Int-U

4.5 (±1)

2 (±0.5)

420 (±55)

AOSe-Sol

5.5 (±2)

1.7 (±1)

350 (±60)

POSe-Int-P

2.5 (±0.5)

556 (±74)

5.8 (±1.6)

POSe-Int-U

2.0 (±1)

550 (±50)

4.6 (±2)

POSe-Sol

1.5 (±1)

500 (± 100)

2.9 (±1)

PBSe-Int-P

20 (±2)

2.3 (±0.3)

1123 (±220)

PBSe-Int-U

15 (±3)

3.0 (±0.5)

850 (±80)

PBSe-Sol

25 (±5)

3.5 (±1)

900 (±100)

0.7 (±0.1)

220 (±20)

20 (±13)

PEA

PTSe-Int-U
a

Errors on the measurements represent the standard deviations of four measurements per

sample.
POSe-Int-U and PTSe-Int-U both had lower tensile strengths and Young's moduli
compared to PBSe-Int-U and AOSe-Int-U, but exhibit different behaviours from one another
during extension as illustrated in Figure 2.10b. The tensile properties of POSe-Int-U were
consistent with those of an elastomeric material and were comparable to poly(1,8-octaidiolcitric acid)48 and poly(glycerol-sebacate)47 which have been shown to exhibit promising
mechanical properties for tissue engineering applications. It is interesting to note that POSeInt-U had a maximum elongation of 556 ± 74% at break which is similar to that of the
arterial and venous cellular lining (up to 260%),49 and much larger than that of tendons (up to
18%).50 On the other hand, PTSe had the lowest tensile strength of 0.7 ± 0.1 MPa. After the
necking point, a decrease in stress was observed until the polymer broke at 220 ± 20. This is
likely due to the flexible ether linkages, which may help the chains to slip easily past each
other to relax the stress.
The effect of MW and MW distribution was also investigated for AOSe, POSe, and PBSe
(see appendix and Table 2.3). For AOSe and POSe, the mechanical properties were not
greatly affected by the MW within the limits of the errors on the measurements. This is in
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contrast to the mechanical properties of polyesters, where high MWs are required in order to
obtain the desired mechanical properties. However, for PBSe, which exhibited elastomeric
properties, the expected trend was observed in that decreasing MW and increasing the PDI
tended to reduce the tensile strength, breaking strain, and Young's modulus.

2.4 Conclusions
A series of PEAs having diverse chemical structures were prepared by Int and Sol
polymerization methods to obtain batches of material with different MWs and PDIs. The
effects of PEA chemical structure and MW on the thermal, rheological, and mechanical
properties were studied with the aim of elucidating structure-property relationship. All of the
PEAs were very thermally stable and as expected, the thermal properties were greatly
affected by the chemical structure of the PEA backbone but less so by the MW
characteristics. The rheological behavior was also significantly affected by the chemical
structure and also by the molecular weight, with more flexible PEAs, and those having lower
Mw and higher PDIs resulting in lower viscosities. The mechanical properties of the PEAs
were diverse, ranging from highly brittle solids to elastomeric materials. MW characteristics
affected the mechanical properties of some, but not all of the PEAs. Overall, these results
confirm previous work demonstrating that diverse thermal properties can be obtained by
varying the chemical structure of PEAs but in addition provide a new framework for
understanding the effects of PEA structure on their rheological and mechanical properties as
well as the effects of MW on the thermal, rheological, and mechanical properties. This
should be useful in the design and development of PEAs with optimal properties for specific
applications.
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Chapter 3

3

A comparison of covalent and noncovalent strategies for
PTX delivery using PEA graft copolymer micelles

3.1 Introduction
Over the past few decades there has been significant interest in the development of new drug
delivery systems to address the problematic properties of drug molecules. 1-6 Some common
challenges encountered with current and potential drugs include low aqueous solubility, short
plasma circulation half-life, susceptibility to rapid degradation in plasma, and high toxicity.7,8
For example, PTX is a highly effective chemotherapeutic drug.9 However, due to its very low
water solubility, it is formulated in a mixture of the surfactant CrEL and ethanol (Taxol).10,11
Unfortunately CrEL is known to cause serious side effects, including hypersensitivity
reactions,12 and is also reported to result in unpredictable pharmacokinetic behaviour.13
Because of the challenges associated with the administration of PTX, the development of
improved delivery systems for PTX has been an active area of research.14-16 Albumin-bound
PTX nanoparticles (Abraxane) were approved in 2005 for the treatment of metastatic breast
cancer and in 2012 for the treatment of non-small cell lung cancer.17 Genexol was approved
in Korea in 2007 for breast cancer treatment18 and is currently in phase II clinical
development in the USA.19 A number of different nanoparticle formulations based on
polymers such as PLGA,20 PLA,21,22 PCL,23,24 chitosan,25,26 and HA27,28 have also been
developed. Micellar systems

based on amphiphilic copolymers

such as

PEO-

phosphatidylethanolamine,29 PEO-polyaspartate,30 PEO-PCL,31 PEO-b-PGLA-b-poly(Lphenylalanine)32 and PEO-b-(PLLA-b-PCL)33 have also been investigated. Many of these
systems have very promising antitumor efficacy and lower toxicity than Taxol. However, a
common limitation encountered in such systems20-33 in which the drug molecule is only
encapsulated through hydrophobic interactions with the micelle or nanoparticle core is the
rapid or "burst" release of drug, in which a large percentage of the drug is released rapidly
over the first several hours. This can limit the lifetime of the drug delivery system and in
some cases can result in high systemic toxicity.14
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The burst release of drug molecules can be mitigated through covalent immobilization
strategies. For example, Cheng and coworkers have reported the polymerization of lactide
from the 2'-hydroxyl moiety of PTX, followed by the formation of well-defined spherical
nanoparticles from these conjugates.34,35 Conjugates of dendrimers36,37 and polymers such as
heparin,38 poly((N-(2-hydroxypropyl) methacrylamide),39 and PLGA40,41 have also been
reported, though care must be taken to maintain the water solubilities/dispersibilities of these
systems due to the hydrophobicity of PTX. The development of nanosized micelles with PTX
covalently immobilized at the micelle core is an attractive strategy for controlling the release
of PTX while at the same time allowing excellent water dispersibility and size control of the
assemblies at the nanoscale. However, thus far, there are only a few examples of this
approach. For example PTX has been conjugated to the pendant carboxylic acid groups of
triblock copolymers based on PEO and random copolymers of L-lactide and (3s)benzoxylcarbonylethyl-morpholine-2,5-dione.42 PTX has also been covalently incorporated
into poly(disulfide amine) based micelles, which contained arginine moieties for co-delivery
of drugs and DNA, though the release of PTX was not studied.43 With the aim of pHdependent PTX release, PTX was very recently conjugated to PEO-PAA block copolymers
via acetal linkages and the resulting amphiphilic copolymers were assembled to form
micelles.44
PEAs are a class of polymers comprising both ester and amide linkages in their
backbones. The amide linkages impart the potential for enzymatic degradation, while the
ester linkages can be degraded through both enzymatic and non-enzymatic hydrolysis.45,46
While a variety of PEA backbones have been reported,45 those composed of amino acids,
dicarboxylic acids and diols are particularly attractive as the constituent monomers can be
selected from a variety of readily available and non-toxic molecules. In recent work, this
class of polymers has been investigated in a wide range of biomedical applications including
drug-loaded microparticles,47 tissue engineering scaffolds,48 vascular stent coatings,49,50 and
hydrogels.51,52 The incorporation of amino acids with pendant side chain functional groups
has allowed PEAs to be functionalized to impart specific properties for biomedical
applications. For example, pendant guanidine groups can impart transfection capabilities, 53
carboxylic acids or amines can modulate of cell adhesion and proliferation on polymer
films,48 and protected amines or thiols can be used to trigger PEA backbone degradation
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upon stimulus-induced protecting group cleavage.54 Utilizing the pendant -amino groups of
L-lysine resides in PEAs, our group has recently reported the synthesis of a series of
amphiphilic PEA-PEO graft copolymers and their assembly into micelles in aqueous
solution.55
Using a PEA containing L-aspartic acid, we describe here use of the pendant carboxylic acid
moieties to conjugate PTX via ester linkages, for a slow, controlled release of drug, as well
as PEO chains to impart amphiphilicity, allowing the resulting graft copolymers to assemble
into nanometer-sized micellar drug depots. To demonstrate the effects of covalent drug
immobilization, we compare this system with an analogous PEA micelle in which the PTX is
physically encapsulated. The release rates and in vitro toxicities of these systems are
compared to demonstrate the potential advantages of covalent drug immobilization in this
system.Experimental section
General procedure and methods. All reactions were run under an argon atmosphere unless
otherwise indicated. Flasks were oven dried and cooled in a dessicator prior to use. Starting
monomers56-58 and amine terminated poly(ethylene glycol)59 (PEO-NH2) with MWs of 5
kg/mol were synthesized as previously reported. Unless noted otherwise, all chemicals were
purchased from commercial suppliers and used as received. Anhydrous CH2Cl2 was obtained
by distillation over CaH2. IR spectra were obtained using a Bruker Tensor 27 instrument
either as films from CH2Cl2 on NaCl plates or as KBr pellets. 1H NMR spectra were obtained
at 400 MHz on a Varian Mercury 400 Spectrometer. Chemical shifts are reported in ppm and
are calibrated against residual solvent signals of CDCl3 (δ 7.27) and/or DMSO-d6 (δ 2.54).
All coupling constants (J) are reported in Hz. SEC data were obtained using a Waters 2695
separations module equipped with a Waters 2414 refractive index detector (Waters Limited,
Mississauga, ON, Canda) and two PLgel 5 μm mixed-D (300 mm × 7.5 mm) columns
connected in series (Varian, Canada). Samples (5 mg/mL) dissolved in the eluent, which
comprised 10 mM LiBr and 1 vol% NEt3 in DMF at 85 °C, were injected (100 μL) at a flow
rate of 1 mL/min. Calibrations were performed using polystyrene standards. PTX was
quantified by isocratic reverse-phase HPLC using a Waters 2695 separations module
(Waters, Milford, USA), a Waters 2998 Photodiiode Array Detector and a LiChroCART
125-4 RP-18 column (5 m, MerckMillipore, Damstadt, Germany). The mobile phase
consisted of water/acetonitrile (40:60 v/v).The flow rate was 1.0 mL/min and the detection
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wavelength was 227 nm. 100 μL of the analyte solution were injected. A calibration curve
was prepared for PTX dissolved in water/acetonitrile (40/60 v/v). Dynamic light scattering
(DLS) was performed on a ZetaSizer Nano instrument from Malvern (Worcestershire, UK)..
Dialysis was performed using Spectra/Por 6 regenerated cellulose membranes from Spectrum
Laboratories with a MWCO of 3.5, 12-14, or 50 kg/mol (Rancho Dominguez, CA, USA).
Synthesis of polymer 3.4. To monomer 3.256 (4.1 g, 5.7 mmol, 0.80 equiv) and sodium
carbonate (1.5 g, 14 mmol, 2.0 equiv) in distilled water (30 mL), monomer 3.358 (0.62 g, 1.4
mmol, 0.20 equiv) in CH2Cl2 (15 mL) was added. After mixing the two phases for 30 min,
sebacoyl chloride (3.1) (1.7 mL, 7.0 mmol, 1.0 equiv.) in CH2Cl2 (15 mL) was added
dropwise over 30 min. After completion (ca. 24 h), the organic layer was separated, washed
with water and brine, and evaporated in vacuo. The resulting crude polymer was then
dialyzed against DMF with a 12-14 kg/mol MWCO membrane for 24 h, changing of the
dialysate every 12 h to provide polymer 4 (2.3 g, 60%). 1H NMR (400 MHz, DMSO-d6): δ
8.21 (d, J = 7.8, 2 H), 7.16-7.28 (m, 8 H), 4.53 - 4.60 (m, 0.4 H), 4.41-4.49 (m, 1.6 H), 3.964.05 (m, 4H), 2.96-3.04 (m, 1.6 H), 2.88 (dd, J = 13.6 and 9.4, 1.6H), 2.68 (dd, J = 16.0 and
5.8, 0.4H), 2.53-2.58 (m, 0.4 H), 2.01 - 2.11 (m, 4H), 1.53-1.59 (m, 1H), 1.37-1.45 (m, 10H),
1.12-1.17 (m, 8H). (KBr pellet, cm-1): FTIR 3312, 3065, 3031, 2928, 2856, 1741, 1640,
1542. SEC: Mn = 29 kg/mol, Mw = 41 kg/mol, PDI = 1.4
Synthesis of polymer 3.5. To polymer 3.4 (1.0 g, 1.7 mmol, 1.0 equiv) in CH2Cl2 (1 mL),
trifluoroacetic acid (1 mL) was added and the reaction mixture was stirred for 2 h. After
completion, toluene (15 mL) was added and the solvent was removed in vacuo to provide the
unprotected polymer in quantitative yield. The resulting polymer was then washed with cold
ethyl acetate (5 mL) three times to provide polymer 3.5 (0.98 g, 98%). 1H NMR (400 MHz,
DMSO-d6): δ 8.19 (d, J = 7.8, 2H), 7.17 - 7.28 (m, 8H), 4.54 - 4.57 (m, 0.4H), 4.43 - 4.49 (m,
1.7H), 3.97 - 4.06 (m, 4H), 2.98 - 3.03 (m, 2H), 2.85 - 2.91 (m, 2H), 2.67 - 2.73 (m, 0.4H),
2.56 - 2.62 (m, 0.4H), 2.02 - 2.08 (m, 4H), 1.59 (br s, 0.6H), 1.46 (br s, 4H), 1.38 - 1.40 (m,
2.4H), 1.16 - 1.22 (m, 2H), 1.12 (br s, 8H). FTIR (KBr pellet, cm-1): 3310, 3062, 3030, 2931,
2852, 1741, 1647, 1543.
Synthesis of PEA–PTX conjugate 3.6. To polymer 3.5, (0.20 g, 0.14 mmol of the pendant
carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PTX (0.063 g, 0.07 mmol, 0.5
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equiv), DCC (0.036 g, 0.17 mmol, 2.4 equiv) and 4-(dimethylamine)pryidine (DMAP) (0.014
g, 0.11 mmol, 0.8 equiv) were added. After 12 h, the reaction was warmed to room
temperature and stirred for another 8 h. The reaction was then filtered out to remove the
dicyclohexylurea byproduct and the filtrate was concentrated under vacuum to give the crude
product. The polymer was then purified by dialysis against DMF with 12-14 kg/mol MWCO
membrane for 24 h, changing the dialysate every 12 h to provide 3.6 (0.21 g, 80%). 1H NMR
(400 MHz, DMSO-d6): δ 9.18 (d, J = 7.0, 0.19H), 8.22 (d, J = 7.4, 2H), 7.97 (d, J = 7.4,
0.47H), 7.85 (d, J = 7.4, 0.44H), 7.71 (d, J = 7.0, 0.2H), 7.65 (d, J = 7.0, 0.42H), 7.40 - 7.57
(m, 1.62H), 7.21 - 7.27 (m, 4H), 7.10 - 7.19 (m, 6H), 6.30 (br s, 0.2H), 5.84 - 5.86 (m,
0.21H), 5.542 - 5.65 (m, 0.2H), 5.32 - 5.42 (m, 0.46H), 4.91 - 4.89 (m, 0.38H), 4.51 - 4.69
(m, 0.59H), 4.42 - 4.48 (m, 2H), 3.96 - 4.06 (m, 4H), 3.57 (d, J = 6.3, 0.2H), 2.97 - 3.02 (m,
2H), 2.80 - 2.91 (m, 2H), 2.25 (d, J = 11.3, 0.28H), 2.21 (s, 0.34H), 2.08 - 2.13 (m, 1.08H),
2.03 (t, J = 7.2, 4H), 1.74 - 1.779 (m, 0.51H), 1.50 (br s, 0.88H), 1.41 - 1.45 (m, 3H), 1.34 1.39 (m, 2.38H), 1.06 - 1.15 (m, 8H), 1.03 (br s, 0.85H), 0.99 (br s, 0.66H). IR (thin film, cm1

): 3295, 3063, 3029, 2929, 2855, 1740, 1653, 1540.

Synthesis of PEA–PEO graft copolymer 3.7. To polymer 3.5, (0.20 g, 0.14 mmol of the
pendant carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PEO-NH2 with a
molecular weight of 5 kg/mol (0.35 g, 0.07 mmol, 0.5 equiv), DCC (0.036 g, 0.17 mmol, 2.4
equiv) and DMAP (0.014 g, 0.11 mmol, 0.80 equiv) were added. After 12 h, the reaction was
warmed to room temperature and stirred for another 8 h. The reaction was then filtered to
remove the dicyclohexylurea byproduct and the filtrate was concentrated under vacuum to
give the crude product. The polymer was then purified by dialysis against DMF using a 50
kg/mol MWCO membrane for 24 hours, changing of the dialysate every 8 h, to provide
polymer 3.7 (0.46 g, 87%). 1H NMR (400 MHz, DMSO-d6): δ 8.22 (d, J = 7.6, 2.11H), 7.24 7.25 (m, 4H), 7.16 - 7.22 (m, 6H), 4.53 (br s, 0.38H), 4.45 (q, J = 7.6, 2H), 4.00 (br s,
0.73H), 3.96 (br s, 4H), 3.60 - 3.64 (m, 0.99H), 3.51 (s, 123H), 3.36 - 3.43 (m, 1.87H), 3.24
(s, 0.87H), 2.99 (dd, J = 5.3 and 13.5, 2H), 2.85 - 2.91 (m, 2H), 2.07 (br s, 0.74H), 2.03 (t, J
= 7.0, 4H), 1.58 (br s, 0.9H), 1.42 - 1.47 (m, 4H), 1.38 (br s, 3.52H), 1.18 (br s, 2.33H), 1.12
(br s, 8H). IR (thin film, cm-1): 3429, 3030, 2871, 1958, 1739, 1653, 1540.
Syntheses of PEA–PTX–PEO graft copolymer 3.8. To polymer 3.6 (0.18 g, 0.06 mmol of
the pendant carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PEO-NH2 with a
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molecular weight of 5 kg/mol (0.25 g, 0.05 mmol, 0.8 equiv), DCC (18 mg, 0.09 mmol, 1.3
equiv) and DMAP (7 mg, 0.05 mmol, 0.8 equiv) were added. After 12 h, the reaction was
warmed to room temperature and stirred for another 8 h. The reaction was then filtered to
remove the dicyclohexylurea byproduct and the filtrate was concentrated in vacuo to give the
crude product. The polymer was then purified by dialysis against DMF using a 50 kg/mol
MWCO membrane for 24 h, changing of the dialysate every 8 h to provide polymer 3.8 (0.35
g, 79%). 1H NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 6.6, 0.13H), 8.22 (d, J = 7.8, 2.19H),
7.97 (d, J = 7.8, 0.5H), 7.85 (d, J = 7.8, 0.4H), 7.71 (d, J = 7.0, 0.2H), 7.64 - 7.67 (m, 0.43H),
7.44 - 7.53 (m, 1.68H), 7.23 - 7.27 (m, 4H), 7.16 - 7.21 (m, 6H), 6.30 (s, 0.18H), 5.84 (t,
0.18H), 5.56 (t, J = 8.20 Hz, 0.17H), 5.35 - 5.43 (m, 0.45H), 4.90 (d, J = 4.69, 0.37H), 4.61 4.63 (m, 0.39H), 4.43 - 4.48 (m, 2H), 3.96 (br s, 4H), 3.67 - 3.69 (m, 0.41H), 3.51 (s, 61H),
3.32 (br s, 2,.9H), 3.00 (dd, J = 5.5 and 13.7, 2H), 2.88 (dd, J = 9.4 and 13.7, 2H), 2.21 - 2.27
(m, 0.57H), 2.08 (br s, 0.97H), 1.99 - 2.05 (m, 4H), 1.73 - 1.77 (m, 0.56H), 1.50 (br s, 1H),
1.41 - 1.45 (m, 4H), 1.38 (br s, 2.58H), 1.11 (br s, 8H), 1.03 (br s, 0.74H), 0.99 (br s, 0.62H).
IR (thin film, cm-1): 3292, 3063, 2890, 1740, 1653, 1540. SEC: Mn = 35 kg/mol, Mw = 100
kg/mol, PDI = 2.8
Micelle formation. (a) Micelles containing covalently conjugated PTX (cov-PEA-PTXmicelles): The PEA-PEO-PTX graft copolymer 3.8 (2.0 mg) was dissolved in THF (0.2 mL).
The solution was stirred rapidly while distilled water was rapidly added to provide a final
volume of 2 mL. THF was then removed by dialysis against distilled water using 12–14
kg/mol MWCO membrane. The micelle solution was then filtered with a microfilter (pore
size: 0.45 μm, Tuffryn® syringe filter, PALL) to eliminate the aggregated particles and dust
prior to size determination.. (b) Micelles containing physically encapsulated PTX (noncovPEA-PTX-micelles): PEA-PEO graft copolymer 3.7 (2.0 mg) was added to 0.15 mL of PTX
in THF (1 mg/mL) and then diluted to 2 mL with water. The THF was then evaporated. Free
PTX was removed by filtration through 0.45 μm filter.
Transmission electron microscopy (TEM). The micelle suspension (prepared as described
above, 20 μL of 0.1 mg/mL) was placed on a Formvar/Carbon grid and was left to stand for 5
min. The excess solution was then blotted off using a piece of filter paper. The resulting
sample was dried in air overnight before imaging. Imaging was performed using a Phillips
CM10 microscope operating at 80 kV with a 40 μm aperture.
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In vitro release of PTX from cov-PEA-PTX-micelles. The in vitro release of PTX was
evaluated by a dialysis method. 2 mL of micelles (PTX concentration: 100μg/mL) were
placed into a pre-swollen dialysis bag with a 3.5 kg/mol MWCO and immersed into 500 mL
of 10 mM phosphate buffer at 37 °C. Dialysis was performed with gentle stirring and the
amount of PTX released into media was measured by HPLC every 24 h for 14 days. At each
time point, an aliquot of 15 mL of the dialysate was withdrawn and the dialysate was
replaced with fresh media. Then, the aliquot was removed via lyophilization and the solid
was redissolved in 1 mL of 60:40 water:acetonitrile. The solution was filtered with a 0.2 μm
pore size (Tuffryn® syringe filter, PALL) filter into a vial for detection of the PTX
concentration by HPLC as described above. The cumulative PTX release was calculated. The
release experiments were conducted in triplicate, and the results presented are the mean 
standard deviation.
In vitro release of PTX from noncov-PEA-PTX-micelles. The release procedure was
performed as described above for PTX-loaded micelles except that dialysis was performed
for 48 h and the amount of PTX released into the media was measured at 1, 2, 3, 5, 7, 8, 10,
24, and 48 h. At each time point, an aliquot of the dialysate (15 mL) was withdrawn and
replaced with an equal volume of fresh buffer. After 48 h, the amount of PTX remaining in
the dialysis bag was also measured using the same method. The release experiments were
conducted in triplicate, and the results presented as the mean  standard deviation.
In vitro anti-tumoral activity. HeLa cells were cultured at 37 °C and 5% CO2 in Dulbecco’s
Modified Eagle Medium (DMEM)(Invitrogen) supplemented with 10% (vol/vol) fetal bovine
serum (Invitrogen) and antibiotics (penicillin and streptomycin, 100 units/mL each). The
cells were seeded into a Nunclon® 96-well U bottom transparent polystrol plate at a density
of 2500 cells per well in a final volume of 100 μL of DMEM. Cells were allowed to adhere
for 24 h at 37 °C in a humidified incubator with 5% CO2. Next, the growth medium was
aspirated and was replaced with either the positive control - sodium dodecyl sulfate (SDS) in
the cell culture medium at concentrations of 0.2, 0.15, 0.10, or 0.05 mg/mL, just the medium
or testing materials. The cells were incubated with cov-PEA-PTX-micelles and noncov-PEAPTX-micelles at PTX concentrations of 25, 12.5, 6.2, 2.5, 1.2, 0.62, 0.31 ng/mL. Micelles
without drug were also prepared as described above and evaluated at concentrations from
300, 30, 15, 7.5, 3.6, 1.5 and 0.37 ng/mL. For comparison, PTX solubilized in CrEL/ethanol
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was prepared according to Lee et al.60 In short, 6 mg of PTX was dissolved in 0.5 mL of
dehydrated ethanol and to this solution 0.5 mL CrEL was added. This mixture was then
sonicated for 30 min. This sample diluted to provide the same PTX concentrations as above.
A control formulation without PTX was prepared using 1/1 CrEL/ethanol. This solution was
diluted similar to similar CrEL/ethanol concentrations used in the PTX formulations
described above to evaluate the toxicity of the vehicle. Eight replicates per concentration
were performed. After 72 h, the media were aspirated and replaced with 110 μL of fresh
medium

containing

0.5

mg/mL

(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide) (MTT) reagent. After 4 h of incubation (37 °C, 5% CO2), the MTT solution was
carefully aspirated and the purple crystals were dissolved by addition of 50 μL of
spectroscopic grade DMSO. After shaking (1 second, 2 mm amp, 654 rpm), the absorbance
of the wells at 540 nm was read using an M1000-Pro plate reader (Tecan). The absorbance of
wells not containing cells but treated by all of the above steps was subtracted as a
background and the cell viability was calculated relative to wells containing cells that were
exposed to just culture medium. No (0%) cell viability was detected for the cells exposed to
the highest concentrations of the positive control sodium lauryl sulfate, confirming the
sensitivity of the assay.

3.2 Results and discussion
3.2.1

Polymer design and synthesis

A PEA backbone based on L-phenylalanine, L-aspartic acid, 1,4-butanediol, and sebacic acid
was selected based on its ease of synthesis by an interfacial method and the presence of
carboxylic acid functional handles for conjugation of the hydrophobic PTX and a hydrophilic
polymer PEO. PEO was chosen as the hydrophilic block for grafting due to its high water
solubility, known biocompatibility in drug delivery applications, and its stealthy properties in
vivo.61,62 Monomers 3.2 and 3.3 (Scheme 3.1) were prepared as previously reported. An
80/20 ratio of 3.2/3.3 was selected for random incorporation into the polymer backbone as
this would allow for sufficient content of PEO and PTX to be conjugated, while still allowing
reasonably high MW polymers to be obtained, as the MW tends to decrease with increased
incorporation of monomers with functional handles.63,64 As shown in Scheme 3.1, an
interfacial polymerization was performed between sebacoyl chloride (3.1) and monomers 3.2
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and 3.3 to provide PEA 3.4. The resulting material had a Mw of 41 kg/mol and a PDI of 1.4,
as measured by SEC in DMF relative to polystyrene standards. Treatment of this polymer
with 1/1 TFA/CH2Cl2 afforded the corresponding carboxylic acid functionalized PEA 3.5.
PEAs having pendant carboxylic acid moieties could not be characterized by SEC due to
interactions of these polar moieties with the column.

Scheme 3.1. Polymer synthesis and functionalization.
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The reaction of PEA 3.5 with 0.5 equivalents of PTX per carboxylic acid moiety in the
presence of DCC and DMAP provided PEA-PTX conjugate 3.6, having 24 wt% PTX,
corresponding to a coupling yield of 90 %. Alternatively, 0.8 equivalents of PEO-NH2 with a
MW of 5 kg/mol under the same conditions afforded the corresponding the PEA-PEO graft
copolymer 3.7 having 50 wt% PEO. An attempt to couple 0.5 equivalents of PTX and 0.5
equivalents of PEO-NH2 simultaneously was unsuccessful, likely due to the coupling of PEO
preventing the subsequent coupling of PTX via steric hindrance, as PEO has a large
hydrodynamic volume. However, it was possible to couple PEO-NH2 to the PEA-PTX
conjugate 3.6 to provide the target PEA-PTX-PEO graft copolymer drug conjugate 3.8. The
resulting polymers were purified by dialysis in DMF followed by water. The PTX and PEO
contents of polymer 3.8 were determined by 1H NMR spectroscopy to be 10 wt% and 50
wt% respectively (see appendix). The resulting polymer had a Mw of 100 kg/mol and a PDI
of 2.8. This PDI is relatively high, but is of less concern for a biodegradable polymer such as
a PEA than for a nondegradable polymer. As the aim is to administer the polymer is as a selfassembled micelle, it is the PDI of the micelles that will be more critical in achieving
uniform and reproducible biological behaviour.

3.2.2

Preparation and characterization of micelles.

A nanoprecipitation method was used to prepare the micelles. To obtain the micelles with
covalently conjugated drug (cov-PEA-PTX-micelle), PEA-PTX-PEO (3.8) was dissolved in
THF, and then water was added with rapid stirring. Finally, THF was removed by dialysis. A
Z-average micelle diameter and PDI of 43  1 and 0.09 respectively were measured by DLS
(Figure 3.1a). This size is ideal for in vivo applications as they can circulate in the blood
without rapid removal by the RES system.
For comparison, PEA-PEO (3.7) was used to prepare micelles with physically
encapsulated PTX (noncov-PEA-PTX-micelle). This was accomplished by dissolving both
5.7 and PTX in THF, followed by water addition and THF evaporation. Filtration through a
0.45 m filter was used to remove unencapsulated PTX, which is essentially insoluble in
water. HPLC was used to measure the efficiency of drug encapsulation in these micelles and
it was found to be 98% (see appendix). In this case, the micelles had a diameter of 80  2 nm
and a PDI of 0.15 as determined by DLS (Figure 3.1a). The larger micelle size in this case

77

can perhaps be explained by the higher hydrophilicity of the micelle core resulting in less
densely packed micelle cores.
TEM was used to image the micelles. As shown in Figures 3.1b and 3.1c, the solid
spherical structures of the micelles were confirmed. Cov-PEA-PTX-micelles had diameters
on the order of 25 nm while the noncov-PEA-PTX-micelles had diameters on the order of 50
nm. This size reduction with respect to the DLS measurements is likely a result of the
difference between the hydrated micelles measured in solution versus the micelles in the dry
state measured by TEM.

Figure 3.1. a) Representative DLS traces of micelles, b) TEM image of cov-PEA-PEOmicelles, c) TEM image of noncov-PEA-PTX-micelles.

3.2.3

In vitro release of PTX from micelles.

The in vitro release proﬁles of PTX from cov-PEA-PTX-micelles and noncov-PEA-PTXmicelles were evaluated using a dialysis method in pH 7.4 phosphate buffer solution at 37
°C. The cumulative release percentages are shown in Figure 3.2. As expected, for cov-PEAPTX-micelles, no initial burst release was observed and the release profile was almost linear
over a period of 14 days, with approximately 40% cumulative drug release over this period
(Figure 3.2a). The slow release of drug can be attributed to the requirement for ester
hydrolysis to occur within the hydrophobic environment of the micelle core, followed by
diffusion out of the micelles core. In contrast, the release of PTX from noncov-PEA-PTXmicelles was much more rapid, with 35% of the PTX released over the first 11 h and more
than 70% over 25 h (Figure 3.2b). In this case the release is controlled by diffusion as a result
of the partitioning between the micelle core and the large volume of aqueous buffer.
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Figure 3.2. In vitro release of PTX from a) cov-PEA-PTX-micelles and b) noncov-PEAPTX-micelles at 37 °C in pH 7.4 phosphate buffer. Data represent the mean and standard
deviation of three independent experiments.

3.2.4

In vitro anti-tumoral activity.

The in vitro cytotoxic activities of the different micelle compositions were evaluated using
MTT assays65 in the HeLa cell line. For comparison, the cytotoxicities of empty micelles,
PTX formulated with its vehicle (50/50 CrEL/ethanol) and the vehicle alone were also
investigated. As shown in Figure 3.3a, PTX formulated with its vehicle was toxic at
concentrations of 6.2 ng/mL and higher. However, the CrEL/ethanol vehicle alone was toxic
at these concentrations, suggesting that it contributes to some extent to the toxicity of this
formulation. As shown in Figure 3.3b, the polymer micelle formulations of PTX were toxic
at similar concentrations to the CrEL/ethanol formutions, with cov-PEA-PTX-micelles
exhibiting toxicity at 6.2 ng/mL and higher and noncov-PEA-PTX-micelles at 2.5 ng/mL and
higher. In general, the cov-PEA-PTX-micelles were less toxic than the noncovalent system,
consistent with the slower release of drug from this system. However, both systems were
highly toxic, suggesting that they may exhibit high anti-cancer activity. In addition, no
toxicity was observed for micelles of copolymer 3.7 formulated without drug at the same
concentrations, suggesting that the vehicle is less toxic that CrEL/ethanol and may be better
tolerated (see appendix).
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Figure 3.3. In vitro cytotoxicity of PTX formulations as measured by the MTT assay
following a 72 h incubation with HeLa cells: a) PTX formulated in CrEL/ethanol and the
CrEL/ethanol vehicle alone; b) cov-PEA-PTX-micelles, noncov-PEA-PTX-micelles.

3.3 Conclusions
In conclusion, we have developed micelles based on PEA-PEO graft copolymers with
covalently conjugated PTX for sustained drug release and have compared their micellization,
PTX release profile, and in vitro toxicity to that of a similar system with noncovalently
encapsulated drug. It was found that the cov-PEA-PTX-micelles exhibit smaller diameters
than the noncov-PEA-PTX micelles and exhibit much slower release of PTX, as expected
due to the requirement for hydrolytic ester cleavage at the hydrophobic micelle core. Both
the cov-PEA-PTX-micelles and noncov-PEA-PTX-micelles exhibit high toxicity towards
HeLa cancer cells, comparable to that of PTX formulated in CrEL/ethanol, while the PEA
vehicle is less toxic than CrEL/ethanol. Overall, these results suggest that PEA-based
micelles are highly promising delivery vehicles for PTX, and that the rate of drug release can
be readily tuned through covalent or noncovalent drug incorporation, or perhaps a
combination of both. Future work will involve their development for in vivo evaluation as
well as the development of actively targeted analogues of these micelles.

80

3.4 References
1.
Backer, M. V.; Aloise, R.; Przekop, K.; Stoletov, K.; Backer, J. M., Molecular
Vehicles for Targeted Drug Delivery. Bioconjugate Chemistry 2002, 13 (3), 462-467.
2.
Liu, S.; Maheshwari, R.; Kiick, K. L., Polymer-based therapeutics. Macromolecules
2009, 42 (1), 3-13.
3.
Moughton, A. O.; Hillmyer, M. A.; Lodge, T. P., Multicompartment Block Polymer
Micelles. Macromolecules 2011, 45 (1), 2-19.
4.
Müller, R. H.; Mäder, K.; Gohla, S., Solid lipid nanoparticles (SLN) for controlled
drug delivery – a review of the state of the art. European Journal of Pharmaceutics and
Biopharmaceutics 2000, 50 (1), 161-177.
5.
Oh, Y.-K.; Senter, P. D.; Song, S.-C., Intelligent drug delivery systems. Bioconjugate
Chemistry 2009, 20 (10), 1813-1815.
6.
Rösler, A.; Vandermeulen, G. W. M.; Klok, H.-A., Advanced drug delivery devices
via self-assembly of amphiphilic block copolymers. Advanced Drug Delivery Reviews 2012,
64, Supplement (0), 270-279.
7.
Uhrich, K. E.; Cannizzaro, S. M.; Langer, R. S.; Shakesheff, K. M., Polymeric
Systems for Controlled Drug Release. Chemical Reviews 1999, 99 (11), 3181-3198.
8.
Arias, J., Drug targeting strategies in cancer treatment: an overview. Mini Reviews in
Medicinal Chemistry 2011, 11 (1), 1-17.
9.
Rowinsky, E. K.; Donehower, R. C., Drug therapy: Paclitaxel (taxol). New England
Journal of Medicine 1995, 332 (15), 1004-1014.
10.
Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, S.
W.; Doyle, T. W., Synthesis and antitumor evaluation of water soluble taxol phosphates.
Bioorganic and Medicinal Chemistry Letters 1993, 3 (6), 1357-1360.
11.
Gennari, A.; Salvadori, B.; Tognoni, A.; Conte, P. F., Rapid intravenous
premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel [3].
Annals of Oncology 1996, 7 (9), 978-979.
12.
Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A., Cremophor EL: The
drawbacks and advantages of vehicle selection for drug formulation. European Journal of
Cancer 2001, 37 (13), 1590-1598.
13.
Sparreboom, A.; van Tellingen, O.; Nooijen, W. J.; Beijnen, J. H., Nonlinear
pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor
EL. Cancer research 1996, 56 (9), 2112-2115.

81

14.
Ma, P.; Mumper, R. J., Paclitaxel nano-delivery systems: A comprehensive review.
Journal of Nanomedicine & Nanotechnology 2013, 4:164.DOI: 10.4172/21577439.1000164.
15.
Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H.,
Paclitaxel: a review of adverse toxicities and novel delivery strategies. 2007, 6, 609-621.
16.
Singh, S.; Dash, A. K., Paclitaxel in cancer treatment: perspectives and prospects of
its delivery challenges. Critical Reviews™ in Therapeutic Drug Carrier Systems 2009, 26
(4).
17.
Green, M.; Manikhas, G.; Orlov, S.; Afanasyev, B.; Makhson, A.; Bhar, P.; Hawkins,
M., Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the
treatment of advanced non-small-cell lung cancer. Annals of Oncology 2006, 17 (8), 12631268.
18.
Montana, M.; Ducros, C.; Verhaeghe, P.; Terme, T.; Vanelle, P.; Rathelot, P.,
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various
cancers. Journal of Chemotherapy 2011, 23 (2), 59-66.
19.
Kim, T.-Y.; Kim, D.-W.; Chung, J.-Y.; Shin, S. G.; Kim, S.-C.; Heo, D. S.; Kim, N.
K.; Bang, Y.-J., Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free,
polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clinical
Cancer Research 2004, 10 (11), 3708-3716.
20.
Feng, S.-S.; Zeng, W.; Teng Lim, Y.; Zhao, L.; Yin Win, K.; Oakley, R.; Hin Teoh,
S.; Hang Lee, R. C.; Pan, S., Vitamin E TPGS-emulsified poly (lactic-co-glycolic acid)
nanoparticles for cardiovascular restenosis treatment. 2007.
21.
Dong, Y.; Feng, S.-S., In vitro and in vivo evaluation of methoxy polyethylene
glycol–polylactide (MPEG–PLA) nanoparticles for small-molecule drug chemotherapy.
Biomaterials 2007, 28 (28), 4154-4160.
22.
Pan, J.; Feng, S.-S., Targeted delivery of paclitaxel using folate-decorated poly
(lactide)–vitamin E TPGS nanoparticles. Biomaterials 2008, 29 (17), 2663-2672.
23.
Dordunoo, S. K.; Jackson, J. K.; Arsenault, L. A.; Oktaba, A. M. C.; Hunter, W. L.;
Burt, H. M., Taxol encapsulation in poly (ɛ-caprolactone) microspheres. Cancer
Chemotherapy and Pharmacology 1995, 36 (4), 279-282.
24.
Devalapally, H.; Duan, Z.; Seiden, M. V.; Amiji, M. M., Paclitaxel and ceramide
co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome
drug resistance in ovarian cancer. International Journal of Cancer 2007, 121 (8), 1830-1838.
25.
Saravanakumar, G.; Min, K. H.; Min, D. S.; Kim, A. Y.; Lee, C.-M.; Cho, Y. W.;
Lee, S. C.; Kim, K.; Jeong, S. Y.; Park, K., Hydrotropic oligomer-conjugated glycol chitosan
as a carrier of paclitaxel: Synthesis, characterization, and in vivo biodistribution. Journal of
Controlled Release 2009, 140 (3), 210-217.

82

26.
Hu, F.-Q.; Ren, G.-F.; Yuan, H.; Du, Y.-Z.; Zeng, S., Shell cross-linked stearic acid
grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel.
Colloids and Surfaces B: Biointerfaces 2006, 50 (2), 97-103.
27.
Al-Ghananeem, A. M.; Malkawi, A. H.; Muammer, Y. M.; Balko, J. M.; Black, E. P.;
Mourad, W.; Romond, E., Intratumoral delivery of paclitaxel in solid tumor from
biodegradable hyaluronan nanoparticle formulations. Aaps Pharmscitech 2009, 10 (2), 410417.
28.
Luo, Y.; Ziebell, M. R.; Prestwich, G. D., A hyaluronic acid-taxol antitumor
bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1 (2), 208-218.
29.
Krishnadas, A.; Rubinstein, I.; Önyüksel, H., Sterically stabilized phospholipid mixed
micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharmaceutical
research 2003, 20 (2), 297-302.
30.
Hamaguchi, T.; Matsumura, Y.; Suzuki, M.; Shimizu, K.; Goda, R.; Nakamura, I.;
Nakatomi, I.; Yokoyama, M.; Kataoka, K.; Kakizoe, T., NK105, a paclitaxel-incorporating
micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the
neurotoxicity of paclitaxel. British Journal of Cancer 2005, 92 (7), 1240-1246.
31.
Yang, R.; Meng, F.; Ma, S.; Huang, F.; Liu, H.; Zhong, Z., Galactose-decorated
cross-linked biodegradable poly(ethylene glycol)-b-poly(ε-caprolactone) block copolymer
micelles for enhanced hepatoma-targeting delivery of paclitaxel. Biomacromolecules 2011,
12 (8), 3047-3055.
32.
Desale, S. S.; Cohen, S. M.; Zhao, Y.; Kabanov, A. V.; Bronich, T. K., Biodegradable
hybrid polymer micelles for combination drug therapy in ovarian cancer. Journal of
Controlled Release 2013.
33.
Tyrrell, Z. L.; Shen, Y.; Radosz, M., Multilayered nanoparticles for controlled release
of paclitaxel formed by near-critical micellization of triblock copolymers. Macromolecules
2012, 45 (11), 4809-4817.
34.
Tong, R.; Cheng, J., Paclitaxel-initiated, controlled polymerization of lactide for the
formulation of polymeric nanoparticulate delivery vehicles. Angewandte Chemie 2008, 120
(26), 4908-4912.
35.
Tong, R.; Cheng, J., Drug-initiated, controlled ring-opening polymerization for the
synthesis of polymer–drug conjugates. Macromolecules 2012, 45 (5), 2225-2232.
36.
Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T.,
Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and
anticancer effect of paclitaxel. Bioconjugate Chemistry 2006, 17 (6), 1464-1472.
37.
Majoros, I. J.; Myc, A.; Thomas, T.; Mehta, C. B.; Baker, J. R., PAMAM dendrimerbased multifunctional conjugate for cancer therapy: Synthesis, characterization, and
functionality. Biomacromolecules 2006, 7 (2), 572-579.

83

38.
Wang, Y.; Xin, D.; Liu, K.; Zhu, M.; Xiang, J., Heparin− paclitaxel conjugates as
drug delivery system: Synthesis, self-assembly property, drug release, and antitumor
Activity. Bioconjugate Chemistry 2009, 20 (12), 2214-2221.
39.
Terwogt, J. M. M.; ten Bokkel Huinink, W. W.; Schellens, J. H.; Schot, M.; Mandjes,
I. A.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H., Phase I
clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymerconjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12 (4), 315-323.
40.
Galic, V. L.; Wright, J. D.; Lewin, S. N.; Herzog, T. J., Paclitaxel poliglumex for
ovarian cancer. Expert Opinion on Investigational Drugs 2011, 20 (6), 813-821.
41.
Singer, J. W., Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular
taxane. Journal of Controlled Release 2005, 109 (1), 120-126.
42.
Xie, Z.; Guan, H.; Chen, X.; Lu, C.; Chen, L.; Hu, X.; Shi, Q.; Jing, X., A novel
polymer–paclitaxel conjugate based on amphiphilic triblock copolymer. Journal of
Controlled Release 2007, 117 (2), 210-216.
43.
Nam, K.; Nam, H. Y.; Kim, P.-H.; Kim, S. W., Paclitaxel-conjugated PEG and
arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and
gene. Biomaterials 2012, 33 (32), 8122-8130.
44.
Gu, Y.; Zhong, Y.; Meng, F.; Cheng, R.; Deng, C.; Zhong, Z., Acetal-linked
paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer
therapy. Biomacromolecules 2013, 14 (8), 2772-2780.
45.
Rodriguez-Galan, A.; Franco, L.; Puiggali, J., Degradable poly(ester amide)s for
biomedical applications. Polymers 2011, 3 (1), 65-99.
46.
Katsarava, R.; Gomurashvili, Z., Biodegradable polymers composed of naturally
occurring α-amino acids. In Handbook of Biodegradable Polymers, Wiley-VCH Verlag
GmbH & Co. KGaA: 2011; pp 107-131.
47.
Guo, K.; Chu, C., Biodegradable and injectable paclitaxel‐loaded poly (ester amide) s
microspheres: Fabrication and characterization. Journal of Biomedical Materials Research
Part B: Applied Biomaterials 2009, 89 (2), 491-500.
48.
Knight, D. K.; Gillies, E. R.; Mequanint, K., Strategies in functional poly(ester
amide) syntheses to study human coronary artery smooth muscle cell interactions.
Biomacromolecules 2011, 12 (7), 2475-2487.
49.
Lee, S. H.; Szinai, I.; Carpenter, K.; Katsarava, R.; Jokhadze, G.; Chu, C. C.; Huang,
Y.; Verbeken, E.; Bramwell, O.; De Scheerder, I.; Hong, M. K., In-vivo biocompatibility
evaluation of stents coated with a new biodegradable elastomeric and functional polymer.
Coronary Artery Disease 2002, 13 (4), 237-241.
50.
Defife, K. M.; Grako, K.; Cruz-Aranda, G.; Price, S.; Chantung, R.; MacPherson, K.;
Khoshabeh, R.; Gopalan, S.; Turnell, W. G., Poly(ester amide) co-polymers promote blood

84

and tissue compatibility. Journal of Biomaterials Science, Polymer Edition 2009, 20 (11),
1495-1511.
51.
Park, Y. D.; Tirelli, N.; Hubbell, J. A., Photopolymerized hyaluronic acid-based
hydrogels and interpenetrating networks. Biomaterials 2003, 24 (6), 893-900.
52.
Pang, X.; Chu, C. C., Synthesis, characterization and biodegradation of poly(ester
amide)s based hydrogels. Polymer 2010, 51 (18), 4200-4210.
53.
Yamanouchi, D.; Wu, J.; Lazar, A. N.; Craig Kent, K.; Chu, C.-C.; Liu, B.,
Biodegradable arginine-based poly(ester-amide)s as non-viral gene delivery reagents.
Biomaterials 2008, 29 (22), 3269-3277.
54.
Mejia, J. S.; Gillies, E. R., Triggered degradation of poly (ester amide) s via
cyclization of pendant functional groups of amino acid monomers. Polymer Chemistry 2013,
4, 1969-1982.
55.
Zilinskas, G. J.; Soleimani, A.; Gillies, E. R., Poly (ester amide)-Poly (ethylene
oxide) Graft Copolymers: Towards Micellar Drug Delivery Vehicles. International Journal
of Polymer Science 2012, 2012.
56.
Guo, K.; Chu, C. C.; Chkhaidze, E.; Katsarava, R., Synthesis and characterization of
novel biodegradable unsaturated poly(ester amide)s. Journal of Polymer Science Part A:
Polymer Chemistry 2005, 43 (7), 1463-1477.
57.
Hashida, M.; Takemura, S.; Nishikawa, M.; Takakura, Y., Targeted delivery of
plasmid DNA complexed with galactosylated poly(l-lysine). Journal of Controlled Release
1998, 53 (1-3), 301-310.
58.
Atkins, K. M.; Lopez, D.; Knight, D. K.; Mequanint, K.; Gillies, E. R., A versatile
approach for the syntheses of poly(ester amide)s with pendant functional groups. Journal of
Polymer Science Part A: Polymer Chemistry 2009, 47 (15), 3757-3772.
59.
Zalipsky, S., Functionalized poly(ethylene glycols) for preparation of biologically
relevant conjugates. Bioconjugate Chemistry 1995, 6 (2), 150-165.
60.
Cheon Lee, S.; Kim, C.; Chan Kwon, I.; Chung, H.; Young Jeong, S., Polymeric
micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for
paclitaxel. Journal of Controlled Release 2003, 89 (3), 437-446.
61.
Harris, J. M.; Chess, R. B., Effect of pegylation on pharmaceuticals. Nature Reviews
Drug Discovery 2003, 2 (3), 214-221.
62.
Greenwald, R. B.; Conover, C. D.; Choe, Y. H., Poly (ethylene glycol) conjugated
drugs and prodrugs: a comprehensive review. Critical Reviews™ in Therapeutic Drug
Carrier Systems 2000, 17 (2).

85

63.
Knight, D. K.; Gillies, E. R.; Mequanint, K., Strategies in functional poly (ester
amide) syntheses to study human coronary artery smooth muscle cell interactions.
Biomacromolecules 2011, 12 (7), 2475-2487.
64.
De Wit, M. A.; Wang, Z.; Atkins, K. M.; Mequanint, K.; Gillies, E. R., Syntheses,
characterization, and functionalization of poly(ester amide)s with pendant amine functional
groups. Journal of Polymer Science Part A: Polymer Chemistry 2008, 46 (19), 6376-6392.
65.

Freshney, R. I., Culture of specific cell types. Wiley Online Library: 2005.

86

Chapter 4

4

Controlled release of PTX from biodegradable PEAs using
UV light as a trigger

4.1 Introduction
In recent years, a wide variety of drug delivery systems have been developed to address the
problematic properties of drug molecules, such as low aqueous solubility, short plasma
circulation time, rapid in vivo degradation and systemic toxicity. The incorporation of
therapeutics into polymeric systems such as nanoparticles, micelles, liposomes, or
polymersomes has been shown to result in enhanced drug solubility/dispersibility, increased
plasma half-life, reduced toxicity, and even enhanced therapeutic efficacy through targeting
to the therapeutic site via EPR effect or through the conjugation of active targeting ligands.1-4
In an optimized case, a drug delivery system would retain its payload during systemic
circulation and release it selectively at the therapeutic target.5 With the aim of achieving this,
stimuli-responsive polymeric materials have been developed for controlled-release drug
delivery systems.6-10
Among the various polymeric systems that have been investigated for drug delivery,
micelles are particularly attractive and have been widely investigated.11-13 They are typically
formed via the self-assembly of amphiphilic copolymers to form sub-100 nm structures
comprising hydrophobic core regions that can serve as reservoirs for hydrophobic drugs, and
hydrophilic shells that stabilize the micellar structure. Their small size and hydrophilic
surface avoid recognition and uptake by the macrophages of RES after intravenous
administration, a crucial requirement for achieving prolonged residence time in the blood
compartment.5 This feature allows accumulation in tumor and other pathological tissues due
to the EPR effect.14
Polymeric micelles that are responsive to environmental changes in pH,6,15,16
temperature,17,18 redox potential19 or external stimuli such as ultrasound20-22 or light 23-25 have
been developed. Among the available stimuli, light is a particularly attractive trigger for use
in controlling the behavior of biomaterials.25 It can be applied externally and does not require
specific chemical reagents or environmental conditions. In addition, many parameters such as
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light intensity and wavelength can be easily controlled and exposure areas with a resolution
as small as 1 µm can be achieved.26 Photo-responsive polymeric micelles have been designed
through the use of photochemical reactions to induce solubility changes in the hydrophobic
block that lead to disintegration of the micelles and the release of physically encapsulated
cargo in response to visible27 or IR23 light. Alternatively, photocleavable o-nitrobenzyl
moieties were incorporated into the main chain of hydrophobic block to achieve micelle
disruption upon irradiation.27,28
We have recently developed a micellar carrier for the anticancer drug PTX based on
amphiphilic PEA-PEO graft copolymers.29 PTX is one of the most effective anti-cancer
drugs used in clinical practice and exhibits strong cytotoxic activity against a variety of
cancers, especially breast and ovarian cancer.30 However, because of its low watersolubility31 (0.25 μg/mL) PTX is currently formulated as a 50:50 mixture of CrEL and
ethanol, called Taxol, which has been found to result in hypersensitivity reactions.30
Consequently, patients receiving this drug require premedication.32 Many drug delivery
systems have been developed for PTX with the aim of improving its properties.33-36
PEAs, polymers containing both ester and amide linkages in their backbones are,
promising materials for a wide range of biomedical applications37-44 as they can undergo
degradation under a variety of enzymatic and non-enzymatic conditions and their monomers
can be selected from a wide range of non-toxic metabolic intermediates. In our previous
work, L-aspartic acid moieties were incorporated into the polymer backbones and the
resulting pendant carboxylic acid groups were used to covalently conjugate PEO, resulting in
an amphiphilic graft copolymer capable of forming micelles, as well as the 2'-hydroxyl group
of PTX via an ester linkage.36,45 In comparison to most PTX drug delivery systems, which
contain PTX only physically incorporated, it was shown that the covalent immobilization of
PTX resulted in a slow and controlled release of the drug without the undesirable burst
release effect which is frequently observed when drug molecules are physically encapsulated
into micelles and nanoparticles.17,46-48 Nevertheless, as ester hydrolysis was quite slow in the
hydrophobic cores of the micelles, it would still be desirable to selectively trigger a more
rapid, "burst" release of PTX in the case of tumors treatment.
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We report here the development of the first backbone photodegradable PEA and its
application in the development of a photosensitive micellar carrier with covalently
conjugated PTX. As shown in Figure 4.1, it was proposed that upon light-induced
degradation of o-nitrobenzyl moieties in the hydrophobic PEA backbone, the micellar
assemblies would be disrupted, resulting in increased exposure of the ester linkages between
PTX and the PEA backbone to water, and thus accelerated hydrolytic release of PTX. To test
this hypothesis, the synthesis of the photodegradable polymers, their self-assembly into
micelles, and their photodegradation are described. Studies were performed to evaluate the
effect of photoirradiation on PTX release and the effect of photoinduced release on the in
vitro toxicity of the micelles.

Figure 4.1. Micellar disruption and proposed acceleration in ester hydrolysis upon UV
irradiation.

4.1 Experimental section
General procedures and materials. Compound 4.2,49 monomer 4.650 and PEO-NH239 with
a molecular weight of 5 kg/mol were synthesized as previously reported. Solvents were
purchased from Caledon Labs (Georgetown, ON). PTX (>99%, P-9600) was purchased from
LC Laboratories. All other chemicals were purchased from Sigma Aldrich (Milwaukee, WI).
Unless noted otherwise, all chemicals were used as received. Anhydrous CH2Cl2 was
obtained by distillation over CaH2. Water was purified using an ultra pure water system
(Barnstead EASYpure® II). Column chromatography was performed using silica gel 60 with
a particle size range of 40-63 µm (SiliCycle Inc, Quebec City, QC). Dialysis was performed
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using Spectra/Por 6 regenerated cellulose membranes from Spectrum Laboratories with a
MWCO of 12-14 or 50 kg/mol (Rancho Dominguez, CA, USA). 1H (400 MHz) and 13C (100
MHz) NMR spectra were obtained on a Varian Inova 400 spectrometer (Varian Canada Inc.,
Mississauga, ON). Chemical shifts are reported in ppm and are calibrated against residual
solvent signals of DMSO ( 2.50, 40.25 ppm). All coupling constants (J) are reported in Hz.
FTIR spectra were obtained using a Bruker Tensor 27 (Bruker Corporation, Milton, ON)
using KBr pellets or thin films from dichloromethane on NaCl plates. High-resolution mass
spectrometry (HRMS) was performed using a Finnigan MAT 8400 electron impact mass
spectrometer. SEC data were obtained using a Waters 2695 separations module equipped
with a Waters 2414 refractive index detector (Waters Limited, Mississauga, ON) and two
PLgel 5 m mixed-D (300 mm × 7.5 mm) columns connected in series (Varian Canada Inc.,
Mississauga, ON). Samples (5 mg/mL) dissolved in the eluent, which comprised of 10 mM
LiBr and 1 % (v/v) NEt3 in DMF at 85°C were injected (100 L) at a flow rate of 1 mL/min
and calibrated against polystyrene standards. DLS was performed on a ZetaSizer Nano
instrument from Malvern (Worcestershire,UK). Ultraviolet-visible (UV-vis) spectroscopy
was performed on a Varian Cary 300 Bio UV–visible spectrophotometer. Photochemical
irradiation was performed using a medium pressure mercury lamp (Hanovia S9 PC 451050
/805221), with 200-400 nm UV light and a receiving power of about 25 mW.cm-2, which was
contained in a quartz water jacket, approximately 10 cm from the solution. The concentration
of PTX was determined by isocratic reverse-phase HPLC using a Waters 2695 separations
module ( Waters , Milford, USA) equipped with a LiChroCART 125-4 RP-18 column (5L
MerckMillipore,Damstadt,Germany), and a photodiiode array detector (Waters 2998). The
mobile phase consisted of water/acetonitrile (60/40 v/v). The flow rate was 1.0 mL/min and
the detection wavelength was 227 nm. 100 L of the analyte solution was injected. A
calibration curve was prepared for PTX dissolved in water/acetonitrile (60/40 v/v).
Synthesis of monomer 4.3. A suspension of L-phenylalanine (4.1) (5.9 g, 35 mmol, 2.2
equiv.) and p-toluenesulfonic acidH2O (6.7 g, 39 mmol, 2.4 equiv.) in toluene (100 mL) was
refluxed at 140 °C with stirring in a flask equipped with a Dean-Stark trap for 2 h to remove
the residual water. To this solution, 2-nitro-1,3-benzenedimethanol (4.2)49 (3.0 g, 16 mmol,
1.0 equiv.) was added and the reaction mixture was heated at reflux for 48 h. The reaction
mixture was then cooled and filtered to isolate the crude product, which was recrystallized
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from water (100 mL) to provide monomer 4.3 (6.6 g, 50%). 1H NMR (400 MHz, DMSO-d6):
δ 8.43 (br s, 6H), 7.66-7.62 (m, 3H), 7.47 (d, J = 8.2, 4H), 7.19 - 7.30 (m, 10H ), 7.10 (d, J =
7.8, 4H), 5.23-5.31 (m, 4H), 4.40 - 4.37 (m, 4H), 3.09-3.06 (m, 4H), 2.29 (s, 6H ); 13C NMR
(100 MHz, DMSO-d6): δ 169.0, 148.2, 145.8.0, 138.2, 132.4, 131.2, 129.7,128.5, 127.7,
125.9, 110.8, 63.3, 53.5, 36.3, 21.2. FTIR (KBr pellet, cm-1): 3313, 2930, 2855, 1735, 1654,
1534, 1499, 1459, 1175. HRMS (m/z): calcd for C26H28N3O6, 478.1978; found, 478.1974
[M]+.
Synthesis of polymer 4.5. Monomer 4.3 (1.0 g, 1.2 mmol, 1.0 equiv.) and sodium carbonate
(0.25 g, 2.4 mmol, 2.0 equiv.) were dissolved in distilled water (30 mL). Sebacoyl chloride
(4.4) (0.21 mL, 1.2 mmol, 1.0 equiv.) diluted in anhydrous CH2Cl2 (15 mL), was added
dropwise over 30 min to the biphasic solution and was allowed to react for 17 h. Upon
completion of the reaction, solvent was removed in vacuo. The resulting polymer was
redissolved in DMF permitting filtration of the insoluble salts. The filtrate was then dialysis
against DMF with MWCO 12-14 kg/mol for 24 h, with changing of the dialysate every 12 h.
The solvent was removed in vacuo to provide polymer 4.5 (0.41 g, 52%). 1H NMR (400
MHz, DMSO-d6): δ 8.26 (d, J = 7.6, 2H), 7.55 - 7.64 (m, 3H), 7.21 - 7.23 (m, 10H), 5.16 5.24 (m, 4H), 4.45 - 4.51 (m, 4H), 2.86 - 2.99 (m, 4H ), 2.0-2.04 (m, 4H ), 1.07-1.45 (m, 8H
). FTIR (KBr pellet, cm-1): 3292, 2928, 2853, 1751, 1654, 1538, 1455, 1174. SEC: Mn = 47
kg/mol, Mw = 64 kg/mol, PDI = 1.3.
Synthesis of polymer 4.7. Monomer 4.3 (0.50 g, 0.61 mmol, 0.80 equiv.) and sodium
carbonate (0.13 g, 1.6 mmol, 2.0 equiv.) were dissolved in distilled water (15 mL). Monomer
4.6 (0.065 g, 0.15 mmol, 0.20 equiv.) was dissolved in CH2Cl2 (5 mL) and added to the
aqueous phase. After stirring for 30 min, sebacoyl chloride (4.4) (0.15 mL, 0.63 mmol, 1.0
equiv.) diluted in anhydrous CH2Cl2 (10 mL), was added dropwise over 30 min to the
biphasic solution and was allowed to react for 24 h. This polymer was purified as described
above for polymer 4.5. (0.24 g, 62%). 1H NMR (400 MHz, DMSO-d6):  8.26-8.30 (d, J =
8.1, 1.86H), 8.21-8.23 (d, J = 7.5, 0.56H), 7.55-7.64 (m, 3.0H), 7.15-7.25 (m, 9.99H), 5.16 5.24 (m, 4.02H), 4.50 - 4.52 (m, 0.59H), 4.45-4.51 (m, 1.94), 4.03-4.07(m, 1.04 H), 2.983.01 (m, 3.95H), 2.53 -2.7 (m, 1.18H), 2.0- 2.08 (m, 4.97 H), 1.36-1.59 (m, 12.31H), 1.071.07 (m, 11.89H). FTIR (thin film, cm-1): 3292, 3061, 2928, 2853, 1751, 1653, 1533, 1363,
1174. SEC: Mn = 39 kg/mol, Mw = 60 kg/mol, PDI = 1.5.
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Synthesis of polymer 4.8. Polymer 4.7 (0.23 g, 0.36 mmol, 1.0 equiv) was dissolved in
CH2Cl2 (1 mL). Trifluoroacetic acid (TFA) (1 mL) was added and the reaction mixture was
stirred for 2 h. Toluene (5 mL) was then added and the solvent was removed in vacuo to
provide the unprotected polymer in quantitative yield. The crude polymer was then washed
with cold ethyl acetate (3 mL) three times to provide polymer 4.8 (0.21 g, 98%). 1H NMR
(400 MHz, DMSO-d6):  8.21-8.23 (d, J = 8.1, 1.69 H), 8.19 (J = 7.5, 0.49H), 7.50-7.59 (m,
2.67H), 7.13 - 7.18 (m, 9.11H), 5.46 - 5.51 (m, 0.48H), 4.40 - 4.46 (m, 1.81), 3.98 (s, 0.95H),
2.81 - 2.93 (m, 3.59H ), 2.51-2.64 (m, 1.14H), 1.96 - 2.15 (m, 6H), 1.49-1.30 (m, 8H),1.191.03 (m, 8H). IR (thin film, cm-1): 3292, 2929, 2855, 1747, 1651, 1455, 1366, 1173.
Synthesis of polymer 4.9. Polymer 4.8 (0.20 g, 0.065 mmol, 1.0 equiv) was dissolved in
distilled CH2Cl2 (4 mL). Then, PTX (0.030 g, 0.027 mmol, 0.50 equiv. relative to pendant
COOH), DCC (0.018 g, 0.087 mmol, 1.2) and DMAP (0.0073 g, 0.059 mmol, 0.80 equiv.
relative to pendant COOH) were added into the above solution at 0 °C. After 12 h, the
reaction was warmed to room temperature and stirred for another 8 h. The byproduct
dicyclohexylurea was removed by filtration, and the resulting polymer was purified by
dialysis against DMF using a 12-14 kg/mol MWCO membrane for 24 h, with changing of the
dialysate every 12 hours to provide polymer 4.9 (0.19 g, 83%). 1H NMR (400 MHz, DMSOd6):  8.91 (d, J = 8.8, 0.55H), 8.27 (d, J = 7.6, 1.88H), 8.20 (d, J = 7.6, 0.49H), 7.98 (d, J =
8.0, 0.50H), 7.89 (d, J = 7.9, 0.50H), 7.70-7.74 (m, 0.44H), 7.55 - 7.65 (m, 3.6H), 7.48-7.50
(m, 0.49H), 7.40-7.43 (m, 0.77), 7.15 - 7.25 (m, 9.55H), 6.29 (br s, 0.53H), 6.18 (d, J = 7.6,
6.17H), 5.88-5.91 (m, 0.32H), 5.39 - 5.43 (m, 0.79H), 5.17 - 5.23 (m, 4.04H), 4.90-4-92 (m,
0.48H), 4.70 (br s, 0.48H), 4.54 - 4.59 (m, 0.92H), 4.46 - 4.50 (m, 1.98H), 4.09 - 4.13 (m,
0.43H), 3.99 - 4.04 (m, 1.28H), 3.62 (d, J = 3.62, 0.53H), 2.97 - 3.04 (m, 2.19H), 2.83 - 2.89
(m, 2.32H), 2.64-2.67 (m, 0.64H), 2.56 - 2.60 (m, 0.80H), 2.23 (s, 0.41H), 2.16 - 2.19 (m,
0.8H), 2.09-2.11 (m, 0.39H), 2.01-2.10 (m, 4.49H), 1.88-1.92 (m, 0.40H), 1.74 - 1.79 (m,
0.65H), 1.62 - 1.66 (m, 0.46), 1.58 (s, 0.86H), 1.45 - 1.51 (m, 1.9H), 1.34 - 1.39 (m, 4.12H),
1.15 - 1.22 (m, 3.98H), 1.02 - 1.07 (m, 7.18H). IR (thin film, cm-1): 3270, 2928, 2854, 1747,
1654, 1553, 1362, 1175.
Synthesis of polymer 4.10. Polymer 4.9 (0.060 g, 0.017 mmol, 1.0 equiv) was dissolved in
distilled CH2Cl2 (4 mL). PEO-NH2 (0.086 g, 0.017 mmol, 1.0 equiv. relative to pendant
COOH), DCC (7.2 mg, 0.025 mmol, 1.5) and DMAP (2.1 mg, 0.017 mmol, 1.0 equiv.

92

relative to pendant COOH) were added into the above solution at 0 °C. The reaction was
carried out under stirring at 0 °C for 12 h and then at room temperature for 8 h. The
byproduct dicyclohexylurea was removed by filtration, and the resulting polymer was
purified by dialysis against water using a 50 kg/mol MWCO membrane for 24 h, changing of
the dialysate every 12 h, to provide polymer 4.10 (0.11g, 74%). 1H NMR (400 MHz, DMSOd6): 9.16-9.21 (s, 0.11H), 8.28 (d, J = 7.0 Hz, 2.1H), 7.79 (d, J = 6.6 Hz, 0.32H), 7.86-7.82
(m, 0.25H), 7.78- 7.81(m, 0.22H), 7.70-7.74 (m, 0.14H), 7.57 - 7.63 (m, 3.26H), 7.41-7.49
(m, 0.78H), 7.13-7.27 (m, 10.77H), 6.29 (br s, 0.14H), 5.81 (d, J = 6.6 Hz, 0.14H), 5.52-5.58
(m, 0.12H), 5.39 - 5.43 (m, 0.35H), 5.16-5.24 (m, 4.02H), 4.88-4.93 (m, 0.25H), 4.62 (br s,
0.28H), 4.45-4.50 (m, 2.22H), 4.01 - 4.10 (m, 0.9H), 3.65-3.70 (m,1.41H), 3.51(s, 154.79H),
3.22-3.26 (m, 1.39H), 3.15-3.20 (m, 0.55H), 2.99 - 3.01 (m, 1.82H), 2.83 - 2.89 (m, 2.11H),
2.64-2.69 (m, 0.30H), 2.32 - 2.36 (m, 0.17H), 2.25 (s, 0.21H), 2.19-2.22 (m, 0.11H), 2.062.09 (m, 0.66H), 2.0-2.03 (m, 4.49H), 1.74-1.78 (m, 0.46H), 1.52-1.60 (m, 0.56H), 1.45 1.51 (m, 1.69H), 1.29-1.40 (m, 3.99H), 1.12-1.25 (m, 4.50H), 0.99-1.07 - 1.07 (m, 8.15H). IR
(thin film, cm-1): 3295, 3063, 3030, 2887, 1747, 1651, 1535, 1497, 1455, 1359, 1280, 1148.
SEC: Mn = 25 kg/mol, Mw = 57 kg/mol, PDI = 2.3.
General procedure for monitoring photodegradation by UV-vis spectroscopy. The
polymer solution was prepared at the concentration of 4 μg/mL in spectroscopic grade
dioxane. To a quartz cuvette 3 mL of solution was transferred and irradiated with UV light
for the selected time interval. UV-vis spectra were obtained following each time interval. For
micelles, the photodegradation was also studied by preparing micelles by the protocol
described below and then diluting them in purified water to 4 μg/mL. They were also
prepared and studied at a higher micelle concentration of 1.5 mg/mL. In this case, at each
irradiation interval 100 μL of micelle solution was diluted to 3 mL with dioxane and the UVvis spectrum was obtained.
General procedure for monitoring photodegradation by 1H NMR spectroscopy. The
polymer solution was prepared at the concentration of 7 mg/mL in DMSO-d6. The solution
was transferred to a quartz NMR tube and irradiated with UV light. 1H NMR spectra were
obtained at selected time intervals.
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Micelle formation. Polymer 4.10 (3.0 mg) was dissolved in THF (0.3 mL). The solution was
stirred vigorously while distilled water was rapidly added to provide a final volume of 3 mL.
THF was then removed by dialysis against distilled water using a 12–14 kg/mol MWCO
membrane. The micelle solution was then filtered with a microfilter (pore size: 0.45 μm,
Tuffryn® syringe filter, PALL) to eliminate dust and aggregates.
TEM. The micelle suspension (prepared as described above, 20 μL of 0.1 mg/mL) was
placed on a Formvar/Carbon grid and was left to stand for 5 min. The excess solution was
then blotted off using a piece of filter paper. The resulting sample was dried under air
overnight before imaging. Imaging was performed using a Phillips CM10 microscope
operating at 80 kV with a 40 μm aperture.
Procedure for monitoring PTX photodegradation by HPLC. Five samples containing 1
mL of PTX in water at a concentration of 0.3 μg/mL were prepared. Each solution was
transferred to a glass cuvette and irradiated with UV light. The concentration of PTX was
measured as described above over 25 min in 5 min intervals.
In vitro release of PTX from PTX-micelles. The in vitro release of PTX from the micelles
of copolymer 4.10 was evaluated by a dialysis method. 3 mL of micelle suspension (PTX
concentration: 0.60 μg/mL) were placed into a pre-swollen 3.5 kg/mol MWCO dialysis bag
and immersed into 500 mL of 10 mM phosphate buffer at 37 °C. Dialysis was performed
with gentle stirring and the amount of PTX released into media was measured every 24 h. At
each time point an aliquot of release media (15 mL) was withdrawn, the complete volume of
dialysate was removed and replaced with fresh media. For analysis of the PTX concentration,
the 15 mL aliquot was dried via lyophilization and the solid was redissolved in 1 mL of
60/40 water/acetonitrile. The solution was filtered with a 0.2 μm pore size (Tuffryn® syringe
filter, PALL) filter into a vial for detection of the PTX concentration by HPLC as described
above. The cumulative PTX release was calculated. The release experiments were conducted
in triplicate, and the results presented are the mean  standard deviation.
In vitro release of PTX from photoirradiated PTX-micelles. The same procedure
described above for the non-irradiated micelles was used except that the micelle solution was
exposed to UV light for 10 min prior to beginning the dialysis.
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In vitro cytotoxicity assay. HeLa cells were cultured at 37 °C and 5% CO2 in DMEM
(Invitrogen) supplemented with 10% (v/v) fetal bovine serum (Invitrogen) and antibiotics
(penicillin and streptomycin, 100 units/mL each). The cells were seeded into a Nunclon®
96-well U bottom transparent polystrol plate at a density of 2500 cells per well in a final
volume of 100 μL of DMEM. Cells were allowed to adhere for 24 hours at 37 °C in a
humidified incubator with 5% CO2. Next, the growth medium was aspirated and was
replaced with either the positive control SDS in the cell culture medium at concentrations of
0.2, 0.15, 0.10, or 0.05 mg/mL, just the medium or testing materials. The cells were then
incubated with resulting micelles of graft copolymer 4.10 with and without 10 min UV
irradiation at PTX concentration of 25, 12.5, 6.2, 2.5, 1.2, 0.62, 0.31 ng/mL. A suspension
solution of polymer without drug 4.8 was also prepared at concentration of 300, 30, 15, 7.5,
3.6, 1.5 and 0.75 ng/mL. For comparison, PTX solubilized in CrEL/ethanol was prepared
according to Lee et al.51 In short, 6 mg of PTX was dissolved in 0.5 mL dehydrated ethanol
and to this solution 0.5 mL CrEL was added. Then this mixture was sonicated for 30 min.
This sample also diluted to provide above concentration. A control formulation without PTX
was prepared using 1/1 Cr EL/ethanol. This solution was diluted similar to PTX formulated
with CrEL/ethanol. Eight replicates per concentration were performed. After 72 h, the media
were aspirated and replaced with 110 μL of fresh medium containing 0.5 mg/mL MTT
reagent. After 4 h of incubation (37 °C, 5% CO2), the MTT solution was carefully aspirated
and the purple crystals were dissolved by addition of 50 μL of spectroscopic grade DMSO.
After shaking (1 second, 2 mm amp, 654 rpm), the absorbance of the wells at 540 nm was
read using an M1000-Pro plate reader (Tecan). The absorbance of wells not containing cells
but treated by all of the above steps was subtracted as a background and the cell viability was
calculated relative to wells containing cells that were exposed to just culture medium. No
(0%) cell viability was detected for the cells exposed to the highest concentrations of the
positive control sodium lauryl sulfate, confirming the sensitivity of the assay.

4.2 Results and discussion
4.2.1

Synthesis of a model photodegradable PEA

Prior to preparing the target photodegradable PTX delivery system, a model photodegradable
PEA was synthesized and studied to confirm its photodegradability. To accomplish this, o-
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nitrobenzyl moieties were selected as the photodegradable units as they have been widely
studied for a variety of applications.25 An -amino acid-based PEA backbone was selected
due to the possibility to readily incorporate amino acids with pendant functional groups for
the grafting of PTX as well as hydrophilic chains for micelle formation. First, as shown in
Scheme 4.1, L-phenylalanine (4.1) was condensed with 2-nitro-1,3-benzenedimethanol (4.2)
in toluene, in the presence of p-toluenesulfonic acid (TsOH) to provide the diester 4.3. While
in principle any amine acid could have been used, L-phenylalanine was ideal as the di-ptoluenesulfonic acid salt of this monomer could be easily purified by recrystallization from
water.

Scheme 4.1. Synthesis of photodegradable monomer 4.3.
As shown in Scheme 4.2, an interfacial polymerization was then performed by the
addition of a solution of sebacoyl chloride (4.4) in CH2Cl2 to a solution of monomer 4.3 in an
aqueous Na2CO3 solution to provide polymer 4.5. The structure of polymer 4.5 was
confirmed through 1H NMR and IR spectroscopy. Based on SEC in DMF, the polymer had a
Mw of 64 kg/mol and a PDI of 1.3. In this design, photodegradable moieties are inserted at
each monomer unit throughout the polymer. This should ensure that upon UV-irradiation, it
should be possible to completely degrade the polymer.

96

Scheme 4.2. Synthesis of the model photodegradable PEA 4.5.

4.2.2

Photodegradation of the model polymer 4.5.

The photodegradation of polymer 4.5 was studied by UV-vis spectroscopy and NMR
spectroscopy. For the UV-vis study, a 4 μg/mL solution of polymer in dioxane was irradiated
using a medium pressure mercury lamp for 120 min and the UV-vis spectra were recorded
every 20 minutes. As shown in Figure 4.2, over the degradation period, a decrease in
absorbance was observed for the band at 260 nm while an increase at 310 nm was observed.
This is consistent with the expected result as the initial nitrobenzyl units absorb at 260 nm,
while the nitrosobenzaldehyde product absorbs at 310 nm.52,53
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Figure 4.2. UV-vis spectra of polymer 5 following different UV irradiation times.
To study the photodegradation by 1H NMR spectroscopy, a 7.5 mg/mL solution of
polymer 4.5 in deuterated DMSO was irradiated with a medium pressure mercury lamp in a
quartz NMR tube for 240 min and spectra were collected every 60 min. As shown in Figure
4.3, the multiplet at 5.15-5.24 ppm corresponding to the methylene groups of the onitrobenzyl ester in the polymer backbone, decreases in intensity. Concomitantly, new peaks
emerge and increase at 8.07-8.12 and 12.61 ppm, corresponding to the expected onitrobenzaldehyde product. SEC traces of the degraded sample showed no polymer peak,
demonstrating complete degradation of the material (see appendix). Overall, these data
demonstrate that polymer 4.5 degrades in the expected manner.
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Figure 4.3. 1H NMR spectra following different UV irradiation periods of a 7.5 mg/mL
solution of polymer 4.5 in DMSO-d6.

4.2.3

Synthesis of
conjugate.

a

photodegradable

amphiphilic

PEA-PTX

Having demonstrated the ability of o-nitrobenzyl esters to impart photodegradability to the
PEA backbone, the next step was to incorporate sites for the conjugation of PTX and for the
grafting of hydrophilic chains to induce micellization. As in our previous work with nonphotodegradable PEAs,29 this was accomplished through the incorporation of L-aspartic acid
units throughout the backbone. As shown in Scheme 4.3, an 80:20 ratio of monomer 4.3 to
the L-aspartic acid-based diester 4.650 was polymerized interfacially with sebacoyl chloride
to provide the random copolymer 4.7. The 80:20 ratio was selected to obtain a sufficient
number of functional handles throughout the polymer backbone, while still maintaining the
maximum number of photodegradable sites. The resulting polymer had an Mw of 60 kg/mol
and a PDI of 1.5 as measured by SEC.
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Scheme 4.3. Synthesis of a photodegradable amphiphilic PEA-PTX conjugate.
The t-butyl protected carboxylic acids on polymer 4.7 were unmasked through treatment
with 1:1 TFA:CH2Cl2 to provide polymer 4.8 (Scheme 4.3). The photodegradation of
polymer 4.8 was studied by 1H NMR spectroscopy and the same changes observed for
polymer 4.5 were also observed for this polymer, suggesting that the incorporation of
monomer 4.6 does not interfere with the photodegradation process. The next step was the
conjugation of PTX to polymer 4.8. This was accomplished by the reaction of 4.8 with 0.5
equiv. of PTX per pendant carboxylic acid moiety in the presence of DCC and DMAP to
provide the conjugate 4.9. This polymer contains a hydrolytically cleavable ester linkage
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between the pendant carboxylic acid moieties of the polymer and the 2′-hydroxyl of PTX,
which is generally more nucleophilic than the 7-hydroxyl because it experiences less steric
hindrance.36,45,54 Based on 1H NMR spectroscopy, the conjugation yield was approximately
80%, corresponding to the functionalization of approximately 40% of the pendant carboxylic
acid moieties with PTX (see appendix). Using this method, it was found that the amount of
PTX content was 16 % by weight.
The final synthetic step was the grafting of hydrophilic chains to induce micellization. As
in our previous work,29 PEO was selected because of its well known biocompatibility in
various therapeutics, as well as its stealthy characteristics, allowing it to prolong the block
circulation of drug delivery systems.55-57 PEO-NH2 with molecular weight of 5 kg/mol was
reacted with polymer 4.9 under the same conditions used for the conjugation of PTX to
provide polymer 4.10 (Scheme 4.3). Based on 1H NMR spectroscopy, approximately 35% of
the carboxylic acid moieties were functionalized with PEO, resulting in a PEA graft
copolymer with 67 wt % PEO and 6 wt% PTX. The resulting polymer had an M w of 56
kg/mol and a PDI of 2.3 as measured by SEC.
It should be noted that the order of PTX and PEO couplings is very important. It was
found that if PEO conjugation was carried out first, the subsequent PTX coupling failed. This
can likely be attributed to the steric influence of PEO, which may block access to unreacted
carboxylates.

4.2.4

Preparation and characterization of micelles

A nanoprecipitation method was used to prepare micelles from polymer 4.10. In short, the
graft copolymer 4.10 was dissolved in THF, a good solvent for this polymer. Water was then
added to induce the aggregation of the PEA to form the micelle core. Finally, the THF was
removed by dialysis. The resulting micelle size was measured by DLS. The z-average
micelle diameter and polydispersity index were 95  5 nm and 0.16 respectively, and a
representative DLS trace is shown in Figure 4.4a. TEM was also performed to verify the
micelle size and morphology measured by DLS. As shown in Figure 4.4b, spherical
assemblies were indeed observed, characteristic of micelles. The diameter of these micelles
was found to be 60 ± 11 nm. The smaller diameter measured by TEM relative to that
obtained by DLS can likely be attributed to their dehydrated state.
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Figure 4.4. a) Representative DLS trace for micelles formed from graft copolymer 4.10; b)
TEM image of micelles formed from graft copolymer 4.10 prior to UV irradiation; c) TEM
of micelles of graft copolymer 4.10 following 20 min of UV irradiation.

4.2.5

Photoinduced dissociation of the micelles

After preparation of micelles, their photodegradation behavior was studied. In this micellar
system, photoirradiation should result in the disintegration of the micellar core due to mainchain degradation of the hydrophobic PEA backbone. Fast photodegradation of the micelles
is expected as multiple photo-cleavable moieties were inserted as a repeating unit into main
chain of the polymer. Zhoa recently reported the preparation of amphiphilic block-copolymer
micelles whose core-shell structure was disrupted under UV irradiation and fast degradation
of the micellar core and hence micelle disruption was observed.27 The fast disintegration of
micelles from copolymer 4.10 was demonstrated by TEM (Figure 4.4c). As described above,
prior to irradiation, the micelles had a relatively uniform diameter of 60 ± 11 nm, while after
20 min of UV irradiation the micelle structures appeared to disappear and instead just some
loose aggregates were observed. These aggregates are likely fragments of the hydrophobic
backbone without PEO, which arise from the backbone degradation and are insoluble in
water. DLS experiments confirmed polymer aggregation with the size of 903 ± 10nm (see
appendix). Photodegradation of the system was also studied by UV-vis spectroscopy. When
performing this study purely in water, the results were complicated by the formation of these
aggregates, which result in some turbidity. However, photodegradation in dioxane provides
the expected changes in the UV-vis spectra (see appendix).
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4.2.6

Photoinduced PTX release

The in vitro release proﬁle of PTX from micelles formed from polymer 4.10 was evaluated in
pH 7.4 phosphate buffer both with and without UV irradiation. As shown in Figure 4.5,
consistent with our previous results for a non-photodegradable system,29 in the absence of
UV irradiation, the release of PTX from the micelles is slow and sustained, with no burst
release, and approximately 40% of the drug released over a period of 2 weeks. The slow
release can be attributed to the requirement for ester bond hydrolysis to occur at the
hydrophobic core of the micelle between PTX and the PEA backbone.
Prior to performing the PTX release experiment with photoirradiation, it was important to
confirm the stability of PTX to UV irradiation. Therefore, an aqueous solution of PTX was
irradiated, and the purity of the drug was evaluated by HPLC. This experiment indicated that
there were no changes in PTX purity following up to 10 minutes of exposure (see appendix).
Therefore, a 10 min irradiation time was chosen for the PTX release study. It was confirmed
by UV-vis spectroscopy that even at the increased concentrations of micelles used in the
release study this 10 min irradiation period was sufficient to obtain significant changes in the
UV-vis spectrum of the polymer, consistent with partial photodegradation of the polymer
backbone (see appendix). As shown in Figure 4.5, after a 10 min UV irradiation of the
micelles, there is an initial burst release of 20% of the PTX over the first 24 h. This can likely
be attributed to the partial cleavage of the photolabile o-nitrobenzyl esters during the 10 min
irradiation, which results in some degree of micelle breakdown and increased exposure of the
ester linkages to water, resulting in accelerated hydrolysis. Following this initial
photoinduced burst release, the release profile follows that of the non-irradiated sample,
which likely corresponds to the release of PTX from some intact micelles or from aggregates
of polymer fragments that contain PTX. These results show that this photodegradable micelle
system is stable but exhibits light-induced PTX release.
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Figure 4.5. In vitro release of PTX from with and without UV-irradiated micelles incubated
at 37 °C in PBS buffer (pH 7.4). Data represent the mean and standard deviation of three
independent experiments.

4.2.7

In vitro toxicity studies

The in vitro cytotoxic activities of the photodegradable PTX-micelles with and without UV
irradiation were evaluated and compared with PTX in its CrEL/ethanol formulation in HeLa
cells using an MTT assay. The micelles formed from polymer 4.8, without PTX as well as
the CrEL/ethanol vehicle were also evaluated. As shown in Figure 4.6a, PTX was toxic (as
defined by a cell viability of <70% that of the control58) at concentrations of 2.5 ng/mL and
higher. The concentration of CrEL/ethanol vehicle required to formulate the higher
concentrations of PTX was also toxic, suggesting that some toxicity at the higher PTX
concentrations can likely be attributed to CrEL/ethanol. In contrast, the photodegradable
PEA vehicle without drug did not exhibit significant toxicity at concentrations up to 300 ng.
The PTX micelles both with and without UV irradiation were less toxic than the
CrEL/ethanol formulation, with toxicity only observed at concentrations higher than 6.25
ng/mL. This can likely be attributed to the gradual release of drug from these systems.
Within the errors on the measurements, both the UV-irradiated and non-irradiated micelles
exhibited similar toxicities. Although the irradiated micelles might be expected to exhibit
higher toxicity, this assay was not sensitive enough to detect this, likely because the
differences in free drug between the two systems may not be sufficient. It is also conceivable
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that the release kinetics of PTX measured in phosphate buffer are not the same as those
within the cellular environment, where the presence of enzymes and pH gradients may also
play a role in mediating ester hydrolysis.

Figure 4.6. In vitro cytotoxicity, as measured by MTT assays in HeLa cells following a 72 h
incubation of a) PTX-CrEL/ethanol and the equivalent dose of CrEL without PTX; b) PTX
micelles with and without UV irradiation and polymer 4.8.

4.3 Conclusions
In conclusion, a backbone photodegradable PEA was developed for the first time and was
demonstrated to completely degrade upon UV irradiation. This chemistry was extended to
the development of photodegradable PEA micelles with PTX conjugated via an ester linkage,
based on the hypothesis that breakdown of the micelles induced by UV light would enable
enhanced ester bond cleavage through increased exposure to water. This multifunctional graft
copolymer was successfully synthesized and was used to prepare sub-100 nm micelles. A
short, 10 min UV irradiation led to decomposition of the micelles, as demonstrated by TEM
and UV-vis spectroscopy. It also resulted in a burst release of 20% of the PTX over the first
24 h, in comparison with the non-irradiated control, which only exhibited 3 % release over
the same time period. This demonstrated that it is indeed possible to modulate the release of
PTX from this system by irradiation. In vitro toxicity studies demonstrated that the drug-free
micelles were non-toxic up to 300 ng/mL, while the PTX-micelles were highly toxic, with
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the irradiated and non-irradiated micelles having similar toxicity. Overall, this work provides
a new photochemically degradable PEA backbone that can serve as a platform for various
applications. It also demonstrates the promise of stimulus-mediated micelle breakdown as a
means to alter the rate of the cleavage of linkages between drugs and polymers.
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Chapter 5

5

Polymer cross-linking: A nanogel approach to enhancing
the relaxivity of MRI contrast agents1

5.1 Introduction
Noninvasive medical imaging plays a critical role in the detection and diagnosis of disease as
well as in the monitoring of disease progression. MRI is a prominent noninvasive imaging
modality due to its excellent spatial resolution, soft tissue contrast, and the absence of
harmful ionizing radiation in its application. Despite its inherent high levels of soft tissue
contrast, contrast agents based on small molecule chelates of Gd(III) are frequently employed
in clinical MRI scans in order to aid in the differentiation between healthy and diseased
tissues.1-3 These agents have enabled significant advancements in MRI over the last couple of
decades. However, they do suffer from some limitations. For example, they typically possess
longitudinal relaxivities (r1) in the range of 3-5 mM-1s-1, only a small fraction of the
theoretically possible value. Thus, high doses are required, which can be problematic for
patients with chronic renal disease.4 It can also limit their applicability in molecular imaging
applications, where target receptors are present only at low concentrations.5 Furthermore,
most these agents are non-targeted, are passively distributed throughout the body, and have
very short circulation times in the blood.1,2,6 This can again limit their abilities to image
specific disease targets.
To address the limitations of small molecule MRI contrast agents, there is currently
significant interest in the development of new nanoscale Gd(III) agents.6,7 Nanosized agents
can exhibit higher relaxivities than small molecules due to their slower tumbling rates in
solution and the resulting increase in rotational correlation time (R). They can also exhibit
prolonged circulation times in the blood, a property that can be tuned based on their size and
architecture. Moreover, nanomaterials typically possess multiple chemical functionalities,

1
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111

which can enable the development of multimodal agents and derivatives targeted to specific
disease sites in vivo. In recent years, many nanoscale scaffolds including linear polymers,8-12
dendrimers,13-15 proteins,16-19 viral capsids,20-22 micelles,23,24 vesicles,25-28 fullerenes,29 and
nanotubes30 have been investigated. Among the above approaches, the conjugation of Gd(III)
complexes to proteins and viral capsids, which are assemblies of proteins, has proven to be
particularly successful. Significant enhancements in relaxivity have been observed, on the
order of 3 to 10-fold relative to the analogous small molecule chelates.16-22 In contrast, the
conjugation of Gd(III) chelates to conventional linear polymers such as polylysine,11 PEO,31
dextran32 or polynorbornene8 have led to more modest 1 to 3-fold improvements in
relaxivity. It is hypothesized that the enhanced relaxivities of protein-based agents result
from their high molecular weights, but also their well-defined, rigidified, 3-dimensional
conformations. In contrast, many linear polymers are highly flexible, allowing the conjugated
chelate to tumble like a small molecule in solution.
For the current work, we proposed that the advantageous “rigidified” property of a
protein could be obtained from a simple covalently cross-linked network based on a
hydrophilic polymer. We describe here the simple, one-step preparation of a cross-linked
polymer nanogel with a size on the order of 10 nm, ideal for in vivo circulation. A derivative
of the clinically used chelate DTPA was conjugated and the properties of the agent were
studied and compared with a control linear polymeric material prepared under the same
conditions in the absence of a cross-linker. High relaxivity and in vivo contrast were
demonstrated for the nanogel.

5.2 Experimental section
General procedures and materials. All reagents were purchased from commercial suppliers
and used without further purification unless otherwise noted. Anhydrous DMF was obtained
from a solvent purification system based on aluminum oxide columns. Pyridine and NEt3
were distilled from CaH2. poly(ethylene glycol) methyl ether methacrylate (PEGMA), N-(2aminoethyl)methacrylamide hydrochloride (AEMA) and Ethylene glycol dimethacrylate
(EGDMA) were purified by passing through a basic alumina column to remove the inhibitor.
Dialyses were performed using Spectra/Por regenerated cellulose membranes with MWCO
of either 1000 or 3.5 kg/mol. 1H (400 MHz) NMR spectra were obtained on a Varian Inova
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400 spectrometer (Varian Canada Inc., Mississauga, ON). Chemical shifts are reported in
ppm and are calibrated against residual solvent signal of D2O ( 4.79 ppm). FTIR spectra
were obtained using a Bruker Tensor 27 (Bruker Corporation, Milton, ON) from KBr disks.
SEC was performed in DMF with 10 mM LiBr and 1 % (v/v) NEt3 at 85 °C using a Waters
2695 separations module equipped 6380 with a 2414 differential refractometer and two
PLgel 5 μm mixed-D (300 mm 7.5 mm) columns from Polymer Laboratories (Agilent). The
calibration was performed using polystyrene standards. DLS was performed in 0.1 M pH 7.4
phosphate buffer on a Zetasizer Nano ZS instrument from Malvern Instruments. The sample
was prepared at a concentration of 2 mg/mL by dissolution of the lyophilized solid in buffer
followed by filtration through a 0.45 m Acrodisc syringe filter (PALL Life Sciences).
AFM was performed using an XE-100 atomic force microscope from PSIA. Samples for
AFM were prepared by spin coating a 100 µL solution of the polymer in methanol (1
mg/mL) onto a  1 cm  1 cm silicon wafer at 4000 rpm for 30 s. Images were obtained by
scanning surfaces in tapping mode using rectangular-shaped silicon cantilevers with a spring
constant of 48 N/m. The data were then refined using the software Nanoscope. TEM was
performed using a Phillips CM10 microscope operating at 80kV with a 40 μm aperture.
Samples were prepared by dropping 20 μL of 0.1 mg/mL polymer sample in water onto a
Formvar®/Carbon grid, letting it stand for 1 minute, then blotting off excess solution using a
piece of filter paper.
Synthesis of nanogel 5.4. PEOMA (5.1) (Mn = 475 g/mol) (600 mg, 1.3 mmol), AEMA,
(5.2) (200 mg, 1.2 mmol), EGDMA (5.3) (200 mg, 1.0), and benzoyl peroxide (100 mg, 0.41
mmol) were dissolved in 20 mL of methanol in a heavy walled Schlenk reaction tube. The
reaction mixture was degassed and then stirred at 75 °C overnight. It was then concentrated
to 5 mL and dialyzed against distilled water for 24 hours using a dialysis membrane with a
MWCO of 1 kg/mol. The solution was then lyophilized to provide the product as a white
solid (300 mg, 30%). 1H NMR (400 MHz, D2O): δ 4.15 (br s, 2.3 H), 3.63 (br s, 29 H), 3.31
(br s, 3.9 H), 3.15 (br s, 2.0 H), 1.87 (br s, 4.1 H), 0.6-1.5 (br m, 7.0 H). FTIR max/cm-1:
3500, 2930, 1730, 1650. SEC: Mn = 19 kg/mol, Mw = 46 kg/mol, PDI = 2.6.
Synthesis of nanogel 5.5. The nanogel 5.4 (43 mg,  50 mol of amine) and the
isothiocyanate derivative of DTPA (p-SCN-Bn-DTPA, Macrocyclics, Dallas, USA) (36.0
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mg, 55 mol,  1.1 equiv. per nanogel amine) were dissolved in 1 mL of dry DMF and dry
NEt3 (0.30 mL, 2.1 mmol) was added. The reaction mixture was stirred overnight at room
temperature and then dialyzed against distilled water for 24 hours using a dialysis membrane
with a MWCO of 3.5 kg/mol. The resulting solution was lyophilized to provide 72 mg of the
product as a white solid. 1H NMR (400 MHz, D2O):  7.0-7.5 (br m, 4 H), 3.9-4.4 (br m, 3.4
H), 3.5-3.8 (br m, 53 H), 3.2-3.5 (br m, 10 H), 2.7- 3.2 (br m, 12 H), 1.91 (br s, 4.4 H), 0.51.5 (br m, 17H). FTIR max/cm-1: 3490, 2930, 1730, 1650, 1540.
Synthesis of nanogel 5.6. The nanogel 5.5 (67 mg) was dissolved in 2 mL of distilled water.
GdCl3·6H2O (54 mg, 0.14 mmol,  2 equiv. per amine) was dissolved in 1 mL of distilled
water and was subsequently added to the nanogel solution. The solution was stirred
overnight, and then dialyzed against distilled water for 24 hours using a dialysis membrane
with a MWCO of 3.5 kg/mol. The resulting solution was lyophilized to provide 57 mg of the
product as a white solid. The Gd content of the nanogel was determined by inductively
coupled plasma mass spectrometry (ICP-MS), performed at the Environmental Analytical
Laboratories of the Saskatchewan Research Council (Canada). Result = 59  1 g Gd/mg
nanogel. FTIR max/cm-1: 3460, 2940, 1730, 1610.
Synthesis of control polymer 5.7. PEOMA (5.1) (Mn = 475 g/mol) (840 mg, 1.7 mmol),
AEMA (5.2) (370 mg, 1.7 mmol), and benzoyl peroxide (100 mg, 0.41 mmol) were dissolved
in 20 mL of methanol in a heavy walled Schlenk reaction tube. The reaction mixture was
degassed and then stirred at 75 °C overnight. It was then concentrated to 5 mL and then
dialyzed against distilled water for 24 hours using a dialysis membrane with a MWCO of 1
kg/mol. The solution was then lyophilized to provide the product as a white solid (264 mg,
26%). 1H NMR (400 MHz, D2O):  4.12 (br s, 1.6 H), 3.45-3.94 (br m, 28 H), 3.21-3.45 (br
m, 4.4 H), 3.05 (br s, 2.0 H), 1.86 (br s, 2.8 H), 0.6-1.37 (br m, 4.7 H). FTIR max/cm-1: 3400,
2900, 1720, 1640. SEC: Mn = 9 kg/mol, Mw =18 kg/mol, PDI =1.9.
Synthesis of control polymer 5.8. The linear polymer 5.7 (98 mg,  138 mol of amine)
and the isothiocyanate derivative of DTPA (p-SCN-Bn-DTPA, Macrocyclics, Dallas, USA)
(32 mg, 50 mol,  0.4 equiv. per nanogel amine) were dissolved in 1 mL of dry DMF and
dry NEt3 (0.84 mL, 6.0 mmol) was added. The reaction mixture was stirred overnight at
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room temperature and then dialyzed against distilled water for 24 hours using a dialysis
membrane with a MWCO of 1 kg/mol. The resulting solution was lyophilized to provide 110
mg of the product as a white solid. 1H NMR (400 MHz, D2O):  7.26 (br s, 4.0 H), 4.08 (br s,
1.8 H), 3.41-3.86 (m, 31 H), 3.28 (s, 7.5 H), 2.60-3.11 (m, 10.9 H), 1.86 (br s, 3.1 H), 0.501.43 (m, 10.4 H). FTIR max/cm-1: 3550, 2890, 1730, 1640.
Synthesis of control polymer 5.9. The linear polymer 5.8 (60 mg) was dissolved in 2 mL of
distilled water. GdCl3·6H2O (50 mg, 0.13 mmol,  2 equiv. per amine) was dissolved in 1
mL of distilled water and was subsequently added to the linear polymer solution. The
solution was stirred overnight, and then dialyzed against distilled water for 24 hours using a
dialysis membrane with a MWCO of 1 kg/mol. The resulting solution was lyophilized to
provide 52 mg of the product as a white solid. The Gd content of the nanogel was determined
by inductively coupled plasma mass spectrometry (ICP-MS), performed at the
Environmental Analytical Laboratories of the Saskatchewan Research Council (Canada).
Result = 58  1 g Gd/mg nanogel. FTIR max/cm-1: 3454, 2933, 1731, 1614.
Relaxivity measurements. The polymer was dissolved in a 100 mM pH 7.4 phosphate
buffer at a concentration of approximately 20 g Gd/mL (exact concentration was
determined by ICP-MS analysis of this solution. Nuclear magnetic resonance dispersion
measurements were acquired using fast field-cycling relaxometry.33,34 Relaxation rates in the
range from 0.01 – 42 MHz (2.35mT – 0.99T) were acquired using a Stelar Spinmaster
FFC2000 1T C/DC relaxometer, (Stelar s.r.l., Italy) at 25°C and 37°C. Data at higher field
strengths was gathered using an insertable field-cycling relaxometer system (MRIn, Stelar
s.r.l., Italy). This system is capable of magnetic field shifts of ±0.25T around a clinical field
strength and was modified to include control of the sample temperature by the addition of
temperature-regulated airflow to the NMR probe. Relaxation rate measurements with the
MRIn apparatus were acquired in the ranges of 55.9 to 71.9MHz (1.5T ± 0.2T) and 119.7 to
135.7MHz (3T ± 0.2T). The relaxivity (r1) was calculated at each field point and temperature
according to the following equation:
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where

is the measured relaxation rate of buffered agent,

is the relaxation

rate of the plain buffer solution in the absence of contrast agent and

is the

concentration of gadolinium determined on a millimolar basis. Typical uncertainties for
measurement of relaxation rates were less than 1%. The uncertainty in r1 was dominated by
the 2% uncertainty in the GdIII concentration.
Animal protocol. All animal experiments were approved by the Animal Use Subcommittee
of the University Council on Animal Care at The University of Western Ontario following
the guidelines of the Canadian Council on Animal Care (protocol # 2010–210). Female CB17 SCID mice were anesthetized using isoflurane (1% in oxygen) and injected with 1×106
MDA-MB-231 cells into the right thoracic mammary fat pad. Briefly, the mice were
anesthetized with isoflurane and an incision was made in the skin over the right thoracic
mammary fat pad, allowing the fat pad to be exposed. Cells were injected into the fat pad in a
volume of 50L and the incision was closed using surgical glue (VetBond™, 3M™).
Imaging protocol. Tumor bearing animals were anesthetized using isoflurane (1% in
oxygen) for all imaging experiments. Pre- and post-injection images were acquired on a 1.5
Tesla clinical MR system (General Electric Medical Systems, Milwaukee, WI) equipped with
a custom-built high performance gradient coil insert (inner diameter =17.5 cm, maximum
gradient strength =500 mT/m, and peak slew rate =3000 T/m/sec) and a custom-built mouse
body solenoid radiofrequency (RF) coil (4cm length, 3cm diameter). Images were acquired
using a 3D spoiled gradient echo (SPGR) pulse sequence. The imaging parameters were:
repetition time of 10 ms, echo time of 2.4 ms, flip angle of 30o, bandwidth of ±31.25 kHz,
field of view of 4 cm, slice thickness of 0.2 mm, isotropic resolution of 200 m, ¾ phase
field of view, and 6 signal averages. The scan time was 19 minutes and 12 seconds. After a
pre-injection image was acquired, the animal was injected with either Magnevist or nanogel
5.6 (both at 0.1 mmol/kg of Gd(III), 100 l) via the tail vein, without removal from the RF
coil or moving the animal position. Post contrast images were acquired immediately after
injection. Image data is displayed as a maximum intensity projection (MIP) through the
entire image stack created using the freeware image analysis program ImageJ.
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5.3 Results and discussion
The monomers PEOMA (5.1), AEMA (5.2) and EGDMA (5.3) were selected for preparation
of the nanogel. The pendant amine functionality on 5.2 should allow for the conjugation of
the DTPA derivative to the resulting nanoparticles, while the 5.1 is hydrophilic and should
enhance water access to the nanogel, a property that is critical in achieving high relaxivity in
MRI contrast agents. Monomer 5.3 was selected as a cross-linking agent and benzoyl
peroxide was used as an initiator. A number of reaction conditions were surveyed in order to
obtain nanogels by a simple free radical polymerization method, without the need for
preparing a stable colloidal suspension. It was found that at low loadings of monomer 5.3 or
low overall concentrations no nanogel was detected, while at very high monomer 5.3 loading
or high overall concentrations, macroscopic gels were formed. Similarly, the amount of the
initiator was also important. At low initiator loadings macroscopic gels were formed, likely
due to a high degree of polymerization, whereas nanogels were formed using 10 mol% of
initiator. Conditions involving a 5.1:5.2:5.3 weight ratio of 60:20:20 (34:37:29 mole ratio)
and 10 mol% of benzoyl peroxide (relative to the total monomer) reproducibly led to the
formation of nanogel 5.4 as shown in Scheme 5.1.
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Scheme 5.1. Synthesis of the nanogel and incorporation of Gd(III) chelates.
The resulting material was characterized by several techniques. 1H NMR spectroscopy in
D2O revealed broad peaks, as expected for a cross-linked polymeric material. The broadness
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and overlap of peaks corresponding to the different monomers made exact quantification
difficult, but peaks corresponding to all monomers were observed in the spectrum (see
appendix). As shown in Figure 5.1, DLS suggested a volume average diameter of
approximately 10 nm and a PDI of 0.61. Both TEM (Figure 5.2) and AFM (see appendix)
revealed the presence of spherical materials, supporting the proposed cross-linked structure.
Analysis by SEC in DMF containing 10 mM LiBr and 1 vol% NEt3 suggested that in
comparison with the polystyrene calibration standards, the material had an Mn of 19 kg/mol
and a PDI of 2.6. This Mn is likely an underestimate of the true Mn due to the branched,
globular structure of the molecule. The relatively high PDI is expected for “non-living” free
radical polymerization conditions, particularly those involving the formation of a branched
network, though it would be ideal to later reduce this polydispersity and that of the
nanoparticles to some extent for in vivo applications. Nevertheless, the distribution of
nanoparticle sizes still lies within the range of sizes that allow for enhanced blood circulation
times through reduced renal filtration, while avoiding uptake by the RES.35

Figure 5.1. Size distribution of the nanogel 5.4 and the linear polymer control 5.7 as
measured by DLS.
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Figure 5.2. TEM image of nanogel 5.4.
To conjugate a Gd(III) chelate, nanogel 5.4 was reacted with a commercially available
isothiocyanate derivative of DTPA to provide 5.5 (Scheme 5.1) and the excess unreacted
chelate was removed by dialysis. This chelate was selected as the eight Gd(III) coordination
sites present in DTPA are retained in this derivative, so the thermodynamic and kinetic
stability of the Gd(III) complex should not be compromised.1-3 1H NMR spectroscopy of
nanogel 5.5 after dialysis confirmed the presence of the conjugated chelate (see appendix).
IR spectroscopy confirmed that any unconjugated chelate was successfully removed by
dialysis as the characteristic C=S stretch from the isothiocyanate at 2130 cm-1 was absent
(see appendix). Finally, Gd(III) was inserted into the chelates by the reaction of nanogel 5.5
with GdCl3 in H2O at pH 7 to provide nanogel 5.6, and the product was purified by dialysis
and lyophilized. At this stage, IR spectroscopic analysis revealed a shift in the C=O stretches
of the ligand from 1650 cm-1 to 1610 cm-1, which is an indication of the successful
coordination of Gd(III).36 ICP-MS was used to quantify the Gd content of the nanogel, which
was measured to be 59  1 g/mg of nanogel. This suggests that approximately 54% of the
theoretically available amines in the nanogel were reacted with the DTPA derivative. As
amines at the core of the nanogel would likely be inaccessible to the bulky chelate, this
number was within the expected range. In addition, the xylenol orange test37 was performed
and only 1.2% of the total Gd(III) was detected, confirming that there was not a significant
fraction of Gd(III) bound non-specifically and that dialysis had effectively removed the
excess Gd(III) for further study of this agent.
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In addition to the nanogel synthesis described above, a series of control experiments were
also performed to further confirm the successful synthesis of the nanogel and to aid in the
evaluation of its properties. To verify the importance of the cross-linker, the polymerization
reaction was performed under the same conditions described above, but in the absence of
monomer 5.3 (Scheme 5.2). The resulting polymer 5.7 was characterized by the same
techniques described above. The 1H NMR spectrum of polymer 5.7 was significantly sharper
than that of nanogel 5.4 as expected for a linear versus cross-linked polymer (see appendix).
In addition, the peaks from monomers 5.1 and 5.2 moieties in the polymer were sufficiently
well resolved to verify that the monomers were indeed both incorporated in a ratio similar to
their feed ratio despite monomer 5.1 being a methacrylate and monomer 5.2 being a
methacrylamide. As shown in Figure 5.1, DLS indicated a distribution of hydrodynamic
diameters centered at approximately 4 nm, significantly smaller than that obtained for
nanogel 5.4. In addition, an Mn of 9 kg/mol and a PDI of 1.9 were obtained from SEC
measurements, again suggesting that the cross-linker played a role in increasing the size of
the polymeric material, as would be expected. TEM showed only random aggregates of
material rather than the spherical particles obtained for nanogel 5.4 and when a sample was
prepared for AFM measurements under the same conditions as for 5.4, polymer 5.7 provided
only a uniform coating of polymer (see appendix). These data are all suggestive of 5.4
possessing a cross-linked spherical structure in comparison with 5.7, which behaved like a
conventional linear polymer. Using the same protocols described above, polymer 5.7 was
reacted with the isothiocyanate derivative of DTPA to provide polymer 5.8. As coupling of
the DTPA isocyanate to the amines on the linear polymer was found to be much more
efficient than to the nanogel, in order to obtain the same overall loading of Gd(III) chelates as
in nanogel 5.6, only 0.4 equivalents of the chelate per amine were added. Following insertion
of Gd(III) to provide 5.9, a Gd content of 58  1 g/mg of polymer was obtained, as
measured by ICP-MS.
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Scheme 5.2. Synthesis of a control linear polymer.
The relaxivity of nanogel 5.6 was measured in 0.1 M pH 7.4 phosphate buffer at
25 C and 37 C using a stand-alone field-cycling relaxometer from 0.01 – 42 MHz. A
second insertable field-cycling relaxometer system was used to characterize this compound at
higher fields. Relaxation rate data was acquired at the same temperatures for magnetic fields
within ±0.25T of clinical field strengths at 1.5 and 3T. Relaxivity was calculated from
separate relaxation rate measurements of the buffered agent and plain buffer solutions and
knowledge of the Gd(III) concentration. On a per Gd(III) basis, at 20 MHz, nanogel 5.6 had
r1 values of 20.8  0.2 mM-1s-1 and 19.5  0.1 mM-1s-1 at 25 C and 37 C respectively. At 60
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MHz, corresponding to the clinical field strength of 1.5 T the r1 value was 17.5  0.4 mM-1s-1
at 37 C, while at 128 MHz (3 T) it was 10.2  0.2 mM-1s-1. As shown in Figure 5.3, 5.6
exhibits an r1 versus frequency curve shape that is characteristic of restricted tumbling
motion of the Gd(III) complex.3,38 In comparison with the clinical agent Magnevist (Gd(III)DTPA), which has a reported relaxivity of 4.6 mM-1s-1 at 20 MHz, this nanogel agent
provides a ~5-fold enhancement in relaxivity. This lies within the range of per ion
enhancements observed upon the conjugation of DTPA derivatives to proteins and viral
capsids.16,17,20 Although the long term stability of the nanogel in solution was not investigated
in detail in the current work, it was found that the relaxivity remained constant when repeated
measurements were performed over a period of a few weeks on the same solution, as did the
size distribution measured by DLS.
Perez-Baena et al. reported the preparation of poly(acrylic acid)-based nanoparticles
based on single polymer chains with Gd(III) chelates incorporated within the cross-linking
moieties.39 However, they obtained an r1 of only 6.8 mM-1s-1. Nam et al. have prepared
chitosan particles bearing conjugated Gd(III) chelates and Cy5.5 dye molecules as dual
modality optical-MRI agents, but their relaxivities were reduced relative to the small
molecule chelates due to entrapment of the Gd(III) chelates within the hydrophobic cores of
the particles, preventing access to water molecules.40 Using polymer nanoparticles based on
cross-linked poly(methacrylic acid) approach, Okada et al. reported r1 values in the range of
20 – 30 mM-1s-1; however, these relaxivities were pH sensitive and these values were only
obtained at pH 4.41 At physiological pH, the relaxivities were ~2-fold lower due to
morphological changes in the polymer structure. In addition, their particles were > 100 nm in
diameter, which is not ideal for in vivo circulation. Hydrogels based on chitosan and
hyaluronate with noncovalently ionized Gd(III)-DOTA were recently reported by Courant et
al. to have very high per ion r1 values on the order of 70 s-1mM-1, but again these nanogels
were very large (> 200 nm in diameter) and would therefore be rapidly cleared from the
blood stream by the reticuloendothelial system.42
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Figure 5.3. Longitudinal relaxivity (r1) of nanogel 5.6 and control linear polymer 5.9 in
phosphate buffer (0.1 M, pH 7.4) as a function of field strength at 37 C.
The relaxivity of the linear control polymer 5.9 was also measured in 0.1 M pH 7.4
phosphate buffer at 25 C and 37 C in the same manner described above. At 20 MHz, it was
found to have r1 values of 17.3  0.2 mM-1s-1 and 15.7  0.3 mM-1s-1 at 25 C and 37 C
respectively. At 60 MHz, corresponding to the clinical field strength of 1.5 T the r1 value was
15.7  0.3 mM-1s-1 at 37 C, while at 128 MHz (3 T) it was 11.5  0.2 mM-1s-1. These results
are in the expected range for the conjugation of DTPA to a linear methacrylate/acrylatebased polymer backbone.43,44
Fitting of the nuclear magnetic resonance dispersion (NMRD) data to SolomonBloembergen-Morgan theory suggested that the enhancement in relaxivity obtained for
nanogel 5.6 versus the linear polymer 5.9 did indeed arise from its restricted motion, as the
R values obtained were 2.7  0.1 ns and 1.6  0.1 ns for 5.6 and 5.9 respectively at 37 C.
Both of these R values are much longer than the R of ~60 ps for Gd(III)-DTPA,1 indicating
that even the linear polymer was not highly flexible prior to cross-linking; however, an
enhancement was still obtained upon cross-linking. The R value for 5.6 is quite similar to
that of MS-325, an albumin-binding derivative of Gd(III)-DTPA, which upon binding to the
protein has been reported to have a R of ~5 ns, depending on the model.45 m was found to be
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568.2  8.5 ns and 624  12 ns for 5.6 and 5.9 respectively at 37 C. This is somewhat longer
than MS-325, which has been reported to exhibit a m of 70 – 296 ns.45 The longer m of the
current agents can likely be attributed to the presence of the oligo(ethylene glycol) chains on
the monomer, as the presence of PEO has been shown to slow water exchange with Gd(III)
complexes.46 While the m for the nanogel 5.6 does not change significantly with temperature
between 25 and 37 C, polymer 5.9 exhibits a decrease in m to 536  11 ns at 25 C. This
was somewhat unexpected, but can perhaps be attributed to the well known
thermoresponsive properties of linear polymers containing pendant oligo(ethylene glycol)
moieties.47 Also noteworthy is that at higher field strengths, the nanogel and linear polymer
become very similar to one another in terms of relaxivity, as the R for the nanogel may
become longer than ideal at these field strengths and the relaxivity becomes limited by other
parameters such as the water residence time m.34
In order to assess the potential of the new contrast agent 5.6 for MRI applications, initial
imaging studies were performed in C.B.-17 SCID mice bearing MDA-MB-231 tumors in
their right mammary fat pad. The mice were injected with either the clinical agent Magnevist
or nanogel 5.6 at a dose of 0.1 mmol/kg of Gd(III). They were imaged at 1.5 T using a T 1
weighted pulse sequence of approximately 20 minutes in length, both prior to injection and
immediately following injection. As shown in Figure 5.4, enhancement was mainly found in
the kidneys and very little enhancement was observed in the vasculature in animals injected
with Magnevist. In contrast, in the case of nanogel 5.6, most of the agent remained in the
vasculature at this time point and excellent contrast was observed, a result likely attributable
to the enhanced r1 of this agent. In addition, as indicated in Figure 5.4d, nanogel 5.6 was
readily visualized in the vasculature serving the tumor (arrow). This result holds promise for
the development of a targeted version of the nanogel agent that can be designed for the
selective visualization of tumors via the incorporation of targeting moieties.

125

Figure 5.4. Maximum intensity projections through the set of coronal images of C.B.-17
SCID mice bearing MDA-MB-231 tumors in their right mammary fat pads. Head, tail, left
and right sides are labeled in image (a) for reference. G = Gut, K = Kidney in contrast
enhanced images. The tumor is circled. a) prior to injection of Magnevist; b) prior to
injection of nanogel 5.6; c) 20 min following injection of Magnevist; d) 20 min following
injection of nanogel 5.6. Imaging was performed at 1.5 T using a T1 weighted imaging
sequence and the doses was 0.1 mmol/kg of Gd(III) in each case.

5.4 Conclusions
A simple, free radical polymerization approach for the preparation of a new nanogel MRI
contrast agent was developed. The resulting nanogel was characterized chemically by
techniques including 1H NMR spectroscopy, SEC, TEM, and AFM, and was compared to a
control polymer that was prepared under the same conditions but in the absence of the crosslinker. The r1 values for the nanogel agent 5.6 and the control polymer 5.9 were measured
and it was found that as expected, the molecular rigidification imparted by the cross-linking
did lead to enhanced relaxivity. In addition, imaging experiments suggest that relative to the
clinical agent Magnevist, the nanogel agent provides increased contrast and enhanced
circulation in the vasculature. The modularity and chemical multivalency provided by this
nanogel platform is currently being exploited for the development of new targeted and
multimodal imaging agents through the conjugation of active targeting ligands and contrast
agents for multiple imaging modalities.
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Chapter 6

6

Conclusions, limitations and future directions

Overall, this thesis investigated the design, synthesis, and evaluation of new polymers for
drug delivery and medical imaging applications. The work was aimed at understanding how
the chemical structures of polymers can be designed to impart specific properties and
functions. For example, it was demonstrated how the polymer backbone can be tuned to
impart varying thermal, mechanical, and rheological properties, and how cross-linking can be
used to control the motion of polymers in solution. In addition, it was shown that tunable
drug release can be achieved through cleavage of chemical linkages in the polymer backbone
as well as between the drug and polymer.
In Chapter 2, the thermal, mechanical and rheological properties of six different PEAs
comprising of differing dicarboxylic acid, diol and amino acid components were thoroughly
investigated. It was found that the thermal properties were significantly influenced by the
particular monomeric combinations. PEAs containing a short diol or nonflexible moieties
were completely amorphous. In contrast, the incorporation of a long chain diol and bulky
amino acid moieties into the polymer backbone led to increased crystallinity. It was
demonstrated that the chemical structure and molecular weights also have a significant effect
on the rheological properties of a material. PEAs with a flexible backbone, and those having
lower MWs and higher PDIs, have lower viscosities. The mechanical properties of the PEAs
were diverse, ranging from highly brittle solids to elastomeric materials. As a limitation, a
small library of monomers have been investigated for this study which can be used as a
starting point for designing PEAs with predictable properties for different combinations of
selected monomers. However, further investigation may be necessary to optimize the
thermal, mechanical and rheological properties for specific applications.
In Chapter 3, a novel micellar delivery system based on a PEA-PEO graft copolymer
covalently conjugated to PTX via a hydrolyzable ester linkage was described. As expected, a
slow release of the drug was observed, with approximately 40% cumulative drug release over
14 days in phosphate buffer (pH= 7.4). In contrast, an analogous construct in where the drug
was simply physically encapsulated showed very rapid release with more than 70% of the
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drug released after only 25 h. Both covalent PEA-PTX micelles and non-covalent PEA-PTX
micelles exhibited comparable cytotoxicity to PTX itself against HeLa cancer cells. On the
other hand, the drug-free micelles were less toxic than the CrEL vehicle, which is beneficial
for in vivo applications. In vitro release of PTX from PEA-PEO-PTX micelles at lower pH
value (4–5) would be ideal to investigate as the proton concentration within the endosomes
and lysosomes of cells is usually higher than that outside of the cells. A study on the
degradation rate of the nanoparticle itself would also be helpful to better understand the
release mechanism. Future work will also focus on studying the bio-distribution of the
micelles and in vivo antitumor efficacy as well as the development of micelles with an
additional active targeting mechanism.
Chapter 4 involved an extension of the design strategy employed in Chapter 3, but
using a PEA with a photodegradable backbone covalently conjugated to both PTX and PEO.
The PTX release profile of the resulting micelles from this copolymer both before and after a
10 min UV irradiation was studied. It was found that irradiation resulted in a burst release of
20% of the PTX over the first 24 h, in comparison with the non-irradiated control, which
only exhibited a 3% release over the same time period. In vitro toxicity studies demonstrated
that the polymers were non-toxic at the concentrations investigated, while the PTX-micelles
were highly toxic, with the irradiated and non-irradiated micelles had similar toxicity.
Photochemically responsive groups in this study were sensitive to UV light, which suffers a
number of drawbacks. Light in the UV and visible regions are strongly absorbed by skin and
tissue and therefore cannot be used for deep-tissue triggering. Moreover, it will damage
tissue at much lower powers than near-infrared. Therefore, the same strategy can be explored
in the future to impart visible or near-infrared photoresponsive linkers into the polymer
backbone. These materials can potentially open up new opportunities and solutions for
biological or biomedical challenges.
.Finally, Chapter 5 described the synthesis and characterization of a Gd(III)-nanogel as an
MRI contrast agent. The nanogel was synthesized by a conventional free radical
polymerization using AEMA as its amine functional handle, PEOMA for its biocompatible
properties and EGDMA as a cross-linker, to construct a rigid amine-functionalized network
polymer. SEC, DLS, TEM, AFM, and other comparisons with a control linear polymer were
consistent with the proposed nanogel structure. p-SCN-DTPA was incorporated onto the
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nanogel as a Gd(III) chelating agent and subsequently, Gd(III) was successfully introduced
into each chelation site. The relaxivities of the Gd(III)-nanogel and the control polymer
agents were measured as a function of field strength. It was found that the increase in
molecular rigidity imparted by cross-linking did lead to enhanced relaxivity. In addition,
imaging experiments suggested that relative to the clinical agent Magnevist®, the nanogel
agent provided increased contrast and enhanced circulation in the vasculature. In the future,
the chemical multivalency offered by this nanogel platform will be explored for the
development of new targeted and multimodal imaging agents through the conjugation of
active targeting ligands and contrast agents for multiple imaging techniques. In addition, it
would be ideal to change the nondegradable methacrylate backbone for a biodegradable
polymer backbone such as a PEA. It is anticipated that methodology could be developed to
achieve this goal.
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Figure A.2.1. 1H NMR spectrum of PCSe (400 MHz; CDCl3).

Figure A.2.2. Overlay of SEC traces for PEAs (Int-U).
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Figure A.2.3. Overlay SEC traces for POSe prepared and fractionated by different methods
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Figure A.2.4. Overlay of TGA traces for POSe prepared by different methods.
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Figure A.2.5. Complex viscosity versus temperature for POSe, showing the effect of MW
and MW distribution.

Figure A.2.6. Complex viscosity versus temperature for PBSe, showing the effect of MW
and MW distribution.
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Figure A.2.7. Complex viscosity versus temperature for PBTe, showing the effect of MW
and MW distribution.

Figure A.2.8. Complex viscosity versus frequency for AOSe, showing the effect of MW and
MW distribution.
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Figure A.2.9. Complex viscosity versus frequency for PBSe showing the effect of MW and
MW distribution.

Figure A.2.10. Complex viscosity versus frequency for PBTe, showing the effect of MW
and MW distribution
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Figure A.2.11. Dog bone sample

Figure A.2.12. Tensile stress versus tensile strain for AOSe

144

Figure A.2.13. Tensile stress versus tensile strain for POSe

Figure A.2.14. Tensile stress versus tensile strain for PBSe
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Figure A.2.15. POSe-Int-U under elongation test

146

Appendix 3: Supporting information for chapter 3

Figure.A.3.1. 1H NMR spectrum of polymer 3.4 (400 MHz, DMSO-d6)

Figure.A.3.2. 1H NMR spectrum of polymer 3.5 (400 MHz, DMSO-d6)
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Figure.A.3. 3. 1H NMR spectrum of polymer 3.6 (400 MHz, DMSO-d6) The amount of
conjugated PTX was calculated from a comparison of the integration of the single peak
corresponding to proton labeled (a) in PTX at 6.3 ppm and the α protons on the
phenylalanine-butanediol monomer unit at 4.42-4.48 ppm.

Figure.A.3.4. 1H NMR spectrum of polymer 3.7 (400 MHz, DMSO-d6)
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Figure.A.3.5. 1H NMR spectrum of polymer 3.8 (400 MHz, DMSO-d6). The amount of
conjugated PTO was calculated from a comparison of the integrations of the single peak
corresponding to PEO proton at 3.51 ppm and the α protons on the phenylalanine-butanediol
monomer unit at 4.42-4.48 ppm.

Figure.A.3.6. SEC traces for polymer 3.4, 3.8.
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Table.A.3.1. Paclitaxel (PTX) loading into PEA-PEG micelles
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Figure.A.3.7. In vitro cytotoxicity of drug-free micelles prepared from PEA-PEO graft
copolymer 3.7 as measured by the MTT assay following a 72 h incubation with HeLa cells
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Appendix 4: Supporting information for chapter 4

Figure.A.4.1. 1H NMR spectrum of monomer 4.3 (400 MHz, DMSO-d6)

Figure.A.4.2. 1H NMR spectrum of polymer 4.5 (400 MHz, DMSO-d6)
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Figure.A.4.3. 1H NMR spectrum of polymer 4.7 (400 MHz, DMSO-d6)

Figure.A.4.4. 1H NMR spectrum of polymer 4.8 (400 MHz, DMSO-d6)
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Figure.A.4. 5. 1H NMR spectrum of polymer 4.9 (400 MHz, DMSO-d6). The amount of
conjugated PTX was calculated from a comparison of the integrations of the single peak
corresponding to the protons on labeled (a) in PTX at 6.30 ppm and the benzylic methylene
protons on the photodegradable monomer unit at 5.25-5.17 ppm.

Figure.A.4.6. 1H NMR spectrum of polymer 4.10 (400 MHz, DMSO-d6)NMR integration of
the peaks corresponding to the PEO at 3.5 ppm and the benzylic methylene protons on the
photodegradable monomer unit at 5.25-5.17 ppm.
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Figure.A.4.7. SEC traces for polymer 4.5, 4.7, 4.10, and photodegradation of polymer 4.5.

Figure.A.4.8. 1H NMR spectra evolution for the photolysis of a 7.5 mg/mL sample of
functional polymer 4.8
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Figure.A.4.9. UV-vis spectra of polymer 4.10 following photoirradiation in a) dioxane (4
μg/mL) and b) water (4 μg/mL).
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Figure.A.4.10. Evolution of HPLC traces for PTX irradiated with UV light for various time
intervals.
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Figure.A.4.11. Photodegradation of micelles formed from polymer 4.10 at a concentration of
1.5 mg/mL in water. At each time point, 100 L of the aqueous suspension was removed,
diluted into dioxane and a UV-vis spectrum was obtained.
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Figure.A.4.12. DLS traces micelles formed from graft copolymer 4.10 after 20 min UV
irradiation.
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Figure.A.4.13. In vitro cytotoxicity of polymer copolymer 4.8 as measured by the MTT
assay following a 72 h incubation with HeLa cells
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Appendix 5: Supporting information for chapter 5

Figure.A5.1. 1H NMR spectrum of polymer 5.4 (400 MHz, D2O )

Figure.A5.2. Size exclusion chromatogram of nanogel 5.4 (DMF with 10 mM LiBr and 1%
(v/v) NEt3, detection based on differential refractive index).
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Figure.A5.3. AFM image of nanogel 5.4.

Figure.A5.4. Size distribution by intensity of the nanogel 5.4. Z-average size is 20 nm. As
shown by the larger peak at ~150 nm, a small degree of aggregation is present but this is not
present in the volume distribution (Figure 5.1 in manuscript) as large objects scatter much
more strongly than small ones and thus account for a very small volume fraction of the
sample.
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Figure.A5.5. 1H NMR spectrum of functionalized nanogel 5.5 (400 MHz, D2O).

Figure.A5.6. Infrared spectra of a) the isothiocyanate derivative of DTPA (p-SCN-BnDTPA), b) nanogel 5.5, and c) nanogel 5.6 illustrating the successful conjugation of the
chelate and coordination of Gd(III).
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Figure.A5.7. 1H NMR spectrum of polymer 5.7 (400 MHz, D2O ) illustrating shaper peaks
than the corresponding NMR spectrum of nanogel 5.4.

Figure.A5.8. Transmission electron micrograph of linear polymer 5.7, illustrating the
formation of random aggregates rather than spherical particles.
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Figure.A5.9. Atomic force microscopy image of linear polymer 5.7 showing the absence of
spherical aggregates.

Figure.A5.10. Longitudinal relaxivity (r1) of nanogel 5.6 and control linear polymer 5.9 in
phosphate buffer (0.1 M, pH 7.4) as a function of field strength at 25 C.
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NMRD Modeling
Longitudinal relaxation was modeled using a modification of the Solomon-BloembergenMorgan theory formulated by R. Lauffer. Contributions from the inner hydration sphere
were included as:

where:
is the spin-lattice relaxation rate due to inner-sphere interactions,
[M] is the molar concentration of the paramagnetic species,
[H2O] is the molar concentration of water
qIS is the inner-sphere hydration number
T1M is the relaxation time for bound inner-sphere water molecules and
τm is the water residency time.
The inner sphere spin-lattice relaxation rate including dipolar and contact interactions was
calculated from the following formula:

.
Constants in this equation include:
, the magnetic permeability of vacuum,
, the gyromagnetic ratio for protons,
, the electronic g-factor,
the total electronic spin for the metal ion,
, the Bohr Magneton,
, the metal ion-proton separation and
, the electron-nuclear hyperfine coupling constant.
are respectively, the proton and electron Larmor precessional frequencies (rad/s)
in the applied magnetic field.
The dipole-dipole correlation time, , depends on the longitudinal electronic spin relaxation
time,
, the water residency time,
and the rotational correlation time, as:
.
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The longitudinal electronic spin relaxation rate has the following dependency:
.
Finally, the scalar relaxation time,

, is equal to:
.

The quantities,
were held at fixed values of 7/2, 0.31 nm, 1 and
respectively. Remaining parameters,
(water residency time),
(rotational
correlation time), (correlation time for modulation of the transient zero-field splitting) and
(electronic relaxation time at zero field) where determined from a non-linear leastsquares fit of this relaxation model to relaxivity data from NMRD measurements using even
weighting of the data. The fitted parameters and their uncertainties (one standard deviation)
are given in Table A.5.1. A graph of the typical fitting results is illustrated in Figure A.5.11.
Table A.5.1. NMRD Fitting Results.
Parameter

Units
ps
ns
ns
ps

Nanogel 5.6
25°C
37°C
39.4 ± 2.6
34.9 ± 1.9
2.72 ± 0.11
2.72 ± 0.10
576.4 ± 9.5
568.2 ± 8.5
313 ± 12
261 ± 8.1

Polymer 5.9
25°C
37°C
40.2 ± 2.5
38.8 ± 2.5
1.68 ± 0.08
1.56 ± 0.08
536 ± 11
624 ± 12
247.3 7.8
225.1 ± 7.8
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Figure.A5.11. Relaxivity of Nanogel 5.6. The Lauffer model for inner-sphere dipole-dipole
relaxation (red circles) has been fit to relaxivities (black squares) derived from NMRD data
at 37°C. The error bars represent a measurement uncertainty of one standard deviation.

Figure.A5.12. Additional MRI images of a tumor-baring animal injected with nanogel 5.6.
(a) Pre-contrast image, (b) post-contrast image. The location of the tumor is highlighted by
the red ovals in both images. The arrows highlight the difference in the contrast in the
vasculature between the pre- and post-contrast images.
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